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Abstract 
The application of positron emission tomography (PET) as a tool for molecular imaging of the brain is 
limited by the availability of suitable radiotracers. In radiotracer development, success or failure of a 
novel compound is determined by numerous physicochemical and pharmacological factors of which 
metabolism represents a particularly important one. Hence, an initial assessment of the metabolic 
properties of a candidate radiotracer at an early stage of the development process prior to expensive 
and time-consuming animal studies is desirable. Various in vitro metabolism models are available for 
the evaluation of candidate drugs in the pharmaceutical sector, however, since drug and tracer 
applications differ fundamentally (especially with regard to the amount of administered substance) the 
question rises whether these models are also capable of providing relevant and valid data for the 
evaluation of radiotracers. In the present work, this question was examined using three xanthine-
derived adenosine A1 receptor (A1AR) ligands, 8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine 
(CPFPX), 8-cyclobutyl-3-(3-fluoropropyl)-1-propylxanthine (CBX) and 3-(3-fluoropropyl)-8-(1-methyl-
cyclobutyl)-1-propylxanthine (MCBX) as model compounds. Radioligands for imaging adenosine 
receptors in vivo are of particular interest for biomedical research since this receptor system has been 
associated with numerous physiological functions (e.g. regulation of sleep) and pathophysiological 
conditions (e.g. Alzheimer’s and Parkinson’s disease). In vivo metabolic stability and metabolite 
patterns of the three A1AR ligands were investigated in the rat model and compared to in vitro data 
generated in rat liver microsomes. Prior to the characterisation of the microsomal metabolism of the 
test compounds, the influence of incubation conditions on the in vitro test results was assessed and the 
microsomal assay was optimised in order to provide physiologically relevant data. Metabolic activity in 
liver microsomes was strongly influenced by the pH value of the buffer medium and the type and 
concentration of the organic solvent used to solubilise the test compounds. Variations of incubation 
matrix composition resulted in variations of individual substrate depletion values of up to 500%, 
whereas substrate depletion ratios proved to be highly constant. In vitro microsomal half-lives (t1/2) of 
the compounds were determined and expressed as ratios for the purpose of later in vitro-in vivo 
comparison. The t1/2 ratios (± SE) of CBX:CPFPX, MCBX:CPFPX and CBX:MCBX were 3.1 ± 0.11, 
1.4 ± 0.029 and 2.2 ± 0.033. In vivo metabolic stability of the 18F-labelled compounds were assessed in 
anaesthetised rats via blood analysis. Plasma clearance (CL) values were calculated and expressed as 
inversed ratios to facilitate direct comparison with in vitro t1/2 ratios. The inversed CL ratios (± SE) of 
[18F]CBX:[18F]CPFPX, [18F]MCBX:[18F]CPFPX and [18F]CBX:[18F]MCBX were 2.6 ± 0.12, 0.82 ± 0.019 and 
3.1 ± 0.15. In vitro t1/2 ratios deviated between 19 and 71% from inverse CL ratios. These deviations 
can be considered small in view of the reduced complexity of the microsomal model and the multitude 
of physiological parameters affecting in vivo pharmacokinetics of a substance. Visual comparison of 
metabolite profiles generated in vitro and in vivo revealed a high degree of similarity. In conclusion, 
both quantitative and qualitative aspects of radiotracer metabolism could be reasonably well predicted 
by microsomal data. This result encourages the implementation of in vitro metabolism studies as an 
integral part of PET radiotracer development. 
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Kurzzusammenfassung 
Der Einsatz der Positronenemissionstomographie (PET) für die molekulare Bildgebung des Gehirns 
wird durch die Verfügbarkeit geeigneter Radiotracer limitiert. Bei der Entwicklung von Radiotracern 
entscheiden zahlreiche physikochemische und physiologische Faktoren über Erfolg oder Misserfolg 
einer neuen Verbindung, allen voran der Metabolismus der Substanz im Körper. Deshalb ist eine erste 
Beurteilung der metabolischen Eigenschaften des potentiellen Radiotracers in einer frühen 
Entwicklungsphase noch vor Durchführung teurer und aufwendiger Tierstudien wünschenswert. Der 
Pharmabranche stehen zahlreiche in vitro-Modelle zur Vorhersage des Metabolismus von 
Medikamentenkandidaten zur Verfügung, allerdings stellt sich die Frage, ob diese Modelle auch im 
Hinblick auf die Evaluierung von Radiotracern valide Daten liefern können, da sich Medikamente und 
Radiotracer in ihrer Anwendung fundamental unterscheiden (besonders hinsichtlich der 
verabreichten Substanzmengen). In der vorliegenden Arbeit wurde diese Fragestellung am Beispiel 
dreier xanthinbasierter Adenosin A1 Rezeptorliganden (A1AR-Liganden), 8-Cyclopentyl-3-(3-
fluorpropyl)-1-propylxanthin (CPFPX), 8-Cyclobutyl-3-(3-fluorpropyl)-1-propylxanthin (CBX) und 
3-(3-Fluorpropyl)-8-(1-methylcyclobutyl)-1-propylxanthin (MCBX) untersucht. Radioliganden für die 
in vivo-Bildgebung von Adenosinrezeptoren sind von besonderem Interesse für die biomedizinische 
Forschung, da dieses Rezeptorsystem mit zahlreichen physiologischen Funktionen (z.B. der 
Schlafregulation) aber auch mit pathologischen Zustanden (z.B. der Alzheimer- und Parkinson-
Krankheit) in Zusammenhang gebracht wird. Die metabolische Stabilität der drei A1AR-Liganden und 
ihre Metabolitenprofile wurden in vivo in der Ratte untersucht und mit in vitro-Daten verglichen, die 
mittels Rattenlebermikrosomen gewonnen wurden. Vor der eigentlichen Charakterisierung des 
mikrosomalen Metabolismus der Testsubstanzen wurde der Einfluss der Inkubationsbedingungen auf 
die Resultate der in vitro-Tests untersucht und das Mikrosomen-Assay im Hinblick auf die Generierung 
physiologisch relevanter Daten optimiert. Die metabolische Aktivität der Lebermikrosomen wurde 
stark vom pH-Wert des Puffers und der Art und Konzentration des zur Auflösung der Testsubstanzen 
verwendeten Lösungsmittels beeinflusst. Änderungen in der Zusammensetzung der Inkubationsmatrix 
führten zu einer Veränderung der individuellen Abbauraten der Verbindungen um bis zu 500%, 
während die Zahlenverhältnisse der Abbauraten zueinander sehr konstant blieben. Die mikrosomalen 
in vitro-Halbwertszeiten (t1/2) der Verbindungen wurden bestimmt und zum Zwecke des in vitro-in 
vivo-Vergleichs als Quotienten ausgedrückt. Die ermittelten t1/2-Quotienten (± Standardfehler) von 
CBX:CPFPX, MCBX:CPFPX und CBX:MCBX betrugen 3.1 ± 0.11, 1.4 ± 0.029 und 2.2 ± 0.033. Die 
metabolische in vivo Stabilität der 18F-markierten Verbindungen wurde an narkotisierten Ratten 
mittels Blutanalyse bestimmt. Die individuellen Plasma Clearance (CL)-Werte der Radiotracer wurden 
berechnet und als inverse Quotienten ausgedrückt, um einen direkte Vergleich mit den in vitro t1/2-
Quotienten zu ermöglichen. Die inversen CL-Quotienten (± Standardfehler) von [18F]CBX:[18F]CPFPX, 
[18F]MCBX:[18F]CPFPX und [18F]CBX:[18F]MCBX betrugen 2.6 ± 0.12, 0.82 ± 0.019 und 3.1 ± 0.15. Die 
Abweichung der in vitro t1/2-Quotienten von den inversen CL-Quotienten lag zwischen 19 und 71%. In 
Anbetracht der reduzierte Komplexität des Mikrosomenmodells und der Vielzahl physiologischer 
Parameter, welche die in vivo-Pharmakokinetik einer Substanz beeinflussen, können diese 
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Abweichungen als geringfügig erachtet werden. Der visuelle Vergleich der in vitro- und in vivo- 
Metabolitenprofile erbrachte einen hohen Grad an Übereinstimmung. Zusammenfassend lässt sich 
sagen, dass anhand der Daten aus Mikrosomenstudien sowohl quantitative als auch qualitative 
Aspekte des Metabolismus der Radiotracer mit angemessener Genauigkeit vorhergesagt werden 
konnten. Dieses Ergebnis ermutigt zur generellen Einbeziehung von in vitro-Metabolismusstudien in 
den Prozess der PET-Radiotracer-Entwicklung. 
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1 Introduction 
1.1 Molecular imaging in neuroscience 
Since the 1970s, nuclear imaging techniques such as X-ray computed tomography (CT), 
single photon emission computed tomography (SPECT) and positron emission tomography 
(PET) revolutionised the field of neuroscience in that they provided the opportunity to 
visualise brain structure and function in the living, intact organism. Whereas CT is restricted 
to anatomical imaging, SPECT and PET allow for the detection and characterisation of 
molecular processes underlying physiological function, which is why they are also referred 
to as molecular imaging techniques. 
Molecular imaging is targeted at biological processes such as gene expression and 
regulation, signal transduction and protein-protein interactions. Nowadays, a variety of 
high-affinity, high-selectivity molecular probes are available for visualising diverse 
molecular targets. Common examples are receptor ligands, enzyme inhibitors, transporter 
substrates, monoclonal antibodies and recombinant proteins. In addition to the classical 
nuclear techniques SPECT and PET, several novel molecular imaging approaches were 
introduced during the past few years, for example nuclear magnetic resonance (NMR)-based 
techniques such as dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and 
magnetic resonance spectroscopy (MRS), optical techniques such as fluorescence and 
bioluminescence imaging and sophisticated ultrasound techniques. A number of 
comprehensive reviews addressing molecular imaging techniques and applications have 
been published recently [1–9]. 
In neuroscience, the various receptor systems of the brain represent valuable targets for 
molecular imaging approaches. High-affinity receptor ligands, equipped with a suitable label 
for external detection, can be utilised to study in vivo receptor expression in normal, healthy 
subjects as well as changes in receptor density due to pathophysiological conditions. 
Positron- or gamma-emitting radionuclides (PET/SPECT nuclides) are particularly suitable 
for labelling ligands aimed at visualising cerebral receptors due to their penetrating 
radiating which is capable of traversing the skull bone. Although being introduced more 
than 40 years ago, SPECT and PET still represent the cornerstone of molecular imaging in 
the field of neuroscience. 
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When comparing both modalities, PET offers several advantages compared to SPECT, for 
example higher sensitivity (approx. 2-3 orders of magnitude), higher spatial and temporal 
resolution and an improved image quality [10]. In addition, generation of quantitative data 
is technically less challenging with PET than with SPECT [11]. Consequently, PET represents 
a powerful tool for molecular neuroimaging with increasing importance in basic and clinical 
neuroscience as well as in pharmacology and drug development [12–22]. 
1.2 Principles of positron emission tomography 
PET uses imaging probes (tracers) which are labelled with positron-emitting radionuclides. 
These radionuclides decay by converting a proton into a neutron while ejecting a positron 
and an electron neutrino (β⁺-decay). The emitted positron travels a short distance in matter 
(e.g. tissue), losing its kinetic energy by collision and scattering events with electrons and 
nuclei of the surrounding atoms. After thermalisation, the positron annihilates with an 
electron resulting in the formation of two 511 keV photons which are emitted 
simultaneously in nearly opposite directions (Fig. 1A). Near-simultaneous detection of these 
photons via a circular array of radiation detectors (usually scintillation detectors) indicates 
the original site of annihilation, which is located on the connecting line between the two hit 
detectors (Fig. 1B). This technique is referred to as annihilation coincidence detection 
(ACD). Acquisition of numerous coincidence events provides the basis for a three-
dimensional reconstruction of the radiotracer distribution inside the subject’s body. 
 
 
Fig. 1. Principle of PET imaging. (A) Electron-positron annihilation following β⁺-decay of a 
radionuclide. Two 511 keV photons are generated and emitted in opposite directions. (B) 
Coincidence detection of the two annihilation photons via a circular detector array [23]. 
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An important prerequisite for accurate quantification of radiotracer concentration in 
various tissues is attenuation correction of the PET raw data. This correction is usually 
based on separate transmission scans using external 68Ga sources or CT. Additional data 
processing steps inevitable for good PET image quality include corrections for scattered 
radiation, random coincidences and detector dead time. A comprehensive summery on PET 
image data correction is given in [24]. 
The spatial resolution achievable in PET imaging is fundamentally limited by two physical 
aspects of positron decay [25, 26]. First, the emitted positron travels a finite distance in 
tissue before annihilation occurs. This distance is denoted as positron range and depends on 
the positron’s kinetic energy and the density of the tissue. For commonly used PET nuclides, 
mean positron ranges in water are in the range of 0.6-3 mm [27]. As a consequence of 
positron travelling, the exact position of the parent nucleus in the body cannot be localised 
precisely, resulting in blurring of the PET images. In terms of image quality, radionuclides 
emitting low-energy positrons are thus preferable. Second, annihilation photons are 
frequently not emitted at exactly 180° to each other, which is due to a residual momentum 
of the positron at the moment of annihilation. This effect, known as non-collinearity or 
acollinearity, results in image blurring that is proportional to the diameter of the detector 
ring. These inherent effects can be significant for special PET applications such as high-
resolution brain imaging or small-animal imaging, however, the main factor that determines 
spatial resolution of conventional human whole-body PET systems is the size of the 
individual detector elements [28]. 
Positron-emitting radionuclides are generally produced with cyclotrons by bombardment of 
a suitable target material with accelerated charged particles (e.g. protons, deuterons or 3He 
particles). Some commonly used positron emitters are listed in Table 1, along with their 
decay characteristics. The positon-emitting isotopes of carbon, nitrogen and oxygen (11C, 
13N, 15O) provide the opportunity of isotopic labelling of biomolecules, thus allowing for 
radiosynthesis of PET radiotracers which exhibit almost identical (bio)chemical 
characteristics as their non-labelled counterparts (except for minor kinetic isotope effects). 
However, the extremely short half-lives of these nuclides limit their applicability. Currently, 
18F represents the most important and most widely used positron emitter for PET. The low 
positron energy of 18F provides high spatial resolution in imaging and its relatively long half-
life of 110 min allows for complex, multi-step radiosynthesis procedures, extended PET 
protocols and commercial distribution of ready-to-use PET radiotracers. Generally, 
18F-labelled PET radiotracers represent analogous fluoro derivatives of biomolecules in 
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which a hydrogen atom or a hydroxyl group was substituted by 18F [29]. In the following 
section, methods for 18F-production and 18F-radiolabelling are discussed in more detail. 
Table 1. Properties of some frequently used positron emitters (from [30–32]) 
Nuclide Half-life Positron branching Emax of positron 
Max. positron range 
in water 
  % keV mm 
11C 20.4 min 99.8 960 3.9 
13N 9.97 min 100 1198 5.1 
15O 2.03 min 99.9 1732 8.0 
18F 109.8 min 97 635 2.3 
64Cu 12.7 h 18 653 2.4 
68Ga 68 min 88 1899 8.9 
89Zr 78.4 h 23 897 3.6 
124I 4.17 d 23 2138 10.2 
 
1.3 Radiolabelling with 
18
F 
Numerous radiochemical techniques are currently known for the radiofluorination of 
organic target molecules. These methods can be divided into electrophilic and nucleophilic 
labelling strategies, depending on the chemical form of the 18F-fluorination reagent involved. 
For electrophilic 18F-labelling, either gaseous [18F]F2 or several less reactive [18F]F2 
derivatives such as acetyl [18F]hypofluorite [33, 34], xenon [18F]difluoride [35, 36] or 
N-[18F]fluorosulfonamides [37] can be used. [18F]F2 is usually produced by bombardment of 
neon gas with deuterons via the 20Ne(d,α)18F reaction. A major drawback of this production 
method is the adsorption of the produced fluorine-18 on the target walls which necessitates 
the addition of carrier [19F]F2 to the target gas to recover radioactivity by isotopic exchange 
[38]. Consequently, specific activities of fluorine-18 obtainable by this production route are 
relatively low (0.03-0.4 GBq/µmol [39]) which precludes radiosynthesis of PET radiotracers 
with high specific activity. Electrophilic radiofluorination methods are thus generally 
restricted to tracer applications which are not particularly sensitive to larger amounts of 
fluorine-19 carrier, for example ADME (absorption, distribution, metabolism and excretion) 
studies. However, given the lack of alternative 18F-labelling strategies, several radiotracers 
of clinical importance are still produced via electrophilic radiofluorination, the most 
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prominent example being 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (6-[18F]fluoro-L-
DOPA) [40, 41]. 
 
For imaging low-abundance brain receptors in vivo, radiotracers with high specific activity 
are required, since the presence of significant amounts of tracer molecules labelled with the 
stable isotope can seriously affect the validity of the data. Nucleophilic 18F-fluorination 
starting from no-carrier-added (n.c.a.) [18F]fluoride ([18F]F⁻) is the method of choice for 
synthesis of radiotracers with high specific activity. N.c.a. [18F]F⁻ is obtained by proton 
irradiation of 18O-enriched water according to the 18O(p,n)18F reaction. Since carrier 
addition is dispensable with this production method, specific activities of more than 
5000 GBq/µmol [39] can be attained. In aqueous solution, the fluoride ion is a weak 
nucleophile due to its strong solvation. Accordingly, nucleophilic 18F-labelling reactions 
routinely involve an azeotropic drying step with acetonitrile to remove the residual water 
followed by redissolution of the dry [18F]fluoride in a dipolar aprotic solvent such as 
acetonitrile, dimethyl sulfoxide or N,N-dimethylformamide. To further enhance nucleophilic 
reactivity of [18F]F⁻, phase transfer catalysts such as the aminopolyether Kryptofix 2.2.2 (in 
combination with potassium carbonate)[42, 43] or tetrabutylammonium salts [44, 45] are 
commonly applied as anion activators. After the drying procedure, [18F]F⁻ is present as 
almost naked, highly nucleophilic anion in polar aprotic solvents. Recently, several 
nucleophilic 18F-labelling strategies have been described which do not require a drying step, 
for example procedures using electrochemical deposition of [18F]F⁻ [46], ionic liquids 
[47, 48] or direct elution of [18F]F⁻ from an anion exchange sorbent with alcoholic solutions 
of iodonium precursors [49]. However, nucleophilic radiofluorinations are still most 
frequently performed with dried [18F]F⁻ in dipolar aprotic media. Under these conditions, 
aliphatic nucleophilic substitution reactions proceed via an SN2 reaction mechanism. High 
radiochemical yields can be obtained with precursors carrying good leaving groups such as 
halides (Br, I) or sulfonates (triflate, mesylate, tosylate). As a consequence of the 
stereospecific SN2 mechanism, displacement of the leaving group by [18F]F⁻ involves 
inversion of the stereochemical configuration of the molecule (Walden inversion). A 
prominent example of aliphatic nucleophilic 18F-labelling is the synthesis of n.c.a. 
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) which proceeds via replacement of the triflate 
leaving group of an acetyl-protected mannose precursor by [18F]F⁻ and subsequent 
hydrolysis to yield the final product (Fig. 2) [42]. With this method, radiochemical yields of 
50-70% and specific activities of about 300-500 GBq/µmol are achievable [50]. 
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Fig. 2. Radiosynthesis of n.c.a. [18F]FDG via nucleophilc 18F-for-triflat exchange [42]. Deprotection can 
be accomplished by either acid hydrolysis (with hydrochloric acid) or base hydrolysis (with sodium 
hydroxide)[51]. 
Aromatic nucleophilic substitution (SNAr) reactions require arene precursors which are 
activated by strong electron-withdrawing substituents such as nitro, cyano or carbonyl 
groups in ortho or para position to the leaving group (Fig. 3). Typical leaving groups are 
nitro and trimethylammonium functional groups or halides [29, 50]. Electron deficient 
heteroaromatic systems (e.g. pyridines) frequently allow for nucleophilic 18F-labelling 
without further activation by electron-withdrawing groups [52]. Radiofluorination of 
electron rich (deactivated) arenes requires more complex synthesis approaches. Various 
innovative strategies have been described to date, for example the use of diaryliodonium 
[53–55] and triarylsulfonium salts [56, 57] as precursors or the application of palladium-
mediated fluoride umpolung which converts the nucleophilic [18F]fluoride to an 
electrophilic 18F-fluorination reagent [58, 59]. Several detailed reviews on current 
developments in 18F-labelling of aromatic compounds have been published recently [60-62]. 
 
 
Fig. 3. 18F-labelling of activated arenes via nucleophilic aromatic substitution [50]. 
Although direct 18F-labelling of target molecules at the final stage of the radiosynthesis 
procedure is desirable in order to maximise the radiochemical yield and to simplify process 
automation, it is frequently inappropriate for complex molecules bearing multiple reactive 
functional groups or for biomolecules such as proteins or peptides which are sensitive to the 
relatively harsh reaction conditions involved in direct radiofluorination. For these target 
substrates, indirect labelling techniques are available which are based on small 18F-labelled 
organic molecules (18F-labelled intermediates) that can be coupled to the desired target 
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structure. Depending on whether they are used for build-up radiosynthesis of small 
monomeric radiotracers or for radiolabelling of macromolecular biomolecules, these 
18F-labelled intermediates are called synthons (in the former case) or prosthetic groups (in 
the latter case) [50]. Typically, synthons and prosthetic groups are prepared by direct 
nucleophilic n.c.a. radiofluoridation of activated, bifunctionalised organic molecules and, in a 
second step, attached to the target structure by, for example, acylation, alkylation, amidation 
or thiol-coupling reactions. Versatile synthons for radiochemical build-up synthesis are 
4-[18F]fluorobenzaldehyde [63–65], 4-[18F]fluoroaniline [66, 67], 4-[18F]fluorobenzylamine 
[68, 69], 4-[18F]fluoroiodobenzene [70–72], 4-[18F]fluorobromobenzene [73–75] and 
4-[18F]fluorophenol [76–79]. For 18F-labelling of peptides and proteins, the amine reactive 
compounds N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) [80–85] and 
4-[18F]fluorobenzoic acid ([18F]FBA) [86–88] as well as the thiol reactive groups 
N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide ([18F]FBAM) [89, 90] and 
N-[2-(4-[18F]fluorobenzamido)ethyl]maleimide ([18F]FBEM) [91, 92] are valuable prosthetic 
groups [60]. The structural formulas of these compounds are shown in Fig. 4. Detailed 
summaries on the application of synthons and prosthetic groups for 18F-labelling of complex 
molecules can be found in [93–99]. 
 
 
Fig. 4. Common prosthetic groups for 18F-labelling of biomolecules [60]. 
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1.4 PET radiotracers for molecular neuroimaging 
1.4.1 Radiotracer development process 
The development of PET radiotracers for molecular imaging of the brain is a 
multidisciplinary process which comprises a number of complex, and often iterative, steps 
(Fig. 5). Initially, a specific biomedical question will be posed by physicians, scientists or 
pharmaceutical companies. This question may arise from unmet needs in diagnosis and 
treatment of patients or, more frequently, from basic scientific issues in brain research 
[100, 101]. Once a biomedical question has been chosen, a suitable molecular target needs 
to be selected. Classical targets for molecular neuroimaging include neuroreceptors 
[102-105] and neurotransmitter transporters [106–108], but also enzymes involved in 
epigenetic modification of gene expression [109–111] or specific protein structures such as 
amyloid plaques [112–116] have recently been targeted. Key criteria for choosing a suitable 
molecular target are target expression and localisation, both of which strongly influence 
later selection of potential lead compounds. Low-abundance targets, for example, demand 
for radiotracers possessing high affinity and high specific activity and nuclear targets 
require penetration of the cell nucleus by the tracer. For identification of lead compounds, 
different strategies can be pursued, including structure–activity relationship (SAR) analysis 
[117] and compound library screening [118, 119]. In many cases, endogenous substances or 
established drugs serve as starting point for lead development. Following identification, lead 
compounds are evaluated and optimised with regard to their physicochemical properties 
(e.g. solubility, lipophilicity, ionisation constants, passive permeability), their affinity and 
selectivity towards the molecular target and their in vitro metabolic stability. Once a 
promising candidate has emerged, strategies to radiolabel this compound are developed. 
Starting from the choice of a suitable radionuclide, a radiosynthesis scheme is designed 
which includes precursor synthesis, incorporation of the radioisotope into the molecule, 
purification of the product, quality control as well as development of an injectable 
formulation of the radiotracer. After successful completion of the radiosynthesis step, 
extensive in vitro and in vivo studies are conducted to evaluate the target binding 
characteristics and pharmacokinetic properties of the novel imaging agent. In vitro studies 
frequently include autoradiographic assessment of radiotracer distribution in brain slices 
and estimation of non-specific binding to cerebral proteins and lipids. In vivo PET imaging is 
carried out in rodents to evaluate blood-brain barrier (BBB) permeability, cerebral 
distribution and cerebral kinetics of the candidate radiotracer. Typically, PET imaging 
sessions involve blood analysis to determine plasma pharmacokinetics of the radiotracer 
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and in vivo metabolite formation. Promising candidates are then taken to non-human 
primate studies to verify the results obtained in rodent experiments. If the novel compound 
shows poor performance in preclinical investigations, especially with regard to brain 
uptake, cerebral kinetics and formation of BBB-penetrant radiometabolites, the process of 
radiotracer design and evaluation has to be iterated. The last stage of radiotracer 
development is the evaluation of the novel agent in humans. Before approval for clinical 
studies is granted, a multitude of regulatory issues must be covered (e.g. radiation 
protection, toxicological safety, good manufacturing practices (GMP) regulations) [120–
124]. Since the regulative requirements became increasingly restrictive during the last 
20 years, the time span between the first successful radiosynthesis of a novel PET 
radiotracer and initial human trials is at least 5-10 years [125]. 
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Fig. 5. Stages in the development of novel PET radiotracers for molecular neuroimaging. 
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1.4.2 Key criteria for PET radiotracers targeting neuroreceptors 
In order to develop a PET radiotracer which is useful for imaging neuronal receptors in vivo 
(especially with regard to quantitative assessment of receptor expression), a number of 
demanding criteria have to be met. In addition to the radiochemical requirements discussed 
above (feasibility of high-specific-activity labelling with an appropriate radionuclide), there 
are also various biochemical and physiological prerequisites which are essential for good in 
vivo performance of a candidate radiotracer [126, 127]: 
• High affinity (<10 nM) 
• Target selectivity 
• Adequate BBB permeability 
• Lack of BBB efflux transporter affinity 
• Suitable brain kinetics 
• Low non-specific binding in brain 
• Low plasma protein binding 
• Adequate pharmacokinetics & metabolism 
• Lack of BBB-penetrant radiometabolites 
Optimisation of these factors primarily aims to ensure a high signal-to-noise ratio (or target-
to-background ratio) which is crucial for the reliable quantification of receptor expression in 
vivo. Several articles have been published in which the influence of the abovementioned 
parameters on PET image quality is discussed in great detail [127–129]. In the following, the 
most important aspects are outlined briefly. 
1.4.2.1 Affinity 
Binding affinity refers to the strength of the binding interactions between a ligand (e.g. 
radiotracer) and its binding site (e.g. neuroreceptor). Since affinity of radioligand binding is 
the reciprocal of the equilibrium dissociation constant KD [130], high-affinity radiotracers 
are characterised by small KD values. Binding affinity is a key factor which strongly 
influences the specific-to-non-displaceable binding ratio and thus the image quality in PET. 
Because this ratio also depends on the number of binding sites available in a particular 
region (Bmax), low-abundant target receptors require tracers with especially high affinity to 
ensure adequate quantification of receptor parameters. Radiotracers used in neuroreceptor 
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imaging typically display affinities between 1 and 0.01 nM [128]. High affinity is generally 
considered advantageously for brain receptor studies, however, extremely high affinity 
values may result in undesirable slow dissociation kinetics which necessitates long 
acquisition times to reliably quantify receptor parameters [131]. This is particularly 
problematic if 11C-labelled tracers are to be used which only allow for short scan durations. 
Consequently, in radiotracer design, the affinity of a novel tracer should be attuned to the 
expected target density in the region(s) of interest. 
1.4.2.2 BBB penetration 
The BBB represents a highly selective regulatory interface which restricts and controls the 
exchange of substances between the central nervous system (CNS) and the peripheral 
circulation [132, 133]. It is formed by brain microvascular endothelial cells which are 
closely connected to each other via tight junctions, thus restricting paracellular diffusion of 
polar substances [134]. A variety of specific carriers and transporters are expressed at the 
BBB which facilitate uptake of nutrients and hormones into the brain or allow for active 
efflux transport of metabolites and xenobiotics out of the brain capillary endothelial cells 
[135, 136]. Important examples of active transporters expressed at the BBB are the 
members of the ATP-binding cassette (ABC) transporter family, a group of transmembrane 
proteins which hydrolyse adenosine triphosphate (ATP) to gain energy for the transport of 
various substrates across cellular membranes [137–139]. The ABC efflux transporter 
P-glycoprotein (P-gp) is of particular interest with regard to the development of CNS drugs, 
as it shows a remarkably broad substrate spectrum and high expression levels at the BBB 
[140–142]. 
Brain entry of a radiotracer is governed by its ability to cross the BBB via passive diffusion 
on the one hand and its affinity for efflux transporters on the other hand. Transmembrane 
diffusion is promoted by low molecular weight (less than 400-500 Da), low hydrogen 
bonding capacity (less than 8-10 hydrogen bonds) and lack of negative charge [143–147]. 
Lipophilicity substantially influences the ability of a tracer to cross cellular membranes via 
diffusion. In general, a high degree of lipid solubility enhances membrane diffusion of a 
compound [148], however, it usually also increases efflux transporter affinity, plasma 
protein binding and metabolic clearance of this compound, which may result in an overall 
reduction of brain uptake. Frequently, a parabolic relationship between lipophilicity and in 
vivo brain uptake could be demonstrated, where compounds with moderate lipophilicity 
(log P/log D of about 2.0-3.5) often showed highest uptake values [149]. Owing to the large 
number of diverse brain efflux transporters expressed at the BBB and the broad substrate 
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specificity of individual efflux pumps – in particular P-gp - the susceptibility of a novel 
radiotracer to brain efflux transport is difficult to predict on the basis of its molecular 
characteristics. Typically, P-gp substrates are neutral or positively charged lipophilic or 
amphiphilic molecules which often contain planar aromatic domains [140, 142, 150, 151]. 
1.4.2.3 Radiotracer metabolism 
In vivo performance of a radiotracer is influenced by both qualitative and quantitative 
aspects of radiotracer metabolism. A major obstacle to brain PET imaging is the appearance 
of radiolabelled metabolites in the brain, either as a result of cerebral metabolism or of 
peripheral generation of brain-penetrant radiometabolites. Brain radiometabolites which 
exhibit considerable affinity for the target receptor seriously confound quantification of 
receptor parameters since the measured PET signal represents specific binding of two 
species with different kinetics. Brain radiometabolites without target affinity contribute to 
the radioactive background and decrease the signal-to-noise ratio. Although kinetic models 
have been developed which account for the non-specific accumulation of radiometabolites 
in brain [152–154], it is generally preferable to avoid formation of troublesome metabolites 
by rational tracer design. 
Metabolism is the main route of elimination for the majority of radiotracers. Fast clearance 
of radiotracer and radiolabelled metabolites from blood decreases the radioactive 
background and thus improves the signal-to-noise ratio. Additionally, since the rate of 
passive diffusion of a radiotracer through the BBB is influenced by the concentration 
gradient across the cellular membrane, rapid decline in plasma radiotracer concentration 
results in accelerated radiotracer washout from brain which facilitates measurement of all 
relevant kinetic parameters in a shorter scanning time [128, 155]. However, if the 
radiotracer is metabolized too excessively, the extent of brain exposure might be 
insufficient, especially if longer acquisition times are required for proper imaging of the 
molecular target. Consequently, metabolic stability of lead compounds should be precisely 
adjusted during the development process to produce promising radiotracers for in vivo PET 
imaging. In the following section, various methods for in vitro and in vivo evaluation of 
radiotracer metabolism are presented. 
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1.5 Evaluation of radiotracer metabolism 
1.5.1 Metabolism of xenobiotics 
Almost immediately after intravenous administration, radiotracers undergo metabolic 
conversion catalysed by a variety of enzymes located mainly in the liver but also in various 
extrahepatic tissues. This process, designated as xenobiotic biotransformation, gives rise to 
metabolites which exhibit physicochemical and physiological characteristics different from 
those of the parent compound. Biotransformation of xenobiotics is subdivided into phase I 
and phase II reactions. Phase I reactions (also referred to as functionalisation reactions) 
include hydrolysis, reduction and oxidation processes which introduce or expose polar 
functional groups (e.g. –OH, –COOH, -NH2). Functionalisation usually results in a moderate 
increase in hydrophilicity of the xenobiotic compound and facilitates the second phase of 
metabolism in which the functionalised compound is coupled to an endogenous substrate 
such as glucuronic acid or glutathione. Phase II conjugation reactions typically increase 
hydrophilicity of the xenobiotic by a large amount, hence promoting its excretion from the 
body. Although the liver has the highest expression levels of most phase I and II enzymes, 
significant enzyme concentrations can also be found in pancreas, gastrointestinal tract, 
spleen, lung, brain and nasal mucosa [156]. On the subcellular level, the major fraction of 
these enzymes is located in the endoplasmic reticulum and in the cytosol, but smaller 
quantities have also been detected in mitochondria, lysosomes and nucleus [157]. 
1.5.1.1 Cytochrome P450 
Cytochrome P450 enzymes (P450s or CYPs) are haem-containing proteins that are present 
in all three domains of life. They play a critical role in the metabolism of endogenous and 
exogenous substrates. In mammals, hepatic P450 isoforms of families CYP1, CYP2 and CYP3 
mediate phase I biotransformation of most xenobiotic compounds [158]. Human P450s, for 
example, account for the metabolism of about 75% of marketed drugs [159]. Mammalian 
P450s are membrane-bound enzymes which are expressed in a variety of tissues, with the 
highest concentration levels found in the endoplasmic reticulum of the liver. P450s 
predominantly catalyse oxidation reactions, although other reaction types have also been 
observed, for example reduction, desaturation, dehydration, ring formation and coupling 
reactions [160, 161]. 
Molecular oxygen (O2) is activated at the haem-iron centre of the P450 enzyme, resulting in 
the insertion of a single oxygen atom into an organic substrate and concomitant reduction of 
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the other oxygen atom to water. The electrons required for this reaction are derived from 
nicotinamide adenine dinucleotide phosphate (NADPH) and supplied via a redox partner 
such as the flavoprotein cytochrome P450 reductase (CPR) [162]. The catalytic cycle of P450 
(Fig. 6) involves a number of subsequent steps [163]: (1) substrate binding followed by 
conformational change of the P450 molecule, (2) transfer of the first electron by CPR and 
reduction of haem-Fe3+ to haem-Fe2+, (3) O2 binding to haem-Fe2+, (4) transfer of the second 
electron by CPR or cytochrome b5, (5) protonation of the Fe3+O2 intermediate to yield an 
Fe3+OOH intermediate, (6) second protonation and generation of a highly reactive 
oxo-Fe4+-species (referred to as Compound 1), (7) oxygen insertion into the substrate, 
dissociation of the oxidised substrate (product) from P450. 
Interruption (uncoupling) of the catalytic cycle leads to the generation of reactive oxygen 
species (ROS). The decay of the Fe3+O2 intermediate gives rise to the release of oxygen as 
superoxide anion (.O2⁻) whereas protonation of the Fe3+OOH intermediate entails formation 
of hydrogen peroxide (H2O2). In eukaryotes, the P450 cycle is poorly coupled, resulting in 
continuous ROS production which causes oxidative stress [164]. 
1.5.2 In vitro metabolism studies 
The use of in vitro metabolism models allows for determination of the metabolic properties 
of a candidate radiotracer at an early stage in the development process. Information on 
metabolic stability and metabolite formation gained in vitro provide guidance for lead 
optimisation and selection of candidates for further in vivo studies. Generally, in vitro 
metabolism studies are relatively inexpensive, time effective and do not require regulatory 
approval which facilitates flexible study design and fast implementation. Several in vitro 
metabolism models are available to date, all of which have their advantages and 
disadvantages (Table 2). Because numerous comprehensive reviews have been published 
on the pros and cons of the individual models [165–173], the following discussion will be 
limited to the microsomal model which was used in the present work. 
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Table 2. Comparison of different in vitro metabolism models employed in preclinical research (from 
[167–169])  
In vitro model Advantages Disadvantages 
Recombinant CYP enzymes High throughput system 
Useful for mechanistic studies 
Commercially available 
High enzyme activities 
Study of only one enzyme at a time 
In vivo relevance questionable 
Microsomes High throughput system 
Useful for intrinsic clearance and 
drug inhibition studies 
Relatively inexpensive  
Minimal loss of enzyme activity 
during storage 
Commercially available 
Only CYP, FMO and UGT enzymes 
Cofactor addition necessary 
Incomplete representation of in vivo 
hepatic function 
 
 
Primary hepatocytes Full ensemble of phase I & II 
enzymes at in vivo levels 
Whole-cell system  
Normal cellular levels of cofactors 
Potential for use in toxicity, drug-
drug interaction and induction 
studies 
Cryopreservation possible 
Commercially available 
Limited viability 
Decrease in enzyme expression & 
activity during culture 
Restricted availability of human 
hepatocytes 
Special equipment required 
 
Liver slices Intact cellular architecture 
Cell-cell connections are preserved 
Complete set of functional enzymes 
and transporters 
Morphological studies possible 
 
Limited viability 
Limited availability (human tissue) 
Complicated technique 
Isolated perfused liver Preserved hepatic architecture 
Bile formation 
Study of hepatobiliary drug 
disposition 
Limited viability 
Limited availability (human tissue) 
Complicated technique 
Poor reproducibility 
Low throughput, not suitable for 
routine use 
CYP, cytochrome P450; FMO, flavin-containing monooxygenase; UGT, UDP-glucuronosyltransferase 
1.5.2.1 Microsomes 
Microsomes are vesicular structures derived from the endoplasmic reticulum of eukaryotic 
cells. They are prepared from tissues involved in xenobiotic biotransformation (most often 
liver tissue) by differential centrifugation [174]. Hepatic microsomes contain P450s, flavin-
containing monooxygenases (FMOs) and UDP-glucuronosyltransferases (UGTs). Since 
P450s and UGTs are responsible for the metabolism of about 90% of marketed drugs [175], 
liver microsomes are widely used to study in vitro drug metabolism at the lead optimisation 
stage. Compared to more complex in vitro models such as hepatocytes or liver slices, 
microsomes are relatively inexpensive, easy to use and can be stored at -80°C for several 
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years with minimal loss of enzyme activity [176, 177]. However, the reduced complexity of 
the microsomal model also limits its physiological relevance. As liver microsomes lack the 
full complement of hepatic enzymes, metabolic pathways observed with microsomes may 
differ from in vivo metabolism. Intracellular compartmentalisation, which is an important 
characteristic of eukaryotic cells, is no longer present in microsomal preparations, thus 
resulting in unrestricted contact of enzymes and substrates which does not reflect the in 
vivo situation. Metabolism studies in microsomes require addition of cofactors such as 
NADPH to support enzyme activity. Addition of excess amounts of cofactor in order to 
maintain stable concentration levels during incubation creates unphysiological conditions, 
whereas in situ cofactor regeneration may influence reaction kinetics and complicate 
interpretation of results. Finally, since microsomes lack the defence mechanisms of vital 
cells, reactive oxygen species generated as a byproduct of oxidative metabolism rapidly 
damage the microsomal enzyme systems which leads to a fast decline of enzyme activity 
during incubation procedures [178]. These factors often hamper in vitro-in vivo 
extrapolation, especially of quantitative data. Nevertheless, liver microsomes are a valuable 
tool for rapid screening of compound libraries and for lead optimisation studies during drug 
development. Additionally, they can be used to produce specific metabolites in sufficiently 
large quantities to enable spectroscopic structure determination. 
Microsomes from different donors are usually pooled to reflect mean enzyme expression 
and activity levels encountered in human or animal populations. Due to the ease of 
preparation, microsomes isolated from hepatic tissue of numerous toxicologically relevant 
species (human, rodent, rabbit, dog, mini pig, monkey) and also extrahepatic microsomes 
(lung, intestine, kidney, skin) are now commercially available, allowing for study of 
extrahepatic metabolism and interspecies comparison. Microsomal assays generally involve 
incubation of the test compound with diluted microsomal protein and required cofactor for 
a certain period of time, followed by termination of the enzymatic reaction and precipitation 
of microsomal protein by addition of organic solvent or trichloroacetic acid. Samples are 
subsequently analysed by HPLC-UV/Vis or HPLC-MS to monitor either loss of parent 
compound (substrate depletion approach) or formation of metabolites (product formation 
approach) [179, 180]. Metabolic stability of a test substrate can be described in terms of 
initial reaction velocity, metabolic half-life or derived parameters such as intrinsic clearance 
which are obtained from the concentration versus time data by linear or non-linear (usually 
exponential) regression. 
In order to produce in vitro metabolism data which are relevant for the in vivo situation, 
microsomal assay conditions must be evaluated and carefully controlled. Parameters such 
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as enzyme and substrate concentration, buffer composition and pH, type and concentration 
of substrate solvent, incubation time and temperature can influence qualitative and 
quantitative aspects of microsomal metabolism of a test compound [181]. Generally, 
incubation parameters should mimic the physiological conditions encountered in vivo as 
closely as possible. With regard to radiotracer evaluation, selection of an appropriate 
substrate concentration to be used in the microsomal assay is particularly problematic. In a 
typical PET study, the average body concentration of a tracer is in the subnanomolar range 
(about 0.1-0.3 nM) [182]. Detection of such low concentrations is often not feasible with the 
classical analytical techniques usually employed in in vitro metabolism studies, especially if 
structure determination of metabolites is required. Consequently, in radiotracer 
development, in vitro metabolism data are often generated using substrate concentrations 
that do not reflect the in vivo scenario, which raises concerns about the relevance of these 
data. 
1.5.3 In vivo pharmacokinetic studies 
Although in vitro metabolism studies provide a fast and simple means of investigating 
specific aspects of radiotracer metabolism, they cannot resemble the complexity of the 
whole organism (at least at present). Metabolism is only one of the many factors influencing 
overall pharmacokinetics (PK) of a radiotracer in vivo, others being distribution and 
excretion processes. In vivo PK studies conducted with laboratory animals are required to 
gain insight into the complex interplay of physicochemical, biochemical and physiological 
parameters which determine the fate of a radiotracer in the body. 
1.5.3.1 Fundamental PK processes 
In vivo PK of a compound is influenced by four interrelated processes, namely absorption, 
distribution, metabolism and excretion (ADME). With regard to the development of 
radiotracers intended for molecular imaging in basic research, absorption is of subordinate 
importance since these tracers are generally administered intravenously. Once injected into 
the systemic circulation, the radiotracer rapidly distributes throughout the body. The extent 
of extravascular distribution depends on the ability of the compound for passive diffusion 
across cellular membranes, its affinity for active uptake and efflux transporters and its 
binding to plasma and tissue proteins and lipids [183]. Metabolism is a major pathway for 
elimination of xenobiotics from the body, although direct renal/biliary excretion of the 
unchanged molecule may also play an important role for several compounds. As already 
stated above, metabolism of xenobiotic compounds involves phase I functionalisation and 
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phase II conjugation reactions and occurs predominantly in the liver. Excretion of 
xenobiotics and their metabolites proceeds via two major routes: (1) renal excretion 
through urine and (2) biliary excretion through faeces. Minor pathways are excretion via 
saliva, milk, tears, respiration and perspiration [184, 185]. 
1.5.3.2 Pharmacokinetic data analysis 
In vivo pharmacokinetic evaluation of a novel radiotracer involves the quantitative 
assessment of tracer concentration in various tissues/organs as a function of time. The 
tracer is usually administered as intravenous bolus and the time course of radioactivity in 
the target organs (for CNS tracers especially plasma and brain) is measured either ex vivo 
via tissue sampling or in vivo via PET. From the resulting activity-time (or concentration-
time) data, pharmacokinetic parameters can be estimated via non-compartmental or 
compartmental analysis. 
Non-compartmental analysis 
In non-compartmental analysis (NCA), the time course of plasma concentration following 
single bolus administration of a radiotracer (or a drug) is regarded as statistical distribution 
curve. NCA uses statistical moment theory to derive PK parameters from this concentration-
time profile [186]. The most important moments for PK analysis, the zero moment (area 
under the curve, AUC) and the first normal moment (mean residence time, MRT), are 
defined as follows: 
  =  ()	
  Eq. 1 
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  Eq. 2 
where t is the time since administration of the radiotracer and C(t) is the plasma 
concentration of the tracer at time t. 
AUC and MRT can be calculated from the plasma concentration-time data either by 
numerical integration using the trapezoidal formula or by fitting the data to polyexponential 
functions of the general form: 
 () =


 Eq. 3 
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Integration of Eq. 3 yields: 
  ()	
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 Eq. 4 
and 
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
 Eq. 5 
The detailed calculations of these two definite integrals are given in the appendix. 
Substituting Eq. 4 into Eq. 1: 
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Substituting Eq. 5 into Eq. 2: 
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In Eq. 3-7, Ai represent the zero-time intercepts of each exponential and λi the individual 
elimination rate constants (macro rate constants). 
The basic pharmacokinetic parameters applied in NCA to describing plasma kinetics of a 
tracer following bolus administration can be estimated from the polyexponential fits of the 
concentration-time data using the definitions of AUC and MRT given above [187]: 
1. Total clearance CL (represents the volume of plasma from which the tracer is completely 
removed per unit time; unit: ml/min)  
  =  ()	
 =

∑ 		
 Eq. 8 
where D is injected radioactivity. 
2. Volume of distribution Vd (proportionality constant between tracer concentration in 
plasma and the amount of tracer in the body; unit: ml/g) 
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 "# = $%  Eq. 9 
where λel is the smallest of the rate constants λi 
3. Terminal half-life t1/2γ (time required for the tracer concentration in plasma to fall by 
50% during the terminal phase; unit: min) 
 /' = ln	(2)$%  Eq. 10 
Non-compartmental analysis is largely independent of a priori assumptions concerning the 
structure of the physiological system (model-independent) and thus a robust, versatile and 
straightforward approach to interpret experimental data. However, NCA is of limited use for 
predictive and explanatory purposes since it provides little to no information on the 
underlying biological and physiological processes which determine disposition of a 
compound in the body. To understand mechanism of tracer pharmacokinetics in the body, 
application of compartmental models is advantageous. 
Compartmental analysis 
In compartmental analysis (or compartmental modelling), disposition of a compound 
(drug/tracer) is described in terms of transfer processes between interconnected, 
pharmacokinetically distinct compartments which constitute the body. Each compartment 
represents a specific chemical state of the compound (e.g. metabolic form or binding state) 
in a particular physical location (e.g. interstitial space, plasma)[188]. Within an individual 
compartment, the concentration of the chemical species is assumed to be homogeneous. The 
rate of exchange of the compound between individual compartments can be described by 
first order kinetics. Accordingly, compartment models can be mathematically represented 
by polyexponential terms or sets of ordinary differential equations. 
Typically, compartment models applied in PK analysis comprise two or more compartments, 
although disposition of several drugs can be accurately characterised by one-compartment 
models. Of the numerous model configurations described in literature, only those which 
were used in the context of the present work will be discussed in more detail in this 
introduction. In the following, the mammillary three-compartment model which was 
applied to interpret the plasma profiles of the evaluated radiotracers is presented. The 
specific compartment models which were used for analysis of the brain PET data are 
described in section 1.6.5. 
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The mammillary three-compartment model is characterised by a central compartment 
connected to two peripheral compartments (Fig. 7). Tracer (or drug) is introduced into and 
eliminated from the system via the central compartment. All transfer processes occur via 
the central compartment, there is no direct exchange between the two peripheral 
compartments. Following intravenous (i.v.) injection, tracer is reversibly transferred from 
the central compartment to both peripheral compartments. The peripheral compartments 
differ with regard to their transport kinetics, so that the time required for equilibration with 
the central compartment varies. These variations result in complex intercompartmental 
distribution and redistribution processes which lead to a triphasic plasma concentration-
time profile with two distinct distribution phases preceding the terminal elimination phase. 
Although the compartments of the model may not have precise physiological correlates, 
common interpretations associate the central compartment with blood and highly perfused 
organs/tissues (e.g. liver), the rapidly equilibrating (“shallow”) compartment with well 
perfused organs/tissues (e.g. kidneys, muscles) and the slowly equilibrating (“deep”) 
compartment with poorly perfused organs/tissues (e.g. fat tissue, skin). The mammillary 
three-compartment model can be described by the sum of three exponentials: 
 () = + + - + ./ Eq. 11 
where t is the time since bolus injection, C(t) is the tracer concentration in plasma at time t 
and  A1-A3 and λ1-λ3 are the model parameters. 
 
 
Fig. 7. Schematic of a mammillary three-compartment model. Tracer enters and leaves the system 
only via the central compartment. Peripheral compartments 1 and 2 differ with respect to their tracer 
exchange kinetics. The shallow peripheral compartment equilibrates rapidly with the central 
compartment, whereas the deep peripheral compartment equilibrates slowly. 
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Multi-compartment mammillary models and their application in pharmacokinetics are 
discussed in detail in [189–192]. A comprehensive summary of the underlying mathematics 
can be found in [187, 193]. 
1.6 Neuroreceptor imaging  
In biology and pharmacology, the term receptor generally denotes a protein structure on the 
surface of a cell or inside a cell that selectively binds to a specific compound and acts as a 
transducer of a physiological signal or mediator of a physiological effect [194]. In molecular 
neuroscience, the diverse postsynaptic transmembrane neurotransmitter receptors 
(neuroreceptors) constitute important objects of investigation. Neuroreceptors can be 
subdivided into two classes, (1) ionotropic receptors (ligand-gated ion channels) which 
contain an ion channel in their structure that opens in response to the binding of a ligand, 
and (2) metabotropic receptors (G protein-coupled receptors, GPCRs) which activate 
internal signalling pathways upon ligand binding. In the context of the present work, 
radiotracers targeted at the adenosine A1 receptor (A1AR), a member of the GPCR family, 
have been investigated. In the following section, the adenosine receptor system is thus 
outlined briefly. 
1.6.1 Adenosine receptors 
Adenosine receptors (ARs) are a family of GPCRs which mediate the physiological actions of 
the purine nucleoside adenosine. To date, four AR subtypes have been identified, denoted as 
A1, A2A, A2B and A3 [195]. These subtypes have different signal transduction pathways and 
distinct, but often overlapping, distribution patterns in tissue. Adenosine is involved in the 
modulation of numerous physiological processes such as sleep and arousal [196–203], but 
also in the development of pathophysiological conditions, for example Alzheimer’s disease 
[204, 205], Parkinson’s disease [206–208], schizophrenia [209] and epilepsy [210, 211]. In 
the CNS, A1 and A2A are the most abundant AR subtypes. In most species, expression of A2A 
receptors is mainly restricted to the striatum and olfactory bulb while A1 receptors are 
widely expressed throughout the brain. In rodents, high A1AR levels can be found in cerebral 
cortex, cerebellum, hippocampus, striatum and thalamus [212-217]. In the human brain, 
A1AR densities are high in hippocampus, striatum, thalamus and cerebral cortex, but low in 
cerebellar cortex [218-220]. 
By now, numerous subtype-selective ligands have been described which can be used to 
study AR expression and distribution in vitro and in vivo. AR agonists have been derived 
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from the endogenous ligand adenosine by modification of the 5’-position of the ribose and 
the C2- and N6-position of the purine heterocycle (Fig. 8). N6-substituted adenosine 
derivatives such as (R)-N6-(2-phenylisopropyl)adenosine (R-PIA)[221], N6-cyclopentyl-
adenosine (CPA)[222] and 2-chloro-N6-cyclopentyladenosine (CCPA)[223, 224] are potent 
and selective A1AR agonists which are also available as tritiated radioligands. 
 
    
          Adenosine              R-PIA              CPA              CCPA 
Fig. 8. Structural formulas of adenosine and selective A1AR agonists derived from adenosine. 
Most AR antagonists reported to data are based on the xanthine structure (Fig. 9). The 
naturally occurring xanthine derivative caffeine represents the prototypical AR antagonist, 
however, since caffeine lacks affinity and subtype selectivity, this compound is of limited 
interest as a tool for the investigation of ARs. Modification of the xanthine structure at C8, 
N1, N3 (and sometimes N7) led to selective and highly affine A1AR and A2AAR antagonists. 
Two important xanthine-type A1AR antagonists are shown in Fig. 9, 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX)[225] and its 18F-labelled analogue, 8-cyclopentyl-3-(3-
[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX)[226]. A comprehensive overview of 
xanthine-based AR antagonist can be found in [227]. 
 
  
 
 
Xanthine Caffeine DPCPX [18F]CPFPX 
Fig. 9. Structural formulas of xanthine, the non-selective AR antagonist caffeine and the selective 
A1AR antagonists DPCPX and [18F]CPFPX. 
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In addition to the aforementioned xanthine derivatives, several classes of non-xanthine AR 
antagonists have been developed, including triazoloquinoxalines, triazoloquinazolines, 
imidazoquinolines and 7-deazaadenine derivatives. Characteristics and application potential 
of these compounds have been review for example in [228–232]. 
1.6.2 Ligand-receptor interactions 
The specific binding of a (radio)ligand to its target receptor can be described by a 
bimolecular reaction scheme which involves the reversible association of a ligand L and a 
receptor R to form a ligand-receptor complex LR [233]: 
 
 
Eq. 12 
where kon is the association rate constant and koff is the dissociation rate constant. Squared 
brackets indicate molar concentrations. 
According to the law of mass action, the rate at which free ligand reversibly binds to free 
(unbound) receptor can by described by: 
 0	12	0331450516 = 789:9: Eq. 13 
The rate at which ligand-receptor complex breaks down is described by: 
 0	12		5331450516 = 78;;9: Eq. 14 
At equilibrium (steady state), the rates of association and dissociation are equal: 
 789:9: = 78;;9: Eq. 15 
Eq. 15 can be rearranged to: 
 
78;;78 =
9:9:9: = <= Eq. 16 
Consequently, the equilibrium dissociation constant KD can be defined both by the ratio of 
dissociation and association rate constants and by the concentration ratio of free species to 
ligand-receptor complex. KD is an intrinsic characteristic of each individual ligand-receptor 
pair and a measure of binding affinity. A low KD value designates high binding affinity. 
k
on
k
off
[L]+[R] [LR]
Introduction 27 
 
Ligands are typically classified according to the effects they provoke on their corresponding 
receptors. Ligands which cause changes in the activity of the receptor upon binding are 
called agonists. Full agonists are capable of activating the receptor to a maximal extent 
whereas partial agonists produce a submaximal response. Inverse agonists reduce the 
intrinsic activity of a receptor. Ligands which bind to a receptor and inhibit the action of an 
agonist without activating the receptor themselves are referred to as antagonists. 
Antagonists are subdivided into several groups depending on their site of binding to the 
receptor (agonist binding site or allosteric site) and on the reversibility of their binding 
(reversible or irreversible)[234]. For radioligand binding studies, antagonists are usually 
favoured over agonists since antagonist binding is generally less affected by confounding 
factors such as pH or local concentrations of nucleotides and mono or divalent cations [235]. 
1.6.3 In vitro radioligand binding studies 
Various in vitro techniques are available to study receptor distribution in tissue or binding 
properties of ligands. One commonly used approach involves the assessment of radioligand 
binding to tissue receptors under equilibrium binding conditions (equilibrium binding 
analysis). Equilibrium binding can be studied either directly via saturation binding assays or 
indirectly via competition binding experiments. In a typical saturation binding assay, a fixed 
concentration of a receptor-containing tissue preparation (e.g. homogenate, membrane 
suspension, tissue section) is incubated with increasing concentrations of a radioligand. 
Once binding equilibrium is achieved, bound ligand is separated from free ligand by 
filtration, centrifugation or washing with buffer and quantified by means of radioactivity 
measurement. Because the radioligand usually does not only bind to its target receptor 
(specific binding), but also to other components of the tissue preparation or the assay 
equipment (non-specific binding), additional measurements have to be conducted in order 
to correct for this non-specific binding. Generally, the level of non-specific binding is 
determined in the presence of high concentrations of an unlabelled competitor. Specific 
binding is then calculated as the difference between total and non-specific binging. One 
possible graphical representation of the results obtained from a saturation binding assay is 
shown in Fig. 10. The specific binding curve asymptotically approaches a plateau value 
which represents the total number of specific binding sites (maximum binding capacity, 
Bmax). The equilibrium dissociation constant KD of the radioligand can be determined as the 
concentration of radioligand at which half of these binding sites are occupied. 
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Fig. 10. Generalised saturation binding plot. Receptor-containing tissue preparations are incubated 
with various concentrations of a radioligand, either in absence (total binding) or presence (non-
specific binding) of a competitor. The concentration of bound radioligand is determined and plotted 
against initial radioligand concentration. Specific binding is calculated as the difference between total 
and non-specific binding. 
Mathematically, the saturation curve can be derived from Eq. 16 using the following 
definition of Bmax: 
 >?@A = 9: + 9: Eq. 17 
Substitution for [R] in Eq. 16 and rearrangement yields: 
 9: = >?@A9:9: + <= Eq. 18 
This equation, which describes a rectangular hyperbola, represents a special case of the 
general Hill equation where the Hill coefficient has been set to one (i.e. non-cooperative 
binding is assumed). 
In competition binding experiments, the ability of an unlabelled ligand to compete with a 
radioligand for binding sites is used to examine ligand-receptor interactions. Typically, 
receptor-containing tissue preparations are incubated with a low, fixed concentration of a 
radioligand with known KD for the specific binding site and increasing concentrations of the 
competing ligand. The amount of specifically bound radioligand is determined and plotted 
against competitor concentration. An important parameter which can be derived from these 
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plots is the IC50, i.e. the concentration of unlabelled competitor that inhibits 50% of the 
specific radioligand binding. Based on the IC50, the affinity of the competitor for the binding 
site can be estimated using the Cheng-Prusoff equation [236]: 
 < = BCD1 + 9:<=F
 Eq. 19 
where Ki is the dissociation constant of the competitor, [L] is the concentration of free 
radioligand and KD is the dissociation constant of the radioligand. Apart from the evaluation 
of novel ligands, competition binding assays may also be used to study receptor subtypes 
and conformations. Further information regarding the conduct and analysis of equilibrium 
binding assays can be found in [233, 235, 237–241]. 
1.6.4 In vivo radiotracer binding studies 
Generally, in vivo imaging of neuroreceptors involves intravenous administration of a 
suitable radiotracer followed by dynamic measurement of radioactivity in the brain. In 
order to extract quantitative information on physiological processes from these imaging 
data, tracer kinetic models are applied. Compartmental models are the most widely used 
approach to analyse time-radioactivity data obtained from brain PET scans. These models 
provide information on the temporal changes in cerebral radiotracer distribution, but not on 
spatial concentration gradients as do complex distributed models [188]. Nevertheless, the 
limited complexity of common compartmental models may also be beneficial with regard to 
the accuracy and reliability of model parameter estimation. As with in vitro radiotracer 
binding studies, the specific binding interactions between radiotracer and receptor are of 
major interest in PET neuroreceptor imaging, however, several additional factors have to be 
taken into consideration, for example the extent of radiotracer delivery to the brain or the 
rate of radiotracer uptake and washout. The specific compartment models applied to in vivo 
radiotracer binding studies usually account for these factors. 
1.6.5 Compartmental models for in vivo radiotracer binding studies 
Two basic compartmental model configurations which are widely applied to PET 
radiotracer-receptor studies are shown in Fig. 11. In these models, a plasma compartment 
and either one or two tissue compartments are arranged in series (catenary models). The 
plasma compartment (CP) represents the concentration of free radiotracer in arterial 
plasma. Strictly speaking, plasma radiotracer concentration is not a compartment of the 
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model since this parameter is measured independently (via blood sampling) and applied to 
the compartment model as a known input function. However, in PET literature, radiotracer 
concentration in plasma is most often denoted as compartment and drawn as a box in 
graphical representations of compartmental models [242]. In the one-tissue compartment 
model (1TCM), only one uniform tissue compartment (C2) is postulated which represents 
cerebral radiotracer concentration. In the two-tissue compartment model (2TCM), the first 
tissue compartment (C2) represents the intracerebral concentration of free and non-
specifically bound tracer (also referred to as non-displaceable compartment) and the 
second tissue compartment (C3) the concentration of specifically bound tracer, i.e. tracer 
bound to its receptor. The intercompartmental transfer of tracer is described by two 
(1TCM) or four (2TCM) rate constants (transfer or fractional rate constants, denoted as 
K1-k4), which reflect the fraction of tracer molecules moving from one compartment to 
another per unit of time. In the 1TCM, there is no differentiation between free, non-
specifically and specifically bound tracer, thus only the exchange of tracer between plasma 
and brain is modelled. Occasionally, the 1TCM is chosen in preference to the 2TCM although 
specific receptor-ligand interactions are anticipated. This might be the case, for example, if 
transfer kinetics between C2 and C3 become so fast that the two compartments cannot be 
distinguished from one another [242] or if radioactivity concentration in brain tissue is very 
low so that background noise interferes substantially with the measurement signal. 
 
 
Fig. 11. Configuration of the 1TCM (A) and the 2TCM (B). CP is the concentration of tracer in arterial 
plasma, C2 and C3 are the tracer concentrations in the respective tissue compartments and K1-k4 are 
the rate constants which describe the reversible transfer of tracer between the compartments. In the 
1TCM, tracer in brain tissue is treated as a single compartment (C2). The 2TCM discriminates 
between intracerebral free and non-specifically bound tracer (non-displaceable compartment C2) and 
tracer specifically bound to the receptor (specific compartment C3). 
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The rate of change in radioactivity concentration in the tissue compartments can be 
described mathematically by ordinary differential equations. 
For the 1TCM: 
 
		 = <G() − 7() Eq. 20 
For the 2 TCM: 
 
		 = <G() − (7 + 7.)() + 7I.() Eq. 21 
 
	.	 = 7.() − 7I.() Eq. 22 
where CP is the time-varying concentration of tracer in arterial plasma (the input function), 
C2 and C3 are the time-varying concentrations of tracer in the two tissue compartments and 
K1-k4 are the fractional rate constants which define the rate of tracer transfer between the 
compartments. 
From the individual kinetic rate constants (micro parameters), additional pharmacokinetic 
system parameters (macro parameters) can be derived: 
1. Total distribution volume VT (defined as the ratio of the tracer concentration in tissue to 
the tracer concentration in plasma at equilibrium) 
1TCM "J = <7 Eq. 23 
2TCM "J = <7 D1 +
7.7IF Eq. 24 
2. Specific distribution volume VS (defined as the concentration ratio of specifically bound 
tracer in tissue to tracer in plasma at equilibrium) 
2TCM "K = <7.77I Eq. 25 
3. Distribution volume of non-displaceable uptake VND (concentration ratio of 
non-specifically bound tracer in tissue compartment C2 to tracer in plasma at 
equilibrium) 
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2TCM "L= = <7 Eq. 26 
for the 1TCM, VND equals VT 
4. Binding potential BPND (concentration ratio of specifically bound to non-displaceable 
tracer at equilibrium) 
2TCM >ML= = 7.7I Eq. 27 
The theoretical foundations of the outlined models and the mathematical solutions of the 
model equations are discussed in detail in [188, 242–245]. 
1.6.6 Logan graphical analysis 
Graphical analysis methods are based on mathematical transformation of the PET data into 
a linear plot whose slope and y-intercept represent pharmacokinetic parameters. An 
important graphical technique developed for determination of the total distribution volume 
VT of reversibly binding radiotracers is Logan graphical analysis (or Logan plot)[246, 247]. 
The Logan relationship can be derived from the differential equation defining the 1TCM 
(Eq. 20) by integration [188]: 
 () = < G(N)	N − 7 (N)	N

  Eq. 28 
Dividing by k2 and C2(t) and rearranging yields: 
 
 (N)	N () = "J ∗
 G(N)	N () −
17 Eq. 29 
In Eq. 28 and 29, CP refers to the radiotracer concentration in arterial plasma (input 
function) and C2 to the radiotracer concentration in brain tissue. The integration variable u 
relates to the continuous input function. The slope of this relationship equals VT in the 
1TCM. If the measured data are not consistent with the 1TCM, the Logan plot becomes linear 
after a certain time. Linear regression is then performed for those later data points and the 
slope represents an estimate of VT. Logan graphical analysis is independent of any particular 
model structure and computationally more robust than iterative non-linear compartmental 
model fits [248, 249]. In the present work, VT values derived from Logan plots served as 
comparison to assess reliability of VT values estimated via compartmental analysis. 
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2 Aims and Objectives 
The development of PET radiotracers is a multidisciplinary process which involves a series 
of iterative steps ranging from molecular target identification to clinical evaluation studies 
in humans. One important stage in this process is the structural modification of promising 
compounds in order to optimise relevant physicochemical and pharmacological parameters 
such as water solubility, target affinity and specificity, non-specific protein binding, blood-
brain barrier permeability and in vivo pharmacokinetics. Adequate pharmacokinetic 
properties are a decisive prerequisite for the successful application of a novel radiotracer in 
neuroimaging studies. Metabolism is one important factor contributing to in vivo 
pharmacokinetics of a radiotracer. Metabolic lability of a candidate radiotracer may result in 
rapid decrease of plasma radiotracer concentration and thus in insufficient brain exposure. 
This is particularly problematic if longer scan durations are required to properly image the 
molecular target. Additionally, fast radiotracer metabolism increases the risk that brain-
penetrant radiolabelled metabolites are generated in sufficient amounts to compromise the 
PET signal. However, metabolic degradation also supports fast clearance of radioactivity 
from the blood pool which, on the one hand, improves the signal-to-noise ratio obtainable 
during the PET scan and thus the image contrast, and, on the other hand, allows for shorter 
scan duration. These aspects illustrate the importance of a precise adjustment of the 
metabolic properties of lead compounds during the development process to produce 
promising imaging agents for in vivo application. Various in vitro techniques are available to 
evaluate metabolic stability of novel compounds during the preclinical stage. The potential 
and the limitations of these methods have been extensively evaluated in the field of drug 
discovery and development, however, with regard to the development of radiotracers, 
studies on the physiological relevance of in vitro metabolism models are rare. Since in vivo 
application of PET radiotracers differs greatly from the application of classical drugs in 
terms of the amount of administered substance (picomoles to nanomoles versus millimoles) 
and the period of time during which the fate of the substance in the body is monitored, the 
question rises whether the conclusions on the physiological relevance and predictive power 
of in vitro metabolism models reached in the context of drug evaluation studies are 
applicable to the field of radiotracer development. 
The aim of this work was to assess the relevance and validity of one of the most commonly 
applied models of in vitro drug metabolism, the microsomal stability assay, as a tool for the 
development of PET radiotracers. This central question should be investigated by 
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comparison of the in vitro metabolic stability and the in vivo pharmacokinetic properties of 
three xanthine-derived adenosine A1 receptor ligands in the rat model. One of these ligands, 
8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX), has already been established 
as PET radiotracer for imaging A1AR in vivo in animals and humans. However, since this 
compound is rapidly metabolised in vivo, considerable efforts have been made to develop 
metabolically stable structural analogues which may exhibit higher plasma levels and, as a 
possible consequence, also enhanced brain uptake. Two recently synthesised cyclobutyl-
substituted analogues of CPFPX, 8-cyclobutyl-3-(3-fluoropropyl)-1-propylxanthine (CBX) 
and 3-(3-fluoropropyl)-8-(1-methylcyclobutyl)-1-propylxanthine (MCBX) were chosen for 
comparative evaluation in the context of this work. 
The first objective was to investigate the influence of in vitro assay conditions (incubation 
matrix composition, concentration of microsomal protein, preincubation time) on the rate of 
metabolism of CBX, MCBX and CPFPX by rat liver microsomes with a particular focus on 
potential changes in the stability rank order of the three test compounds. Based on the 
results of these studies, the microsomal stability assay should be optimised in such a way as 
to provide physiological relevant metabolism data which are only marginally influenced by 
in vitro artefacts or bias. The optimised microsomal assay configuration should then be used 
to determine the in vitro metabolic stability of the test compounds. 
The next step was to evaluate the in vivo pharmacokinetic properties of CBX, MCBX and 
CPFPX in the rat model. For this purpose, the 18F-labelled compounds had to be 
administered to the animals and the time-course of plasma concentration measured 
invasively. From these data, suitable PK parameters had to be derived which enable the 
comparison of in vitro and in vivo metabolic stability of the test compounds. 
Subsequently, microsomal stability data and in vivo pharmacokinetic data should be 
compared in a suitable way and the possibilities and limitations of predicting in vivo 
radiotracer metabolism from in vitro metabolism data should be discussed. Special 
emphasis should be laid on the potential influence of confounding physiological factors such 
as plasma protein binding on the accuracy and reliability of prediction. In addition to the 
quantitative aspects of radiotracer metabolism, the utility of in vitro metabolism studies as 
predictive tool regarding the occurrence and relevance of individual metabolic pathways in 
vivo should be assessed. For this purpose, in vitro and in vivo metabolite profiles of CBX, 
MCBX and CPFPX generated in the rat model should be compared. 
In order to gain further insights into the qualitative and quantitative aspects of the 
metabolism of the test compounds, additional in vitro metabolism studies should be 
conducted using liver microsomes obtained from humans and various preclinical animal 
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species. These investigations should also provide a basis for selecting the most appropriate 
animal species for future in vitro and in vivo evaluation of novel xanthine-derived A1AR 
ligands. 
As a final point, cerebral distribution and kinetics of the three radiotracers should be 
comparatively evaluated using both in vitro autoradiography and in vivo PET. The results of 
these examinations should be discussed with special focus on the potential correlation 
between in vivo metabolic stability and cerebral kinetics of the test compounds. 
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3 Materials and Methods 
3.1 Chemicals 
Reduced β-nicotinamide adenine dinucleotide 2′-phosphate (NADPH) was purchased from 
Roche Diagnostics (Mannheim, Germany). β-Nicotinamide adenine dinucleotide 
2′-phosphate (oxidised form, NADP⁺), glucose-6-phosphate (G6P), glucose-6-phosphate 
dehydrogenase (G6P-DH), magnesium chloride (MgCl2), superoxide dismutase (SOD), 
catalase (CAT), plumbagin, diphenyleneiodonium chloride (DPI), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 4-morpholinepropanesulfonic acid (MOPS), 
2-amino-2-(hydroxymethyl)propane-1,3-diol (TRIS), potassium phosphate, tetra-n-butyl-
ammonium bromide (TBAB), guanosine-5'-triphosphate (GTP), N,N-dimethylformamide 
(DMF), dimethyl sulfoxide (DMSO), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 
ethylenediamine-tetraacetic acid (EDTA), acetic acid (HAc) and sodium hydroxide (NaOH) 
were purchased from Sigma-Aldrich (Steinheim, Germany). Reagent grade acetonitrile 
(ACN), methanol (MeOH), ethyl acetate, hexane and isopentane were obtained from Merck 
(Darmstadt, Germany). For preparation of eluents and buffers, aqua ad iniectabilia (water 
for injection) from B. Braun Melsungen (Melsungen, Germany) was used. Isoflurane for 
anaesthesia was purchased from CP-Pharma (Burgdorf, Germany). 
3.2 Substrates, reference standards and precursors 
All substrates, reference standards and precursors listed in Table 3 were synthesised and 
characterised in our laboratories except for CPFPX precursor which was purchased from 
ABX GmbH (Radeberg, Germany). 
  
Materials and Methods 37 
 
Table 3. Substrates, reference standards and precursors used in this work. TPSA and log P values 
were calculated with Molinspiration Property Calculator (Molinspiration Cheminformatics). 
Structural formula, numbering Name, physicochemical properties 
1 
 
8-Cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine 
(CPFPX) 
MW: 322.38 g/mol 
Log P: 2.93 
TPSA: 72.69 Å2 
2 
 
8-Cyclobutyl-3-(3-fluoropropyl)-1-propylxanthine 
(CBX) 
MW: 308.35 g/mol 
Log P: 2.19 
TPSA: 72.69 Å2 
3 
 
3-(3-Fluoropropyl)-8-(1-methylcyclobutyl)-1-propyl-
xanthine 
(MCBX) 
MW: 322.38 g/mol 
Log P: 2.82 
TPSA: 72.69 Å2 
4 
 
8-Cyclopentyl-3-(3-tosyloxypropyl)-7-pivaloyloxymethyl-1-
propylxanthine 
(CPFPX precursor) 
MW: 588.72 g/mol 
5 
 
8-Cyclobutyl-3-(3-mesyloxypropyl)-7-pivaloyloxymethyl-1-
propylxanthine 
(CBX precursor) 
MW: 498.59 g/mol 
6 
 
3-(3-Mesyloxypropyl)-8-(1-methylcyclobutyl)-7-pivaloyl-
oxymethyl-1-propylxanthine 
(MCBX precursor) 
MW: 512.62 g/mol 
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Structural formula, numbering Name, physicochemical properties 
7 
 
3-(3-Fluoropropyl)-8-(3-oxocyclopent-1-en-1-yl)-1-propyl-
xanthine 
(CPFPX metabolite) 
MW: 334.35 g/mol 
8 
 
8-(Cyclopent-3-en-1-yl)-3-(3-fluoropropyl)-1-propyl-
xanthine 
(CPFPX metabolite) 
MW: 320.36 g/mol 
9 
 
8-(Cyclopent-1-en-1-yl)-3-(3-fluoropropyl)-1-propyl-
xanthine 
(CPFPX metabolite) 
MW: 320.36 g/mol 
10 
 
3-(3-Fluoropropyl)-8-(3-hydroxycyclopentyl)-1-propyl-
xanthine 
(CPFPX metabolite) 
MW: 338.38 g/mol 
11 
 
3-(3-Fluoropropyl)-8-(2-hydroxycyclopentyl)-1-propyl-
xanthine 
(CPFPX metabolite) 
MW: 338.38 g/mol 
MW, molecular weight; log P, octanol-water partition coefficient; TPSA, topological polar surface area 
3.3 In vitro metabolism 
3.3.1 Microsomes 
Human liver microsomes (HLM, total P450 content: 0.286 nmol/mg protein), dog (Beagle) 
liver microsomes (DLM), mini pig (Göttingen) liver microsomes (MPLM), mouse (CD-1) liver 
microsomes (MLM), monkey (rhesus) liver microsomes (RMLM) and rat (Sprague Dawley) 
liver microsomes (RLM) were purchased from Thermo Fisher Scientific/Life Technologies 
(Darmstadt, Germany). 
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3.3.2 General microsomal incubation procedures 
All microsomal incubations were conducted at 37°C with continuous gentle agitation 
(300 rpm) using a thermomixer device (Thermomixer Comfort, Eppendorf, Hamburg, 
Germany). Cofactor NADPH was added either directly (protocol A) or generated in situ using 
a cofactor regeneration system (CRS) consisting of NADP⁺, G6P and G6P-DH (protocol B). 
Total incubation volume was 500 µl (single time point assays) or 1000 µl (multiple time 
point assays). 10 mM stock solutions of CBX, MCBX and CPFPX were prepared in DMSO or 
DMF and stored in the dark and at 4°C up to one year. 1 mM working solutions were freshly 
prepared every month and stored in the dark at room temperature (21°C). Generally, liver 
microsomes (0.4 mg/ml microsomal protein), substrate (8 µM), MgCl2 (3.3 mM) and, for 
protocol B, G6P (3.3 mM) and G6P-DH (0.4 U/ml) were mixed with buffer and preincubated 
for 5 min at 37°C. Reaction was initiated by addition of preheated (37°C) NADPH (1.3 mM, 
protocol A) or NADP⁺ (1.3 mM, protocol B). Aliquots (100 µl) were removed at appropriate 
time points (including one sample removed directly after cofactor addition, i.e. t = 0 min) 
and added to an equal volume of methanol/acetonitrile (50:50, v/v, -20°C) to terminate the 
reaction. The samples were homogenised on a vortex mixer (1 min, 21°C) and centrifuged 
(20,000 rcf, 10 min, 21°C) to sediment precipitated protein. The supernatants were 
analysed on a Knauer smartline HPLC-UV/VIS system (Knauer, Berlin, Germany) equipped 
with a manual sample injector (Rheodyne type 7125) and a 500 µl sample loop. Isocratic 
elution was performed using a Kromasil 100-5 C18 (4.6x250 mm) analytical column 
(AkzoNobel, Bohus, Sweden) and a mobile phase composed of ACN/H2O/HAc 48:52:0.2 
(v/v/v). Injection volume was 50 µl, flow rate 1 ml/min and detection wavelength 275 nm. 
Specific incubation conditions and deviations from the general procedures are listed in the 
following sections. Substrate depletion was calculated from the area ratios of the analyte 
peak, using the value at t = 0 min as 100%. 
3.3.3 Evaluation of incubation conditions 
3.3.3.1 Influence of buffer medium, substrate solvent and cofactors 
CBX, MCBX and CPFPX (8 µM) were incubated with RLM (0.4 mg/ml microsomal protein) 
for 30 min in a final volume of 500 µl according to either protocol A or B. For individual 
assays, buffer composition (buffer substance, concentration, pH), substrate solvent 
(substance, final concentration), and cofactor supply (NADPH, CRS) were varied according 
to Table 4. Aliquots sampled at 0 and 30 min were processed as described above. 
Incubations were conducted in quadruplicate. The data were analysed for statistically 
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significant differences between incubation parameter sets by performing one-way ANOVA 
(p<0.05) with post-hoc Tukey test. 
Table 4. Individual composition of microsomal assays used for evaluation of incubation conditions. 
Assays were conducted as described in general incubation procedures. 
Incubation 
No. 
Buffer  Substrate Solvent 
Protocol* 
NADPH 
Final Conc. Substance Concentration pH  Substance Final Conc. 
  mM    vol %  mM 
1 Phosphate 100 7.4  DMF 0.8 B  
2 MOPS 100 7.4  DMF 0.8 B  
3 HEPES 100 7.4  DMF 0.8 B  
4 HEPES 200 7.4  DMF 0.8 B  
5 HEPES 500 7.4  DMF 0.8 B  
6 HEPES 50 7.4  DMF 0.8 B  
7 HEPES 100 6.8  DMF 0.8 B  
8 HEPES 100 8.2  DMF 0.8 B  
9 HEPES 100 7.4  DMF 0.8 A 1.3 
10 HEPES 100 6.8  DMF 0.8 A 1.3 
11 HEPES 100 8.2  DMF 0.8 A 1.3 
12 HEPES 100 7.4  DMF 1.5 B  
13 HEPES 100 7.4  DMF 2.0 B  
14 HEPES 100 7.4  DMSO 0.08 B  
15 HEPES 100 7.4  DMSO 0.8 B  
16 HEPES 100 7.4  DMSO 1.5 B  
17 HEPES 100 7.4  DMSO 2.0 B  
18 HEPES 100 7.4  DMSO 0.08 A 1.3 
19 HEPES 100 7.4  DMSO 0.8 A 1.3 
20 HEPES 100 7.4  DMSO 2.0 A 1.3 
21 HEPES 100 7.4  DMSO 0.8 A 1.0 
22 HEPES 100 7.4  DMSO 0.8 A 0.78 
23 HEPES 100 7.4  DMSO 0.8 A 0.26 
* protocol A, direct addition of NADPH; protocol B, addition of CRS 
3.3.3.2 Influence of enzyme concentration 
CPFPX (8 µM, stock solution in DMSO) was preincubated with RLM (0.2, 0.4 or 0.8 mg/ml 
microsomal protein) in HEPES buffer (100 mM, pH 7.4, 3.3 mM MgCl2) for 3 min at 37°C. 
Reaction was commenced by addition of preheated NADPH (1.3 mM). Aliquots were 
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sampled at 0 and 3 min and processed as described in general procedures. Incubations were 
conducted in quadruplicate. An external calibration curve (see below) was used to quantify 
the concentration of CPFPX in the samples. Initial velocities (v0) were derived from the 
slopes of the concentration-time graphs, plotted against the concentration of microsomal 
protein and analysed via linear regression analysis. 
External calibration curve 
Seven CPFPX calibration standards (1-12 µM) were prepared from the CPFPX stock solution 
by dilution with eluent and injected into the HPLC (single injection). The chromatographic 
conditions were analogous to those applied to regular microsomal samples (see general 
procedures). The resulting peak area versus concentration data were fitted to a linear 
regression model (Fig. 12). 
 
Fig. 12. External calibration curve for quantification of CPFPX in microsomal extracts. 
Chromatographic conditions were the same as described in general microsomal incubation 
procedures. Each calibration standard was injected once. 
3.3.3.3 Influence of preincubation time 
RLM (0.4 mg/ml microsomal protein), MgCl2 (3.3 mM) and NADPH (1.3 mM) were mixed 
with HEPES buffer (100 mM, pH 7.4) and preincubated for 2, 10, 30, 60 and 120 min at 37°C. 
Addition of CPFPX (8 µM, stock solution in DMSO) initiated the enzymatic reaction which 
was allowed to proceed for 5 min. CAT (1 U/ml, 1500 U/ml), SOD (100 U/ml, 1000 U/ml) or 
a mixture of both CAT and SOD (1000 U/ml each) was added to several incubations to 
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evaluate the effect of ROS scavengers on enzyme lability. Samples taken at 0 and 5 min were 
processed and analysed as described above. Incubations were conducted in triplicate. 
3.3.4 Stability assessment of NADPH 
Stability of NADPH during incubation was examined using procedures that resembled 
microsomal incubation protocols A and B. NADPH (1.3 mM) was incubated at 37°C either in 
buffer alone (HEPES, 100 mM, pH 7.4, 3.3 mM MgCl2) or in buffer containing microsomal 
protein (0.4 mg/ml RLM). EDTA (5 mM), DPI (25 µM, 100 µM), or plumbagin (1 µM) was 
added to some incubations to test for potential effects on NADPH stability. Aliquots sampled 
from the incubation mixture at appropriate time points were quenched by rapid dilution 
(1:100) with cold (-20°C) potassium phosphate buffer (100 mM, pH 9.0) containing 10 mM 
TBAB. Quenched samples were kept at -20°C until HPLC analysis. The suitability of the 
quenching protocol was evaluated via repeated analysis of samples within a time interval of 
24 h. Isocratic HPLC elution was performed using a Kromasil C18 column (see general 
procedures), a mobile phase consisting of MeOH/potassium phosphate buffer (100 mM, 
pH 6.0, 10 mM TBAB) 25:75 (v/v) and a flow rate of 1 ml/min. Detection wavelengths were 
340 and 260 nm to monitor both NADPH and NADP⁺. Incubations were conducted in 
triplicate. 
Additionally, the time-course of NADPH regeneration from CRS was studied. RLM 
(0.4 mg/ml microsomal protein), MgCl2 (3.3 mM), G6P (3.3 mM) and G6P-DH (0.4 U/ml) 
were mixed with buffer and preincubated for 5 min at 37°C. Enzymatic reaction was 
initiated by addition of preheated NADP⁺ (1.3 mM). Aliquots were removed at appropriate 
time points and processed as described above. 
3.3.5 In vitro microsomal half-life determination 
For determination of in vitro microsomal t1/2, depletion-time profiles of CBX, MCBX and 
CPFPX in RLM and HLM were generated using incubation protocol A with optimised 
parameters. 
CBX, MCBX and CPFPX (8 µM, stock solutions in DMSO, final DMSO concentration 0.8%) 
were incubated with either RLM (0.5 mg/ml) or HLM (3.0 mg/ml) in HEPES buffer 
(100 mM, pH 7.4, 3.3 mM MgCl2). After 5 min of preincubation, the reaction was initiated by 
addition of NADPH (1.3 mM, preheated to 37°C). Final incubation volume was 1 ml. Aliquots 
were removed at 0, 2, 5, 10, 15, 20, 25 and 30 min (RLM) or 0, 5, 10, 15, 20, 30 min (HLM) 
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and processed as described in general procedures. RLM assays were conducted in triplicate, 
HLM assays in duplicate. Data were analysed via non-linear curve fitting. 
3.3.6 Species differences in microsomal metabolism 
To assess interspecies variations in microsomal activity, CBX, MCBX and CPFPX (8 µM, stock 
solutions in DMSO) were incubated with 0.4 mg/ml RLM, MLM, DLM and MPLM, 0.4 and 
2.0 mg/ml HLM and 0.04 mg/ml RMLM according to protocol A. Incubation time was 
30 min, total volume 500 µl. All incubations were conducted in quadruplicate. 
To generate species-specific in vitro metabolite profiles, CBX, MCBX and CPFPX (10 µM) 
were incubated with liver microsomes according to protocol A (1 ml total incubation 
volume). The respective incubation times and microsomal protein concentrations are given 
in Table 5. Blank samples were included containing all matrix components except for 
substrate. Following incubation, samples were quenched with 2 volumes of ACN/MeOH 
(50:50, v/v, -20°C), vortexed (1 min, 21°C), centrifuged (20,000 rcf, 10 min, 21°C) and 
evaporated to dryness using a centrifugal vacuum concentrator (Concentrator 5301, 
Eppendorf) set to 45°C. Samples were subsequently reconstituted with 160 µl HPLC eluent 
consisting of ACN/H2O/HAc 35:65:0.1 (v/v/v) and centrifuged for 3 min at 20,000 rcf 
(21°C). 25 µl of the clear supernatant was injected onto a Kromasil C18 column (see general 
procedures) equipped with a 3 mm NH2 guard column (OPTI-GUARD, Optimize 
Technologies). Flow rate was 1 ml/min, detection wavelength 275 nm. Peaks in the 
chromatograms were distinguished from matrix components by visual comparison with the 
blank samples. Retention factors (k) of the metabolites were calculated as 
 7 = P −   Eq. 30 
with tR, retention time and t0, dead time. 
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Table 5. Species-specific microsomal incubation conditions for generation of in vitro metabolite 
profiles. All other parameters are specified in the general incubation procedures (protocol A). 
Microsomes Substrate 
Microsomal protein 
concentration 
Incubation time 
  mg/ml min 
HLM CBX, MCBX, CPFPX 0.8 180 
RLM CBX, MCBX, CPFPX 0.4 30 
MLM CBX, MCBX, CPFPX 0.4 30 
DLM CBX, MCBX, CPFPX 0.8 45 
MPLM CBX 0.8 45 
 MCBX, CPFPX 0.8 30 
RMLM CBX 0.04 45 
 MCBX, CPFPX 0.04 30 
 
3.3.7 Enone metabolite formation 
In preliminary studies, the potential enone precursor species 8-11 (8 µM) were incubated 
with RLM (0.4 mg/ml) and HLM (0.8 mg/ml) for up to 4 h according to protocol A. Multiple 
samples were taken during incubation and processed as described in general procedures. 
The samples were analysed with regard to the appearance of 7 in the chromatograms. Peak 
identities were verified by comparison of the retention times with standard solutions of 7 
and by conduction of additional spike experiments. 
The time-course of formation of 7 from precursor 9 was assessed by incubation of 9 (4 µM) 
with either 1.0 mg/ml HLM for 150 min or 0.4 mg/ml RLM for 100 min according to 
protocol A with prolonged centrifugation (15 min) of the quenched samples. 
Chromatographic separation was performed on a Kromasil C18 column (see general 
procedures) equipped with a 3 mm NH2 guard column (OPTI-GUARD, Optimize 
Technologies) and an eluent composed of ACN/H2O/HAc 45:55:0.1 (v/v/v). All other 
chromatographic parameters were the same as those described in general procedures. 
3.4 Radiotracer production 
[18F]CPFPX was synthesised in-house as described previously [226]. [18F]CBX and 
[18F]MCBX were synthesised analogous to [18F]CPFPX with minor adjustments of the 
chromatographic separation procedure (HPLC column: Kromasil 100-5 C18, 250x10 mm 
(AkzoNobel, Bohus, Sweden); eluent: MeOH/H2O/HAc 60:40:0.2 (v/v/v)). Radiochemical 
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purity of the first [18F]CBX batches ranged from 95% to 97%. These batches were used 
exclusively for metabolism studies where radiochemical purity is not a critical parameter. 
For evaluation of brain kinetics and in vitro autoradiography, only batches with 
radiochemical purity >98% were used. 
3.5 In vitro autoradiography 
Whole brains of female Wistar rats were rapidly removed after decapitation of the animals 
and immediately frozen in isopentane (-50°C). The brains were cut into 20 µm slices using a 
Leica CM3050 cryostat (Leica Biosystems, Nussloch, Germany) which was set to a 
temperature of -20°C. Sections were thaw-mounted onto silica-coated object slides, dried 
for 1 h at 37°C and stored in vacuum-sealed plastic bags at -80°C until use. Slices were 
preincubated in 50 mM TRIS buffer (pH 7.4) for 10 min (21°C) and subsequently incubated 
in 50 mM TRIS buffer (pH 7.4) containing 100 µM GTP and 0.4-0.5 nM [18F]CBX, [18F]MCBX 
or [18F]CPFPX for 120 min (21°C). For estimation of non-specific binding, the competing 
ligand DPCPX (13 µM) was added to some incubations. The slices were washed twice in 
TRIS buffer (21°C) for 1 min, immersed in deionised water (4°C) to remove salt and dried 
under a stream of dry, warm (30°C) air for about 15 min. Subsequently, the dry slices were 
exposed to a phosphor imaging plate for 3-5 min, scanned with a phosphor imager 
(BAS 5000, Fujifilm, Düsseldorf, Germany) and analysed with appropriate software (AIDA 
Image Analyzer V4.13, Raytest, Straubenhardt, Germany). To estimate total and non-specific 
binding of the radiotracers, regions of interest (ROIs) were drawn around the entire brain 
slices and deposited energies within these ROIs were quantified. Specific binding was 
calculated as the difference between total and non-specific binding. Mean values were 
determined from 7-8 incubated slices per tracer. 
3.6  In vivo pharmacokinetics 
3.6.1 Animals 
All animal experiments were conducted in accordance with the German Animal Welfare Act 
and approved by the governmental authorities (AZ: 84-02.04.2014.A496). Adult male 
Sprague Dawley rats (n = 33, body weight = 505 ± 43 g) were housed two to three per cage 
under standard conditions (12-h light/12-h dark cycle, 22°C) with access to food and water 
ad libitum. Data sets of 26 animals were included in the evaluation. 
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3.6.2 Blood sampling and analysis 
The animals were anesthetised with a mixture of isoflurane/oxygen (5% isoflurane during 
induction, 1.5–2% during maintenance of anaesthesia). Respiratory rate and body 
temperature were controlled during anaesthesia and kept within physiological ranges. A 
catheter was placed in the right femoral artery for blood sampling; another catheter was 
placed in the tail vein for radiotracer application. [18F]CPFPX, [18F]MCBX or [18F]CBX 
(21 ± 2.5 MBq (0.44 ± 0.22 nmol) in a volume of 1 ml physiological saline solution) was 
administered over 1 min using a syringe pump (model 44, Harvard Apparatus, Holliston, 
USA). Arterial blood samples (ca. 200µl) were collected at regular time intervals throughout 
the 180-min measurement. Details on the blood sampling procedure can be found in [215]. 
Total blood sampling volume was keep below 10% of the circulating blood volume of the 
animal. The blood samples were weighted and measured in a γ-counter (ISOMED 2100, MED 
Nuklear-Medizintechnik Dresden GmbH, Dresden, Germany) to calculate whole blood 
radioactivity concentration. Plasma was separated by centrifugation (3000 rcf, 3 min, 21°C), 
weighted and measured in the γ-counter to calculate plasma radioactivity concentration. 
Fractions of unchanged tracer and radiometabolites in plasma were assessed by radio-thin 
layer chromatography (TLC) analysis. Aliquots (45 µl) of plasma were mixed with 3 volumes 
of methanol/acetonitrile (50:50, v/v, 4°C), vortexed (1 min, 21°C) and centrifuged 
(20,000 rcf, 5 min, 21 C) to sediment precipitated protein. Aliquots (5 µl) of the 
supernatants were spotted on a TLC plate (SIL G-25, 10x20 cm, Macherey-Nagel, Düren, 
Germany). The TLC plate was developed with ethyl acetate/hexane, 75:25 (v/v), dried and 
subsequently imaged for 50 min with an electronic autoradiography system (InstantImager, 
Canberra-Packard, Rüsselsheim, Germany). Using the implemented InstantImager software, 
ROIs were defined for unchanged tracer and metabolites. Radioactivity within these ROIs 
was quantified and used for calculation of the fraction of unchanged tracer. Retardation 
factors (Rf) of the metabolites were calculated as the ratio of the migration distance of the 
metabolite (centre of the spot) to the migration distance of the solvent front. To determine 
the recovery of radioactivity after the extraction step, aliquots (5 µl) of both supernatant 
and native plasma were spotted on a separate TLC plate which was not developed. This 
plate was imaged simultaneously with the first one. Recovery was calculated as the ratio of 
radioactivity in supernatant to that in plasma, corrected for the dilution factor. Whole blood 
and plasma time-activity curves (TACs) were generated and decay corrected to the time of 
tracer injection. Standardised uptake values (SUVs) of whole blood and plasma were 
calculated according to the following formula [250]: 
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 Q" = R(0′ T⁄ ) Eq. 31 
where r is the radioactivity concentration, a’ is the amount of injected radioactivity (decay 
corrected) and w is the body weight. For both whole blood and plasma, a specific density of 
1 g/ml was assumed. Plasma SUV versus time data were fitted to triexponential functions. 
Total clearance (CL), volume of distribution (Vd) and terminal half-life (t1/2γ) of the tracers 
were estimated from the fitted parameters via non-compartmental analysis (see section 
1.5.3.2). 
3.6.3 Plasma protein binding 
An additional blood sample was taken before tracer injection to assess the plasma protein 
binding of the tracer. 200–300 µl of the separated plasma was spiked with tracer (5-6 kBq) 
and incubated for 1 h at 37°C and 300 rpm in a thermomixer device (Thermomixer Comfort, 
Eppendorf, Hamburg, Germany). Plasma proteins were removed via ultrafiltration using 
Microcon-30 kDa centrifugal filter units (Merck Millipore, Darmstadt, Germany). The filter 
units were centrifuged for 20 min at 14,000 rcf and 37°C. Radioactivity in equal volumes 
(50 µl) of spiked plasma and filtrate was measured in a γ-counter. Calculated free fractions 
were used only for comparison of the physicochemical properties of the tracers. For kinetic 
analyses, a free fraction of 1 was assumed for all tracers. 
3.6.4 Brain PET imaging 
Four animals per tracer received an additional brain PET scan which was performed on a 
Siemens Inveon PET/CT Multimodality System (Siemens, Erlangen, Germany). The 
catheterised animals were positioned in the scanner with the brain in the field of view. Prior 
to tracer administration, a 20-min transmission scan (57Co source) was carried out to 
correct for attenuation. PET acquisition (180 min) started simultaneously with tracer 
injection. List-mode PET data were reframed into a dynamic sequence of 12x10 s, 6x30 s, 
15x60 s, 8x300 s and 12x600 s frames. The data were corrected for random coincidences, 
scattered radiation and attenuation, rebinned into 2-dimensional sinograms (Fourier 
Rebinning Algorithm) and reconstructed via filtered backprojection (ramp filter, cutoff: 0.5). 
The final datasets consisted of 159 slices with an image voxel size (x, y, z) of 0.7764, 0.7764, 
0.796 mm (matrix size (x, y, z, t): 128, 128, 159, 53). 
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3.6.5 Analysis of brain PET data 
Brain PET data were analysed using the PMOD V 3.4 software package (PMOD Technologies 
LLC, Zürich, Switzerland). Three-dimensional regions of interest were drawn manually or 
semi-automatically (iso-contour algorithm) around the entire brain. Whole brain TACs and 
SUVs were calculated, assuming a specific density of 1 g/mL for brain tissue. Time-weighted 
average SUV images (time window: 0-60 min post injection (p.i.); SUV maximum set to 
5 g/ml) were generated for visual illustration. Cerebral pharmacokinetics of [18F]CPFPX, 
[18F]MCBX and [18F]CBX were evaluated using both graphical and compartmental analysis. 
Metabolite corrected arterial plasma TACs served as input functions for kinetic modelling. 
Logan graphical analysis was used to determine total cerebral distribution volume (VT) of 
the tracers. Individual transfer rate constants and macro parameters were estimated from 
two-tissue compartment model fits of dynamic whole brain PET data. For [18F]CBX, only VT 
and specific volume of distribution (VS) could be estimated reliably from 2TCM fits of the 
data, therefore, additional one-tissue compartment model fits were used to derive the influx 
and efflux rate constants K1 and k2. Iterative fitting was performed using a Levenberg-
Marquardt algorithm (non-linear least squares minimisation procedure). Residual 
weighting took into account frame duration, radioactive decay and, if appropriate, measured 
uptake. The fractional blood volume was fixed to a value of 3.6% [251]. No correction was 
applied for the time delay between the blood and tissue activity curves. The applied 
pharmacokinetic methods and models are described in detail in sections 1.6.5 and 1.6.6. 
3.7 Statistical methods 
Values are given as mean ± SD unless stated otherwise. For statistical analyses, OriginPro 
2015G (OriginLab, Northampton, USA) and GraphPad Prism 4 (GraphPad Software, La Jolla, 
USA) were used. Significant differences between the means of individual test groups were 
assessed by using either an independent two-tailed t-test or a one-way analysis of variance 
(one-way ANOVA) followed by a post-hoc Tukey test. The significance level was set to 0.05. 
Normal distribution of the data and homogeneity of variances were assumed. In the 
following, the principles of the applied methods are outlined briefly. A comprehensive 
summary including the mathematical principles can be found in [252]. 
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3.7.1 Independent t-test 
The independent t-test is a statistical hypothesis test which is commonly used to determine 
whether the means of two independent (unrelated) groups differ significantly from each 
other. It is based on the t-distribution which represents a continuous, bell-shaped 
probability distribution similar to the normal distribution [253]. The t-distribution is used 
to estimate population parameters from small samples of populations with (nearly) normal 
distribution. The independent t-test discriminates between two statistical hypotheses: the 
null hypothesis which states that there is no difference between the means of the two 
groups and the alternative hypothesis which states that there is a difference between them. 
When performing a t-test, the group means, standard deviations and group sizes are used to 
calculate the t-test statistic (t-value) from which a p-value is derived which represents the 
probability that the null hypothesis is true, i.e. that the means of the two groups are not 
significantly different. The p-value is then compared to a pre-set significance level (α) which 
indicates the risk of rejecting the null hypothesis although it is true. If the p-value is less 
then α, the null hypothesis is rejected and the two test groups are stated to be significantly 
different. Typically, the significance level is set to 0.05, this means that a 5%-risk of 
erroneously rejecting the null hypothesis (type 1 error) is accepted. A t-test can be 
performed in either one-tailed or two-tailed configuration, depending on the exact 
formulation of the alternative hypothesis. With the one-tailed t-test, statistical significance is 
tested in only one direction of interest, i.e. the test determines either if one mean is greater 
than another mean or if it is less, but not both. In contrast, the two-tailed t-test evaluates 
significance in both directions simultaneously and thus allows for statements on whether 
two means are significantly different from each other irrespective of whether the effect is 
positive or negative. 
3.7.2 One-way ANOVA 
The one-way ANOVA is employed to test for significant differences among three or more 
group means. ANOVA uses F-tests [254] to determine whether the variability between 
group means is larger than the variability within the groups. If the ratio of between-group 
variability to within-group variability (F-value) is high enough, the null hypothesis (which 
states that the group means are equal) can be rejected. As with the t-test, a p-value (the 
probability that the null hypothesis is true) is calculated from the F-test statistic and 
compared to a pre-set significance level α. The null hypothesis is rejected if the p-value is 
lower than α. The one-way ANOVA is the simplest form of ANOVA tests, since it examines 
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the effect of only one factor on a dependent variable [255]. This is equivalent to the t-test. 
Following a significant ANOVA test result, a post-hoc analysis is performed to determine 
which group means are significantly different. In this work, the Tukey test [256] was applied 
to compare the individual means. The Tukey test compares each mean to every other mean 
(all pairwise comparisons) while controlling the increase in type 1 error arising from 
multiple statistical testing. A concise summery on the principles of the Tukey test can be 
found in [257]. 
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4 Results and Discussion 
4.1 In vitro microsomal metabolism 
4.1.1 Influence of incubation conditions on substrate depletion 
4.1.1.1 Incubation matrix composition 
Generally, evaluation of microsomal incubation conditions was done within physiologically 
relevant parameter ranges. The effects of changes in incubation matrix composition on the 
metabolic depletion of CBX, MCBX and CPFPX are summarised in Fig. 13. From these data, 
the ratios of depletion of CBX and MCBX to CPFPX were calculated (Fig. 14). The results of 
statistical data analysis (significant group differences) are listed in Table 6. 
In order to assess the potential influences of the buffer substance on microsomal 
degradation of the test compounds, three buffers were compared which are frequently used 
in enzyme assays: sodium phosphate, MOPS and HEPES buffer. TRIS buffer, although 
offering a suitable pH range, was excluded from the evaluation, since preliminary tests 
showed that this buffering agent adversely affects chromatographic performance during 
sample analysis. Metabolic activity in liver microsomes (as measured by substrate 
depletion) was about 25% higher in HEPES than in sodium phosphate buffer. With MOPS 
buffer, comparable increases in metabolic activity were obtained for CBX and MCBX, 
whereas for CPFPX, depletion in MOPS and sodium phosphate buffer did not differ 
significantly. Since HEPES buffer provided best support of enzymatic degradation of CBX, 
MCBX and CPFPX in RLM and exhibited good chromatographic properties, this buffer type 
was chosen for all further incubations. 
The reduced metabolic activity observed with sodium phosphate buffer could possibly be 
attributed to an inhibitory effect of the phosphate ion towards G6P-DH [258], which may 
result in a deceleration of NADPH regeneration, or to the complexation of Mg2+ ions which 
are known to exhibit a stimulatory effect on the microsomal metabolism of several 
substrates [259]. It is also conceivable that differences in the ionic strength of the buffer 
preparations [260] may lead to conformational alterations of the enzymes which affect 
substrate binding and conversion. However, as the influence of the buffer type on metabolic 
activity was not particularly pronounced, this parameter is not considered critical. 
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The effect of buffer concentration on substrate depletion was evaluated using HEPES buffers 
ranging from 50–500 mM. This concentration range reflects physiological intracellular ionic 
strength which is typically in the range of 150-200 mM [261]. Since buffer molecules are 
generally the main ionic species in microsomal stability assays, buffer molarity can be 
considered decisive for in vitro ionic strength. Medium buffer concentrations (100 or 
200 mM HEPES) proved to be favourable in terms of metabolic activity. Increasing the 
buffer concentration from 100 to 500 mM caused a significant decrease of CPFPX depletion 
(by 13%), but not of CBX and MCBX depletion. Decreasing the buffer concentration from 100 
to 50 mM resulted in reduced depletion of MCBX and CPFPX (by 14% and 25%, 
respectively), but also in a marked shift of the pH value of the incubation matrix towards 
more acidic conditions (approx. pH 7.2), indicating an insufficient buffer capacity. Further 
studies on the influence of buffer pH on substrate depletion clearly showed an adverse effect 
of lower pH values on enzyme activity (see below), which suggests that the deceleration of 
substrate degradation observed with the use of 50 mM HEPES buffer is caused by the pH 
shift rather than by the lower ionic strength of the medium. 
The influence of pH on metabolic activity was quite pronounced. For both protocol A 
(NADPH) and protocol B (CRS), substrate depletion was highest in microsomal incubations 
conducted at pH 7.4. At a pH value of 6.8, CBX depletion decreased by 44% (protocol A) or 
48% (protocol B), MCBX depletion by 45% (protocol A) or 58% (protocol B) and CPFPX 
depletion by 51% (protocol A) or 65% (protocol B). When incubations were conducted 
according to protocol A, an increased pH value of 8.2 resulted in a considerable reduction of 
CPFPX and MCBX depletion by 29% and 37%, respectively. In contrast, when incubations 
where conducted using a CRS (protocol B), the more basic conditions only affected CPFPX 
depletion in a significant way (12% decrease). The varying magnitude of pH dependent 
decrease in metabolic activity observed when NADPH was supplied either directly or via a 
CRS might be a consequence of different pH optima of the individual enzymes involved in 
the catalytic cycle. G6P-DH typically shows maximum catalytic activity at pH values above 
7.4 depending on the buffer medium [262]. Enhanced supply of NADPH by G6P-DH could 
partially compensate negative effects of increased pH values on catalytic activity of 
cytochrome P450 enzymes or cytochrome P450 reductase, resulting in a less pronounced 
decline of substrate metabolism. 
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Fig. 13. Influence of incubation matrix composition on depletion of CBX, MCBX and CPFPX in rat liver 
microsomes. Bars represent the loss of substrate during an incubation period of 30 min. For every 
data set, the detailed composition of the incubation matrix is given in Table 4. Data represent the 
mean ± SD of four independent experiments. Results of statistical evaluation are given in Table 6. 
Studies on the effect of organic solvents on enzyme activities were limited to DMF and 
DMSO due to the inadequacy of other frequently used solvents (alcohols, alkanes, ketones, 
tetrahydrofuran) to dissolve sufficient quantities of the xanthine derivatives. DMF exhibited 
considerably higher inhibitory potential than DMSO. Depletion of the test compounds was 
16–42% lower when incubations contained 0.8% DMF instead of 0.8% DMSO and 97–145% 
lower when incubations contained 2.0% DMF instead of 2.0% DMSO. Since DMSO proved to 
be favourable in terms of enzyme activity, investigations concerning the influence of 
cofactor supply (NADPH vs. CRS) were conducted exclusively with DMSO. At DMSO 
concentrations above 0.08%, direct addition of NADPH resulted in a marked enhancement 
of metabolic activity. Substrate depletion was increased by 19-29% compared to 
incubations using a CRS. However, at 0.08% DMSO, direct addition of NADPH did not result 
in considerable differences in metabolic activity. 
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Table 6. Results of statistical evaluation of the data visualised in Fig. 13. Evaluation was performed 
using one-way ANOVA with post-hoc Tukey test. P<0.05 was considered statistically significant. 
Parameter Means comparison Significant difference 
Buffer type 
MOPS vs. Phosphate CBX, MCBX 
HEPES vs. Phosphate CBX, MCBX 
HEPES vs. MOPS CPFPX 
Buffer concentration 
HEPES 200 mM vs. 100 mM - 
HEPES 500 mM vs. 100 mM CPFPX 
HEPES 500 mM vs. 200 mM CBX, CPFPX 
HEPES 50 mM vs. 100 mM MCBX, CPFPX 
HEPES 50 mM vs. 200 mM CBX, CPFPX 
HEPES 50 mM vs. 500 mM CPFPX 
pH (CRS) 
pH 6.8 vs. pH 7.4 (CRS) CBX, MCBX, CPFPX 
pH 8.2 vs. pH 7.4 (CRS) CPFPX 
pH 8.2 vs. pH 6.8 (CRS) CBX, MCBX, CPFPX 
pH (NADPH) 
pH 6.8 vs. pH 7.4 (NADPH) CBX, MCBX, CPFPX 
pH 8.2 vs. pH 7.4 (NADPH) CBX, MCBX, CPFPX 
pH 8.2 vs. pH 6.8 (NADPH) MCBX, CPFPX 
DMF concentration 
DMF 1.5% vs. 0.8% CBX, MCBX, CPFPX 
DMF 2.0% vs. 1.5% CBX, MCBX, CPFPX 
DMF 2.0% vs. 0.8% CBX, MCBX, CPFPX 
DMSO concentration 
(CRS) 
DMSO 0.8% vs. 0.08% (CRS) CBX, MCBX, CPFPX 
DMSO 1.5% vs. 0.08% (CRS) CBX, MCBX, CPFPX 
DMSO 1.5% vs. 0.8% (CRS) MCBX, CPFPX 
DMSO 2.0% vs. 0.08% (CRS) CBX, MCBX, CPFPX 
DMSO 2.0% vs. 0.8% (CRS) CBX, MCBX, CPFPX 
DMSO 2.0% vs. 1.5% (CRS) CPFPX 
DMSO concentration 
(NADPH) 
DMSO 0.8% vs. 0.08% (NADPH) MCBX, CPFPX 
DMSO 2.0% vs. 0.08% (NADPH) CBX, MCBX, CPFPX 
DMSO 2.0% vs. 0.8% (NADPH) CBX, MCBX, CPFPX 
NADPH concentration 
NADPH 1.0 mM vs. 1.3 mM - 
NADPH 0.78 mM vs. 1.3 mM - 
NADPH 0.78 mM vs. 1.0 mM - 
NADPH 0.26 mM vs. 1.3 mM MCBX, CPFPX 
NADPH 0.26 mM vs. 1.0 mM MCBX, CPFPX 
NADPH 0.26 mM vs. 0.78 mM CBX, MCBX, CPFPX 
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With regard to the enzyme-substrate systems evaluated in the present study, DMF showed 
considerably stronger inhibitory effects on microsomal metabolism than DMSO. By contrast, 
Hickman et al. observed only slight inhibition of caffeine N3-demethylation in HLM by DMF 
but substantial inhibition by DMSO [263]. The insufficient transferability of results obtained 
with quite similar enzyme-substrate systems becomes even more apparent when comparing 
the extent of inhibition produced by a particular solvent. The inhibitory effect of DMSO on 
P450 1A2 has been the subject of numerous studies with sometimes controversial results. 
Some authors reported only slight inhibition of biotransformation at DMSO concentrations 
of up to 2% [264–266], whereas others observed a medium to high inhibitory potential even 
at concentrations as low as 0.2% [263, 267, 268]. The test systems used in these studies 
differed with regard to enzyme preparation (microsomes, isoenzymes, hepatocytes), species 
from which the enzymes originated (human, rat), test substrate/test reaction (phenacetin O-
deethylation, caffeine N3-demethylation) and composition of the incubation medium. These 
widely varying results illustrate that the inhibitory potential of organic solvents on a given 
enzyme-substrate system cannot be predicted reliably on the basis of published studies 
which used slightly different experimental setups, but has to be investigated experimentally. 
Increasing DMSO concentrations had more pronounced effects on metabolic activity when 
NADPH was supplied indirectly via a CRS. Apparently, DMSO did not only inhibit the 
CYP/CPR system, but also G6P-DH, resulting in further reduction of substrate depletion 
rates. Only at very low DMSO concentrations (0.08%), this additional effect becomes 
negligible, so that no significant difference could be observed between incubations 
conducted according to either protocol A or B. Although DMSO concentrations below 0.1% 
proved to be advantageous in terms of enzyme activity, pipetting minimum liquid volumes 
(0.4 µl) did result in poor assay precision. Final concentrations of substrate and DMSO in the 
incubation matrix varied considerably between repeated assays (regardless of the pipetting 
technique used). Additionally, preliminary tests showed that the addition of an adequate 
amount of DMSO helps to stabilise the poorly water soluble xanthine derivatives in aqueous 
solution. Hence, a final DMSO concentration of 0.8% was considered acceptable for further 
microsomal assays. Although this concentration appears quite low, it greatly exceeds the 
amount of organic solvents applied in vivo in the context of a typical PET scan (adjuvants or 
residual impurities in the tracer injection solution). This difference between in vitro and in 
vivo situations, which is difficult, if not impossible, to overcome (at least for the hydrophobic 
compounds used in this work), may account for discrepancies in in vitro-in vivo 
comparisons. 
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Fig. 14. Influence of incubation matrix composition on depletion ratios of CBX and MCBX to CPFPX in 
rat liver microsomes. Bars represent the quotient of percentage degradation of CBX and CPFPX and 
MCBX and CPFPX, respectively. Note that the depletion ratios are only slightly affected by changes in 
the composition of the incubation matrix. Ratios were calculated from the mean values (n=4) of 
substrate depletion, error bars represent the SD estimated via error propagation. 
A reduction of the NADPH concentration from 1.3 mM (standard assay condition) to 
0.78 mM did not affect microsomal metabolism of CBX, MCBX and CPFPX significantly. 
Further reduction to 0.26 mM diminished MCBX and CPFPX depletion by about 20%, 
whereas CBX depletion was not affected in a significant way. These results clearly indicate 
that small to medium variations in NADPH concentration caused by depletion or incomplete 
reduction of NADP⁺ via G6P/G6P-DH do not influence substrate degradation to a relevant 
extent, since NADPH is present in high excess in the microsomal assay (millimolar 
concentration of NADPH, micromolar concentration of substrate). 
In summary, modification of incubation matrix composition resulted in variations in 
substrate depletion of up to 300% for the slowly metabolised CBX and up to 500% for the 
quickly metabolised MCBX and CPFPX. In contrast, depletion ratios (CBX to CPFPX and 
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MCBX to CPFPX) proved to be highly constant. The mean values were 0.53 ± 0.06 
(CBX:CPFPX) and 0.83 ± 0.06 (MCBX:CPFPX). These figures illustrate that a relative 
quantification approach such as the calculation of depletion ratios allows for statements on 
metabolic stability that are rather insensitive to variations of the test conditions. 
4.1.1.2 Concentration of microsomal protein 
The impact of varying concentrations of microsomal protein on substrate depletion kinetics 
was studied by measuring initial velocities of CPFPX metabolism in rat liver microsomes. 
Since most microsomal incubations carried out in this work were done at concentrations of 
0.2 to 0.8 mg/ml microsomal protein, this range was used for evaluation. As can be seen in 
Fig. 15, the initial velocity tracked almost linearly with increasing protein concentration. A 
weighted linear regression model could be fitted to the dataset with an adjusted R² of 
0.9917. A doubling of the protein concentration resulted in an approximate doubling of the 
initial velocity. It can thus be anticipated that, within the concentration range evaluated, 
sufficient comparability of initial velocity data measured at different concentrations of 
microsomal protein is ensured. Given the high degree of physicochemical similarity between 
the test compounds, it seems reasonable to assume that these findings can be transferred to 
CBX and MCBX. 
 
Fig. 15. Dependence of the initial reaction velocity on the concentration of microsomal protein. A 
weighted linear model was fitted to the data. Each data point represents the mean ± SD of four 
independent determinations. 
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4.1.2 Enzyme stability in vitro 
4.1.2.1 Effect of preincubation 
Prolonged preincubation of microsomal matrix with NADPH resulted in a rapid decrease of 
metabolic activity (Fig. 16). After 30 min of preincubation, depletion of added CPFPX was 
reduced by 34% compared to the value obtained with a preincubation time of only 2 min. 
After 120 min, metabolic activity was diminished by 89% and CPFPX degradation could 
hardly be observed. No significant differences in CPFPX depletion could be observed when 
preincubation (60 min) was conducted in the presence of both medium and high 
concentrations of the antioxidant enzymes catalase and superoxide dismutase. 
 
Fig. 16. Decrease of microsomal activity as a consequence of prolonged preincubation periods. CPFPX 
depletion was assayed in RLM following preincubation of microsomal protein with NADPH. 
Concentrations of CAT and SOD were as follows: CATa = 1 U/ml, CATb = 1500 U/ml, SODa = 100 U/ml, 
SODb = 1000 U/ml, CAT&SOD = 1000 U/ml (each). Data represent the mean ± SD of three 
independent experiments. *Significant difference from 2 min (p<0.05, two-tailed t-test) 
Inactivation of P450 enzymes in microsomal assays is a frequently observed phenomenon 
the causes of which are still controversially discussed. In addition to mechanism-based 
inhibition occurring during catalytic turnover of substrates which form active intermediates 
that bind covalently to the enzyme, inactivation processes have also been observed in the 
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absence of any substrate. The formation of reactive oxygen species was identified as a key 
factor for P450 inactivation, although there still remain some uncertainties regarding the 
influence of the particular sources of ROS production in the microsomal system. Generation 
of ROS is an inevitable side effect of the catalytic cycle of P450, resulting from uncoupling of 
the electron transfer chain [164, 269, 270]. P450 dependent generation of ROS is considered 
a major cause of enzyme inactivation and lipid peroxidation in hepatic tissue. Alternatively, 
ROS formation due to NADPH oxidase (NOX) activity in microsomal preparations has been 
proposed by several authors [271–273]. 
Addition of CAT and SOD to the microsomal incubation matrix was reported to prevent 
hydrogen peroxide formation [274], microsomal lipid peroxidation [271] and P450 
inactivation [178]. However, in the present study, no restoring effect of CAT and SOD could 
be observed (Fig. 16). Since the mechanisms of ROS action on microsomal targets are not yet 
fully understood, the effectiveness of incubation additives is likely to vary largely from one 
particular system to another. Different effects of ROS formed either directly at the active site 
of the P450 enzyme or accumulating in the surrounding matrix were reported [275], as well 
as variations in ROS action in dependence of the source of the enzyme and the composition 
of the incubation matrix [270, 276]. It might also be possible that CAT and SOD exhibit an 
inhibitory effect on several P450 isoenzymes which counteracts the potential benefits of 
ROS detoxification. 
In view of the pivotal role of NADPH in the process of enzyme inactivation, further studies 
on the fate of NADPH in microsomal assays were conducted in order to determine 
incubation conditions that allow for minimisation of undesired side effects. The results of 
these investigations are presented in the following section. 
4.1.2.2 Stability of NADPH during incubation 
The stability of NADPH in buffer and in microsomal incubation matrix with or without 
specific additives is shown in Fig. 17. NADPH proved to be quite stable in HEPES buffer 
(100 mM, pH 7.4, 3.3 mM MgCl2). After 3 h of incubation at 37°C, the concentration of 
NADPH dropped by only 17%. When NADPH was incubated in the presence of microsomal 
protein (0.4 mg/ml RLM), a steep, monoexponential decrease in concentration could be 
observed. After 3 h, the concentration of NADPH dropped by almost 77%. UV detection at 
260 nm revealed a simultaneous increase of the NADP⁺ peak, indicating an oxidation of 
NADPH rather than decomposition (Fig. 18). Addition of EDTA (5 mM) could not prevent the 
fast loss of NADPH. Addition of plumbagin (1 µM) even accelerated NADPH loss. However, 
addition of DPI could prevent consumption of NADPH even at low concentrations (25 µM). 
60 Results and Discussion 
 
 
Fig. 17. Time course of NADPH loss during incubation in buffer or microsomal incubation matrix. 
Incubations were conducted at 37°C. Data points represent the mean ± SD of three independent 
experiments. 
 
Fig. 18. NADPH consumption in RLM. NADPH was incubated in buffer containing microsomal protein. 
One sample was analysed directly after mixing of all components (black chromatogram), another 
after an incubation period of 3 h (red chromatogram). The decrease of the peak area of the NADPH 
peak is accompanied by an increase of the peak area of the NADP⁺ peak, indicating oxidative 
consumption of NADPH in the microsomal matrix. Detection wavelength was 260 nm. 
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Fig. 19. Time-course of in situ NADPH regenerated via G6P/G6P-DH. The value obtained from the first 
sample taken at 5 min was set at 100% (initial value). Data points represent the mean ± SD of three 
independent experiments. 
In situ cofactor regeneration via the G6P/G6P-DH system resulted in a stable NADPH level 
during the first 30 min (Fig. 19). After 60 min, the concentration of NADPH was still above 
90% of the initial value. When incubation times were extended, NADPH concentration 
decreased in an almost linear manner, resulting in a 42% reduction of NADPH after 3 h. 
It is well-known that the chemical stability of NADPH in solution is adversely affected by low 
pH values (below pH 8) and by the presence of several ionic species such as phosphate and 
acetate ions [277, 278]. While the buffer system chosen for the present study proved to be 
favourable in terms of NADPH stability, the addition of microsomal protein led to a dramatic 
acceleration of NADPH loss. Nevertheless, it seems unlikely that the mere reduction of the 
NADPH concentration accounts for the decrease in enzymatic activity observed with 
prolonged preincubation periods (section 4.1.2.1). The loss of NADPH in microsomal matrix 
was about 23% after 30 min (compare Fig. 17), hence the remaining NADPH concentration 
in the incubation matrix was about 1.0 mM. As discussed in section 4.1.1.1, reduction of the 
NADPH concentration from 1.3 mM to 1.0 or even 0.78 mM did not result in a significant 
reduction of substrate metabolism in microsomal assays. This strengthens the hypothesis 
that the actual reason for the loss of metabolic activity is enzyme inactivation rather than 
shortage of the cofactor. 
Complementary to the previously described studies concerning the influence of antioxidant 
enzymes on metabolic activity (section 4.1.2.1), the potential of several non-enzymatic 
additives to prevent NADPH loss (and thus NADPH-dependent ROS formation) during 
incubation was investigated. 
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It has been reported that addition of EDTA to microsomal incubations could prevent 
NADPH-dependent lipid peroxidation, probably by chelating non-haem iron which may act 
as a catalyst in the formation of the highly reactive hydroxyl radical [279–282]. This 
pathway does not appear relevant for the system used in the present study, since addition of 
5 mM EDTA did not result in a considerable change of NADPH loss. It is possible that, in the 
studies cited above, the lack of high purity chemicals and sophisticated technical equipment 
led to a higher content of iron in the microsomal incubations than usually encountered 
today. This might be an explanation for the ineffectiveness of metal chelating agents 
observed in the present study as well as in other studies conducted in the recent past [276, 
283]. Another explanation might be that the iron-mediated formation of lipid peroxides 
represents only a small proportion of the overall processes triggered by the ongoing 
consumption of NADPH in the microsomal matrix. Since the present study focused on the 
loss of NADPH, not on lipid peroxide formation, the contradictory observations concerning 
the effect of EDTA become understandable. 
The naphthoquinone derivative plumbagin has been shown to inhibit NADPH-dependent 
ROS generation in cells expressing NOX4 [284] and to prevent lipid peroxidation in 
microsomal assays [271]. In terms of NADPH consumption, addition of plumbagin to the 
incubation matrix led to an accelerated decline of the NADPH concentration (Fig. 17). It is 
most probable that plumbagin served as a substrate for P450 and thus provoked the 
utilisation of NADPH in the catalytic cycle. On the basis of this result, it cannot be ruled out 
that plumbagin is effective in inhibiting ROS generation and P450 inactivation in the model 
system studied in this work, but since the presence of a competing substrate would 
adulterate the result of a microsomal stability assay, plumbagin proved not to be an 
appropriate incubation additive. 
Addition of DPI, on the other hand, nearly abolished enhanced NADPH loss (Fig. 17). Since 
the diphenyleneiodonium cation acts as a potent uncompetitive inhibitor of flavoenzymes 
such as NOX, CPR, nitric oxide synthase (NOS), xanthine oxidase, NADH ubiquinone 
oxidoreductase, NADH dehydrogenase, G6P-DH and also P450 [285–287], these results 
clearly confirm that the loss of NADPH in microsomal incubations is a consequence of 
enzyme activity and not of mere chemical degradation. However, due to the lack of 
specificity of DPI, the relative contribution of the individual enzyme systems to NADPH 
consumption and ROS formation cannot be clearly differentiated. Moreover, the inhibitory 
potential of DPI on P450 and CPR precludes the use of this agent in regular microsomal 
stability assays. Since the main goal of the present study was the optimisation of microsomal 
incubation conditions rather than the elucidation of the molecular mechanisms underlying 
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enzyme inactivation, no additional investigations on ROS production and ROS actions were 
conducted. 
The final aspect of the investigations on NADPH stability in microsomal assays was the 
potential benefit of using a CRS instead of adding NADPH directly to the incubation matrix. 
The depletion profile displayed in Fig. 19 shows that in situ NADPH regeneration allows for 
a stable NADPH level only during the first 30 min of incubation, followed by a steep 
concentration decline. It is highly likely that G6P-DH is also adversely affected by ROS 
generated during incubation, resulting in a deceleration of NADP⁺ reduction. The presumed 
advantage of using a CRS in order to maintain a constant NADPH level during long term 
microsomal incubations could therefore not be confirmed. 
To summarise, neither antioxidant enzymes nor enzyme inhibitors or metal chelators 
proved to be suitable additives for microsomal stability assays in terms of preventing the 
fast decrease of enzymatic activity in vitro. Although some of these agents might have been 
successful in preventing formation of ROS or impeding the deleterious actions of ROS on the 
P450 system, these agents also interfered unfavourably with other components of the 
microsomal assay. The defence mechanism that viable cells use to protect themselves from 
the actions of ROS cannot be readily mimicked in the microsomal model system. The 
addition of one or two antioxidant agents does not reflect the complex interplay of a 
multitude of enzymes and substances present in the cell, many of which may not even be 
known at present. Additionally, the different magnitude of compartmentalisation in the 
microsomal model system and in intact, viable cells may contribute to differences in ROS 
formation and action as well as to differences in the efficacy of antioxidants. Therefore, the 
most promising strategy to avoid misleading data seems to be the shortening of the 
incubation periods used in microsomal stability assays. Short incubation periods that 
nevertheless ensure sufficient substrate depletion for adequate quantification and kinetic 
modelling can be realised by adjusting the microsomal protein concentration used in the 
assay. However, this approach can be limited by high protein binding of the substrate, 
oxygen diffusion limitation in highly protein-rich matrices, problems in sample preparation 
or economic considerations. An alternative concept could be the correction of depletion data 
by previously measured enzyme inactivation rates, as suggested by Foti and Fisher [178]. 
4.1.2.3 Criteria for the choice of optimal incubation conditions 
Evaluation and optimisation of microsomal assay conditions were aimed at providing an 
optimal basis for in vitro-in vivo comparison of metabolism data. In order to determine a set 
of optimal incubation conditions, the individual parameters were adjusted according to the 
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following aspects: (1) physiologically relevant size/level, (2) maximum substrate depletion 
(i.e. maximum catalytic activity). 
For parameters such as pH value, buffer molarity (i.e. ionic strength) and concentration of 
cofactors, literature data on the physiologically relevant levels are either varying or 
incomplete. These parameters were optimised with regard to maximum catalytic activity 
within the ranges reported in literature. Maximum catalytic activity was considered as 
decisive criterion since it reflects absence (or low extent) of in vitro enzyme inhibition. 
Several parameters (e.g. incubation temperature, substrate concentration) have not been 
subjected to evaluation but instead set to a fixed value since the physiological levels of these 
parameters are known or because of technical and analytical restrictions. The body 
temperature of the anesthetised rats used in the in vivo experiments of the present study 
was held at about 37°C, hence this temperature was also chosen for microsomal incubations, 
regardless of the actual temperature optimum of the particular enzymes. The initial 
substrate concentration was set to 8 µM since this value represented a reasonable 
compromise between analytical requirements (e.g. limit of quantification) and the limited 
solubility of the substrates in aqueous media. 
The pronounced inhibition and degradation of microsomal enzymes caused by organic 
solvents or NADPH-dependent ROS formation in the incubation matrix were considered as 
in vitro artefacts without equivalent in the intact organism. Thus, incubation conditions 
were adjusted so as to minimise these negative effects. Although ROS formation is a natural 
phenomenon occurring in the living cell, the consequences on enzyme integrity are not the 
same as in a simplified in vitro system. Living cells contain large concentrations of 
antioxidants that protect cellular components from the damaging effects of ROS. 
Additionally, vital cells can replace corrupted enzymes by newly synthesised ones and hence 
maintain a constant level of metabolic activity over a prolonged period of time. Since both 
tactics cannot be adequately simulated in vitro, the effects of ROS formation on microsomal 
enzymes were minimised by reduction of the incubation periods rather than addition of 
radical scavengers. 
The choice of a suitable organic solvent was hampered by the difficult solubility 
characteristics of the three xanthine derivatives. Solvents which proved to be capable of 
dissolving sufficient amounts of substrate (DMF & DMSO) also exhibited an inhibitory effect 
on the respective enzymes. Since enzyme inhibition was less pronounced with DMSO than 
with DMF, DMSO was chosen as standard solvent for all further assays. The optimal 
concentration of DMSO in the final incubation mixture was determined by balancing 
Results and Discussion 65 
 
negative (enzyme inhibitory) and positive (substrate solubility improving) effects of the 
organic solvent on the system. 
The concentration of microsomal protein (i.e. the enzyme concentration) for in vitro t1/2 
assays (see following section) was adjusted as to ensure depletion of 30 – 70% substrate 
during an incubation period of maximal 30 min. These conditions allow for a comprehensive 
evaluation of the kinetic characteristics of the substrate-enzyme system (initial lag phase, 
linear phase, plateau phase) as well as for non-linear curve fitting. In order to ensure good 
comparability of the data, microsomal protein concentrations used in the in vitro t1/2 assays 
were the same for all three substrates. 
4.1.3 In vitro metabolic stability of CBX, MCBX and CPFPX 
Following evaluation of incubation conditions, a set of optimal conditions was determined 
for examination of substrate depletion kinetics in RLM. Incubations were conducted in 
100 mM HEPES buffer at pH 7.4 and 37°C using a microsomal protein concentration of 
0.5 mg/ml and a substrate concentration of 8 µM. NADPH (1.3 mM) was added directly to 
the incubation matrix and DMSO concentration was kept below 1%. The incubation time 
was limited to 30 min to minimise the effect of enzyme degradation. 
The depletion-time profiles of CBX, MCBX and CPFPX in RLM are shown in Fig. 20. With all 
three substrates, an initial lag phase could be observed, resulting in a sigmoidal shape of the 
depletion profiles. Consequently, a logistic regression model of the following general form (a 
variant of the Hill equation) was applied for data analysis: 
 V =  − 1 + W XXY
Z +  Eq. 32 
with A1, initial value; A2, final value; x0, centre and p, power. 
A1 and A2 were fixed at 100 and 0 (percentage substrate remaining). This gave the final 
fitting equation: 
 V = 1001 + W XXY
Z Eq. 33 
In this equation, the centre value x0 represents the time point at which the substrate 
concentration has dropped down to 50% of the initial value. Thus, x0 is equivalent to the 
half-life t1/2. 
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The fitted curves are displayed in Fig. 20. In order to evaluate parameter stability, additional 
fits were carried out with reduced data sets in which the last sampling points were omitted. 
Adjusted R² values, reduced χ² values and derived half-lives are listed in Table 7. 
 
Fig. 20. Kinetics of CBX, MCBX and CPFPX depletion in RLM. Data were fitted to a logistic model. 
Dotted curve: all data points were included into the fit. Dashed curve: the last data point (t = 30 min) 
was excluded from the fit. Solid curve: the last two data points (t = 25 min, 30 min) were excluded 
from the fit. Data points represent the mean ± SD of three independent experiments. 
In vitro half-lives of MCBX and CPFPX were insensitive to restrictions of the fitted data 
range. Relative standard deviations of t1/2 were ≤1.4%. CBX was more affected by changes in 
data set size; the relative standard deviation of t1/2 was 7.3%. Goodness-of-fit criteria and 
visual inspection of the fitting curves and residual plots were decisive for the exclusion of 
the last data point (t = 30 min) for all substrates. The in vitro half-lives derived from this 
shortened depletion curves were used to calculate in vitro t1/2 ratios. The in vitro t1/2 ratio 
(± SE) of CBX to CPFPX was 3.1 ± 0.11, that of MCBX to CPFPX 1.4 ± 0.029 and that of CBX to 
MCBX 2.2 ± 0.033. These ratios were used for in vitro-in vivo comparison (see section 4.2.3). 
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Table 7. Results of non-linear regression analysis of the data visualised in Fig. 20. The data sets 
selected for calculation of in vitro t1/2 ratios are marked in bold. 
Substrate 
Number of fitted 
data points 
Adjusted R² Reduced \ t1/2 (SE) 
    min 
CBX 8 0.99535 1.00334 47.2 (2.2) 
MCBX 8 0.99895 0.64237 19.7 (0.22) 
CPFPX 8 0.99724 2.55596 14.1 (0.28) 
CBX 7 0.99832 0.32810 43.6 (1.4) 
MCBX 7 0.99944 0.28287 20.0 (0.18) 
CPFPX 7 0.99770 1.83781 14.2 (0.26) 
CBX 6 0.99978 0.03541 40.9 (0.56) 
MCBX 6 0.99951 0.19568 20.2 (0.22) 
CPFPX 6 0.99820 1.14559 14.4 (0.25) 
R², coefficient of determination; t1/2, in vitro half-life; SE, standard error of the parameter 
Common approaches to describe and compare the kinetics of enzymatic reactions are to 
derive initial velocities from the initial linear phases of the reaction progress curves or to fit 
the experimental data to an exponential model in order to derive the metabolic half-life. The 
latter procedure is equally suitable for in vitro metabolism data and in vivo pharmacokinetic 
data. In the present study, an alternative approach was chosen to account for the unusual 
kinetic characteristics of CBX, MCBX and CPFPX metabolism in RLM. As a consequence of an 
initial lag phase, the depletion profiles of these substrates were markedly sigmoidal in 
shape. This effect occurred independently of incubation conditions, substrate and enzyme 
concentrations or NADPH supply. Similar observations were made during in vitro evaluation 
of other xanthine derivatives synthesised at INM-5 (unpublished results). A critical 
assessment of the physiological relevance of this phenomenon is crucial for deciding which 
fitting model is the most appropriate for the data. The observed lag phase could possibly be 
attributed to a delayed reconstitution of the P450/CPR/NADPH/substrate system after 
mixing all components together. Since component mixing is an artificial process that does 
not occur in the living cell in a comparable manner, lag phases caused by this effect would 
clearly be in vitro artefacts which do not reflect intrinsic properties of the enzyme-substrate 
system under examination. Consequently, inclusion of the lag phase into kinetic modelling 
would not be appropriate. On the other hand, the initial lag phase could also be due to the 
interaction of multiple catalytic pathways with different kinetics. In this case, similar kinetic 
behaviour can be anticipated in vivo, hence inclusion of the lag phase into the model fit 
appears reasonable. Two observations indicate that the latter assumption is more likely to 
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be valid. First, the sigmoidal shape of the depletion curves could be observed independently 
of the specific conditions and procedures used in the assay (initiating and mixing 
procedures, NADPH supply, enzyme-substrate concentration ratios, preincubation time). If 
reconstitution processes would be causal for the shape of the depletion curve, variations in 
assay conditions and procedures would be likely to affect this shape. Second, in vitro and in 
vivo metabolite profiles of the prototypical xanthine derivative CPFPX revealed numerous 
catalytic pathways including metabolite species resulting from multiple attacks of P450 1A2 
(and potentially other P450 isoforms) on the parent structure [288–290]. It is thus quite 
probable that the initial lag phase results from the unequal kinetic characteristics of the 
various catalytic pathways and hence is a consequence of the intrinsic properties of the 
enzyme-substrate system rather than an in vitro artefact. Since analogous processes can be 
postulated in vivo with reasonable certainty, the initial lag phase was included in the model 
fit. As a consequence of this decision, derivation of initial velocities was considered 
inappropriate since the initial lag phase did not represent all kinetic aspects of substrate 
metabolism. Fitting the data to the logistic function (Eq. 33) provided better results in terms 
of goodness-of-fit criteria than a biexponential fit. Moreover, the combination of two half-
lives derived from the biexponential fit complicates the comparison between different 
substrates as well as the comparison between in vitro and in vivo data. In contrast, 
application of the logistic fitting equation results in only one half-life that characterises the 
progress of the whole depletion curve and thus facilitates quick and simple comparison and 
ranking of metabolic stability data. 
4.1.4 Species differences in microsomal metabolism 
Although this work focused on the metabolism of CBX, MCBX and CPFPX in the rat model, 
additional in vitro studies were conducted using liver microsomes of several other species, 
including humans. The objectives of these additional studies were, first, to elucidate the 
causal mechanisms leading to the qualitative differences between in vitro and in vivo 
metabolite profiles as observed with rodents, but not with humans [288] and second, to 
assess the suitability of common preclinical animal species for evaluation of xanthine-
derived A1AR tracers. 
In the first part of this section, metabolic activity towards the test compounds is compared 
among species (quantitative metabolic differences) and in the second part, variations in 
metabolite profiles are discussed (qualitative metabolic differences). Since human 
microsomal metabolism deviated substantially from that of non-human animals, additional 
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quantitative and qualitative studies were conducted using human liver microsomes. The 
results of these investigations are presented in the last part of the section. 
4.1.4.1 Quantitative differences 
Interspecies differences in the microsomal metabolism of CBX, MCBX and CPFPX were 
studied using human, rat, mouse, dog, mini pig and rhesus monkey liver microsomes. The 
results of the quantitative depletion studies are shown in Fig. 21. 
Metabolic activities (as measured by substrate depletion) varied widely across species. 
Highest metabolic activity was measured in rhesus microsomes. Percentage substrate 
depletion obtained with 0.04 mg/ml rhesus microsomes was in the same range as with 
0.4 mg/ml rodent microsomes. On the other hand, substrate depletion in human 
microsomes was extremely low. Using a standard assay concentration of 0.4 mg/ml 
microsomal protein, percentage substrate depletion of CBX, MCBX and CPFPX was less than 
10% during 30 min of incubation. In order to increase the statistical power of the 
experiment, incubations were repeated using 2.0 mg/ml human microsomal protein. The 
metabolic activities of mini pig and dog microsomes were comparable to each other. 
Percentage substrate depletion measured in microsomes of these relatively large species 
was about 50% lower than in rodent microsomes, but significantly higher than in human 
microsomes (with the exception of CBX depletion in mini pig and human microsomes, which 
were of comparable magnitude). 
Depletion ratios and rank order of metabolic stability of the test compounds were less 
variable across species than total metabolic activity. Again, metabolism in human 
microsomes was a noticeable exception. Whereas the microsomal stability ranking of CBX, 
MCBX and CPFPX was comparable among non-human animal species (CBX being the most 
stable and CPFPX the least stable compound), a different ranking was observed with human 
liver microsomes. When incubated with 2.0 mg/ml human microsomal protein, MCBX was 
the most stable and CBX the least stable compound. Incubations conducted at 0.4 mg/ml 
human microsomal protein were not used for evaluation of the ranking order since the 
statistical power was insufficient due to the very low depletion rates. 
To further investigate the deviating kinetics of human microsomal metabolism of the test 
compounds, additional time-course studies were conducted which allowed for 
determination of in vitro t1/2. The results of these studies are presented in section 4.1.4.4. 
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A 
B 
Fig. 21. Quantitative species differences in microsomal metabolism of CBX, MCBX and CPFPX. (A) 
Percentage substrate depletion in liver microsomes of various species during an incubation period of 
30 min. Concentration of microsomal protein was 0.4 mg/ml, except for Humana (2.0 mg/ml) and 
Rhesusb (0.04 mg/ml). Data represent the mean ± SD of four independent experiments. (B) Depletion 
ratios of CBX and MCBX to CPFPX, calculated from the data visualised in A. Bars represent the 
quotient of percentage degradation of CBX and CPFPX and MCBX and CPFPX, respectively. 
Species-dependent differences in microsomal metabolism can be attributed to the following 
main factors: (1) different levels of total microsomal P450, (2) different levels of individual 
P450 isoforms, (3) variations in the functional characteristics of individual P450 isoforms 
(catalytic activity, substrate specificity, preferred reaction pathways). 
Rat Mouse Mini pig Dog Human Humana Rhesusb
0
20
40
60
80
100
Su
b
st
ra
te
 d
ep
le
ti
o
n
 /
 %
 CBX
 MCBX
 CPFPX
Rat Mouse Mini pig Dog Human Humana Rhesusb
0.0
0.5
1.0
1.5
2.0
2.5
D
ep
le
ti
o
n
 r
at
io
 CBX:CPFPX
 MCBX:CPFPX
Results and Discussion 71 
 
Quantitative differences in microsomal metabolism resulting from different levels of total or 
individual P450 enzymes can often be dealt with by application of scaling factors or by 
adjustment of the protein concentration used in the microsomal assay. In contrast, 
interspecies differences in the functional characteristics of an enzyme may result in 
fundamental quantitative and qualitative metabolic differences which may render a 
particular animal species unsuitable as predictive model for e.g. the human metabolism. 
Since manufacturer's data on total P450 content were only available for the human 
microsomes used in the present study, but not for the non-human animal species, literature 
data on total microsomal P450 content reported for these species (see Table 8) were used 
as reference values for discussion. 
Table 8. Total microsomal P450 content reported for various species 
Species 
Total microsomal P450 content 
nmol/mg microsomal protein 
[291] [292] [293] [294] [295] 
Human 0.307 ± 0.160 0.231 ± 0.013 0.31 ± 0.09 n.d. 0.29 ± 0.06 
Rat 0.673 ± 0.050 0.444 ± 0.016 0.58 ± 0.02 n.d. n.d. 
Mouse n.d. 0.719 ± 0.041 0.48 ± 0.04 n.d. n.d. 
Mini pig n.d. n.d. n.d. 0.798 ± 0.145 n.d. 
Dog 0.385 ± 0.036 0.685 ± 0.031 n.d. n.d. n.d. 
Monkey 1.030 ± 0.106a 1.195 ± 0.089b 0.74 ± 0.02a n.d. 0.95 ± 0.08b 
n.d., not determined; a cynomolgus monkey, b rhesus monkey 
In the following discussion of interspecies differences in expression levels and functional 
characteristics of individual P450 isoforms, the focus is on P450 1A2, which is considered 
the main enzyme involved in phase I metabolism of CPFPX and its analogues [289]. At 
present, information on hepatic P450 1A2 levels is not available for all species used in this 
study. In humans, P450 1A2 accounts for about 13% of the total P450 content [296], in rats 
for about 2% [297] and in dogs for about 4% [298]. Basal hepatic levels of P450 1A2 in 
macaques are generally reported to be low or even undetectable [299–303], however, 
Shimada et al. measured comparable levels of P450 1A2 in liver microsomes of cynomolgus 
macaques and humans [291]. 
Obviously, interspecies differences in total and isoform specific P450 content cannot fully 
account for the large variations in metabolic activity towards the tested xanthine 
derivatives. Microsomal P450 levels reported in Table 8 are about 2-3 times higher in 
rodents and about 3 times higher in rhesus and cynomolgus monkeys than in humans. By 
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contrast, depletion of MCBX and CPFPX measured in rodent microsomes was 7-14 times 
higher than in human microsomes. In rhesus monkey microsomes, depletion of CBX, MCBX 
and CPFPX was about 24, 93 and 150 times higher than in human microsomes. This is 
particularly noteworthy since, as mentioned above, the constitutive hepatic expression of 
P450 1A2 in rhesus monkeys is questionable. It is probable that P450 isoforms other than 
1A2 are responsible for degradation of the test substrates in macaques, rendering this 
animal model less useful for prediction of the pharmacokinetic characteristics of xanthine-
derived A1AR ligands in humans. 
Numerous studies on interspecies variations in catalytic activity of P450 1A2 toward 
various marker substrates have been published so far, revealing large differences not only in 
enzymatic activity of the homologues 1A2 enzymes, but also in substrate specificity [291, 
304–310]. Interestingly, the rate of caffeine metabolism, which was studied by Berthou and 
colleagues, was two times higher in human liver microsomes than in rat liver microsomes 
and 1.4 times higher than in monkey liver microsomes [304]. Despite the high degree of 
structural similarity between caffeine and the xanthine-derived compounds evaluated in the 
present study, species-specific metabolism of these substances seems to differ substantially. 
However, it is important to note that the apparent differences in depletion kinetics may be 
partially attributed to the different qualities of the microsomal material used in both 
studies. In the present study, pooled microsomes prepared from liver tissue of 50 donors 
were used in order to minimise the effect of interindividual variations in enzyme 
concentration and activity. The microsomes used by Berthou et al. were prepared from 
tissue of a single donor and showed exceptionally high values for P450 content and caffeine 
biotransformation [311]. This experimental aspect may have led to a deviating assessment 
of the metabolic activity of human microsomes relative to other species. 
To summarise, interspecies differences in metabolic activities towards CBX, MCBX and 
CPFPX are pronounced and not readily surmountable by simple scaling approaches. The 
metabolic stability ranking observed with human microsomes did not match any of the 
tested animal species. Based on these results, the relevance of animal microsomes as a 
model for human pharmacokinetics of the test compounds must be doubted. However, it 
should be considered that metabolism data generated using human liver tissue preparations 
might be biased as a result of the specific conditions encountered during sampling and 
preparation of human tissue. First, human liver tissue obtained from diagnostic biopsies 
might be pathologically changed which could lead to altered functional characteristics. 
Second, post-mortem times preceding actual tissue preparation are generally longer for 
human than for animal autopsy tissue (due to regulatory requirements, for example). It has 
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been shown by various authors that enzyme activity decreases rapidly in post-mortem liver 
tissue as a result of autolysis [312–316], especially if the liver tissue is left in situ at room 
temperature. The consequences of post-mortem enzyme stability on the results obtained by 
microsomal stability assays have not yet been definitively clarified. 
4.1.4.2 Qualitative differences 
Metabolite profiles resulting from biotransformation of CBX, MCBX and CPFPX by human, 
rat, mouse, dog, mini pig and rhesus monkey liver microsomes are shown in Fig. 22 - Fig. 24. 
Peaks were assigned as metabolites only if they were clearly distinguishable from matrix 
components (by comparison with blank samples) and if the peak areas were of considerable 
size in the chromatogram of at least one species. Minor components eluting in close vicinity 
to the injection peak were disregarded. The assigned metabolite peaks are listed in Table 9 
together with their retention times and retention factors. Since mass-spectrometric data 
were not hitherto available to clarify peak identities, peaks were matched solely by 
comparison of the retention times. The main goal was a straightforward assessment of 
qualitative differences in number and relative abundance of metabolites in liver microsomes 
of different species in order to identify the most promising preclinical species for evaluation 
of xanthine-derived A1AR tracers. 
Microsomal metabolism of CBX produced at least 8 metabolites of which A1 and A5 where 
dominant in all species. Regarding human in vitro biotransformation of CBX, metabolite 
profiles generated by rhesus monkey and mini pig microsomes exhibited the highest degree 
of similarity. Biotransformation of MCBX produced at least 10 metabolites. Metabolite B3 
was dominant in the profiles of all species, whereas peak area ratios of metabolites B5-B7 
were highly variable. Human microsomal metabolism of MCBX was most closely 
approximated by rodent microsomes. Biotransformation of CPFPX by human and rodent 
microsomes has been extensively studied by Bier et al. [288]. As a supplement, microsomes 
of three common non-rodent preclinical species were used in the present study in order to 
select the most predictive animal species for human metabolism of CPFPX and its analogues. 
Species-specific microsomal biotransformation of CPFPX resulted in at least 12 metabolites. 
Of particular interest was the in vitro formation of the enone metabolite 7, which was 
hitherto considered to occur only in human microsomes. Since this compound was available 
as reference standard, the corresponding peak in the human chromatogram could be 
identified by its retention time (C9, 9.8 min). As can be seen in Fig. 24, the dog metabolite 
profile also shows a peak eluting at 9.8 min, suggesting formation of 7 in dog microsomes. 
An initial mass spectrometric analysis indicated the presence of the expected [M+H]+ quasi-
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molecular ion, but since the signal was relatively low, further analyses are to be conducted 
in order to verify the chemical identity of the metabolite. 
In summary, no single animal species could accurately predict qualitative human 
microsomal metabolism of all three substrates. Regarding CBX and MCBX, comparison of the 
metabolite profiles suggests that microsomal metabolism of these substrates generates 
similar metabolites in all species, but in varying relative amounts. In the case of CPFPX, 
formation of the enone metabolite 7, a dominant species in the human metabolite profile, 
could only be observed in dog microsomes (with reservations regarding the final 
spectroscopic identification). Because it would be impracticable to evaluate the most 
predictive animal species for every single test substrate, a reasonable approach could be a 
combined analysis of in vitro metabolic data obtained from at least two different animal 
species. This concept may help to recognise species differences in metabolic pathways in an 
early stage of development and to assess the impacts of these differences on the desired 
characteristics of the new chemical entity. Regarding the evaluation of CPFPX analogues, the 
beagle dog appears to be a promising species for in vitro metabolic stability studies (and 
possibly also for in vivo pharmacokinetic testing), complementing standard rodent studies. 
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Fig. 22. Biotransformation of CBX in liver microsomes of various species. HPLC-UV chromatograms 
were generated at 275 nm. For reasons of clarity, only metabolite peaks which account for at least 
10% of the total metabolite peak area were labelled in the chromatograms. A full list of metabolites is 
given in Table 9. 
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Fig. 23. Biotransformation of MCBX in liver microsomes of various species. HPLC-UV chromatograms 
were generated at 275 nm. For reasons of clarity, only metabolite peaks which account for at least 
10% of the total metabolite peak area were labelled in the chromatograms. A full list of metabolites is 
given in Table 9. 
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Fig. 24. Biotransformation of CPFPX in liver microsomes of various species. HPLC-UV chromatograms 
were generated at 275 nm. For reasons of clarity, only metabolite peaks which account for at least 
10% of the total metabolite peak area were labelled in the chromatograms. A full list of metabolites is 
given in Table 9. 
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Table 9. Metabolites of CBX, MCBX and CPFPX generated in liver microsomes of various species 
Substrate Peak fraction Retention time Retention factor Species 
  min   
CBX 
A1 4.8 0.9 h, r, m, d, mp, rh 
A2 5.3 1.1 (h), r, (m), mp, rh 
A3 5.6 1.2 h, r, m, d, mp, rh 
A4 6.0 1.4 (r), (m), mp, (rh) 
A5 9.6 2.9 h, r, m, d, mp, rh 
A6 10.4 3.2 (h), (r), d, (mp) 
A7 12.1 3.9 (h), r, m, d, (mp), (rh) 
A8 16.6 5.7 (h), r, m, d, (mp), rh 
CBX 17.2 5.9 h, r, m, d, mp, rh 
MCBX 
B1 5.3 1.1 r, mp 
B2 5.7 1.3 (r), m, (d), (mp), (rh) 
B3 6.3 1.5 h, r, m, d, mp, rh 
B4 7.1 1.8 (h), m, d, (rh) 
B5 8.0 2.2 h, r, m, d, mp, rh 
B6 8.6 2.4 h, r, m, d, mp, rh 
B7 8.9 2.6 h, r, m, d, mp, rh 
B8 12.9 4.2 (h), m, d, mp, (rh) 
B9 21.7 7.7 h, r, m, d, (mp), (rh) 
B10 31.6 11.7 h, r, m, d, (mp), (rh) 
MCBX 33.1 12.3 h, r, m, d, mp, rh 
CPFPX 
C1 5.5 1.2 h, r, m, d, mp, rh 
C2 5.9 1.4 h, r, m, d, mp, rh 
C3 6.3 1.5 h, r, m, d, (mp), (rh) 
C4 7.4 2.0 (h), r, m, d, mp, rh 
C5 7.9 2.2 h, r, m, d, mp, rh 
C6 8.3 2.3 h, r, m, d, mp, rh 
C7 8.7 2.5 (h), r, (m), (d), (rh) 
C8 9.0 2.6 (r), m, (d), (rh) 
C9 9.8 2.9 h, d 
C10 12.2 3.9 h, r, m, d, mp, rh 
C11 21.4 7.6 (h), r, m, (mp), rh 
C12 34.0 12.6 r, (m), (d) 
CPFPX 29.4 10.8 h, r, m, d, mp, rh 
h, human; r, rat; m, mouse; d, dog; mp, mini pig; rh, rhesus 
brackets indicate minor peaks 
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4.1.4.3 Enone metabolite formation in liver microsomes 
Formation of the enone metabolite 7 represents a major metabolic pathway in human in 
vivo and in vitro CPFPX metabolism [288–290]. Thus, blockage of this pathway is considered 
a promising approach to enhance metabolic stability of CPFPX analogues. Remarkably, in 
rodents, 7 is generated exclusively in the living animal, but not in liver microsomes [288]. 
To elucidate the potential causes of this phenomenon and to assess its relevance for both in 
vitro-in vivo comparison and comparison among species, microsomal metabolism studies 
were conducted in both rat and human liver microsomes using four potential precursor 
species (8-11) which were all found to be present in the human microsomal metabolite 
profile. Of these primary metabolites, only 9 served as precursor for the formation of 7 in 
human liver microsomes. This biotransformation passed via an intermediate which could be 
separated chromatographically (Fig. 25). Mass spectrometric analyses supported the 
hypothesis that this intermediate may contain a cyclopentenol moiety instead of the 
cyclopentenone moiety of 7, thus being most probable 3-(3-fluoropropyl)-8-(3-
hydroxycyclopent-1-en-1-yl)-1-propylxanthine (12). 
 
Fig. 25. Biotransformation of 9 in HLM (black chromatogram) and RLM (red chromatogram). Enone 
(7) formation can only be observed in HLM. Chromatograms were smoothed by applying a moving 
average algorithm (filter width 2). Detection wavelength was 275 nm. 
The time course of formation of 7 and 12 in human liver microsomes is shown in Fig. 26A. It 
can be seen that (1) the formation of 7 still proceeded after 9 was completely depleted and 
that (2) the concentration of 12 started declining after a certain incubation period. Both 
observations confirm a pathway that proceeds from 9 via 12 to 7 (Fig. 27). In comparison, 
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the time course of metabolism of 9 in rat liver microsomes is given in Fig. 26B. Apparently, 
formation of 12 proceeded as previously observed in human liver microsomes, but the final 
oxidation step which converts the hydroxy compound into a ketone did not take place. No 
enone peak could be detected in the respective chromatograms (Fig. 25). Consequently, the 
concentration of 12 increased until 9 was completely depleted, but then stayed at the same 
level throughout the remaining incubation period. 
It seems plausible that the ability of oxidising 12 is a special feature of human (and 
potentially dog) P450 1A2. Previous studies on CPFPX biotransformation using recombinant 
human 1A2 isoenzyme preparations [289] clearly indicated that all reaction steps leading 
from CPFPX to 7 can be catalysed by human P450 1A2 alone, i.e. no further enzymes are 
required for this complex multi-oxidation reaction pathway. In contrast, rodent microsomal 
P450 1A2 enzymes are seemingly unable to catalyse the last oxidation step leading to the 
ketone (or at least not to a significant extent). This is readily explainable by species 
differences in the active site structures of the particular enzymes, resulting in different 
functional characteristics (substrate specificity, reaction pathways). The formation of 7 in 
the living rodent, which might seem paradoxical at first sight, could be a consequence of the 
catalytic action of enzymes other than hepatic P450 1A2. Since intermediate metabolites are 
subjected to systemic circulation in the living animal, they will be exposed to a multitude of 
hepatic and extrahepatic enzyme systems. It is conceivable that extrahepatic P450 
isoenzymes or alcohol oxidoreductases complete the reaction pathway by oxidising 12. The 
exact mechanism of in vivo formation of 7 in rodents remains to be elucidated in future 
studies. 
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A 
B 
Fig. 26. Kinetics of biotransformation of 9 in HLM (A) and RLM (B). In both HLM and RLM, 
degradation of 9 (black curve) results in the formation of an intermediate alkenol compound (red 
curve). In HLM, this intermediate is subsequently metabolised to 7 (blue curve). Formation of 7 
cannot be observed in RLM. Data points represent the mean ± SD of three independent experiments. 
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Fig. 27. Proposed mechanism of enone (7) formation in HLM. Three distinct biotransformation steps 
are necessary to convert CPFPX (1) into the enone metabolite (7). Steps 1 and 2 occur in both RLM 
and HLM, whereas step 3, the final oxidation of the hydroxy intermediate (12) to the carbonyl 
compound, can only be observed in HLM. 
4.1.4.4 Time-course of CBX, MCBX and CPFPX metabolism in HLM 
As apparent from the preceding sections, human microsomal metabolism of CPFPX and its 
analogues shows noticeable qualitative and quantitative deviations from any other species. 
Since tracer development in most cases pursues the goal of human application, kinetics of 
human in vitro metabolism of the test substances is of special interest. In addition to the 
fixed-time experiments presented in section 4.1.4.1, microsomal time-course studies were 
performed in order to assess the kinetic characteristics of substrate metabolism in human 
liver microsomes. These data were fitted to the logistic model described in section 4.1.3. The 
resulting depletion curves are shown in Fig. 28. In vitro t1/2 of CBX, CPFPX and MCBX were 
25, 34 and 43 min, respectively. Interestingly, the depletion curves of MCBX and CPFPX 
intersected at about 13 min, resulting in a change of the stability rank order. This might be a 
consequence of an overlap of different catalytic pathways realised at one and the same 
substrate species. However, the physiological relevance of this phenomenon is difficult to 
assess. Enzyme inactivation resulting from prolonged incubation periods or enzyme 
inhibition caused by accumulation of metabolites in the incubation matrix may affect the 
course of the depletion curves at later time points. Since, as a consequence of the low 
depletion rates of the xanthine derivatives in HLM, extended incubation periods are almost 
inevitable in order to fully assess depletion kinetics, these problems are far from easy to 
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resolve. Further investigations are required to determine whether the observed behaviour 
is an intrinsic property of the particular enzyme-substrate system or an in vitro artefact. 
 
Fig. 28. Kinetics of CBX, MCBX and CPFPX depletion in HLM. Data were fitted to the same logistic 
model that was applied for depletion kinetics in RLM (see section 4.1.3). Data points represent the 
mean of two independent experiments. 
4.2 In vivo pharmacokinetics 
4.2.1 Plasma kinetics 
Kinetics of [18F]CBX, [18F]MCBX and [18F]CPFPX in rat plasma following i.v. bolus 
administration are compared in Fig. 29. Since inter-individual variations in plasma kinetics 
within the test groups were relatively small, mean data sets were used for pharmacokinetic 
analysis. Plasma kinetics of the three tracers could not be adequately described by the 
simple biexponential model frequently applied in pharmacokinetic analysis [317–319]. 
Examination of the semi-logarithmic SUV versus time plots (not shown) revealed three 
distinctive kinetic phases associated with the decline of tracer concentration in plasma. 
Consequently, a triexponential model was chosen for curve fitting. Plasma clearance, volume 
of distribution and terminal half-life were estimated from the fitted parameters via non-
compartmental PK analysis (Table 10). Highest clearance was observed with [18F]CBX, 
lowest clearance with [18F]MCBX. Clearance ratios (± SE) were as follows: 
[18F]CBX:[18F]CPFPX=0.39 ± 0.019, [18F]MCBX:[18F]CPFPX=1.2 ± 0.028, [18F]CBX:[18F]MCBX= 
0.32 ± 0.016. Terminal half-life of [18F]CBX was 1.8 times longer than that of [18F]CPFPX and 
1.6 times longer than that of [18F]MCBX. Half-lives of [18F]CPFPX and [18F]MCBX did not 
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differ in a statistically significant way. Volumes of distribution varied only slightly 
(190-362 ml), thus comparable distribution of the tracers throughout the body can be 
presumed. 
Table 10. Pharmacokinetic parameters derived from triexponential fits of the plasma activity versus 
time data visualised in Fig. 29. Values were calculated according to Eq. 8-10 given in section 1.5.3.2. 
Absolute errors were estimated from SEs of the individual fitting parameters via error propagation. 
Tracer Number of animals Vd (SE) CL (SE) t1/2γ (SE) 
  ml ml/min min 
[18F]CBX 8 190 (21)b 1.50 (0.068)bc 88.1 (8.8)bc 
[18F]MCBX 9 362 (24)ac 4.65 (0.081)ac 54.0 (3.4)a 
[18F]CPFPX 8 263 (23)b 3.81 (0.057)ab 47.8 (4.1)a 
Vd, volume of distribution; CL, total clearance, t1/2γ, terminal half-life; SE, standard error; 
a significantly different from 
[18F]CBX; b significantly different from [18F]MCBX; c significantly different from [18F]CPFPX (p<0.05, one-way ANOVA 
with post-hoc Tukey test) 
With all tracers, metabolic degradation started immediately after i.v. injection (Fig. 29B). At 
1 min p.i., parent fractions had already declined to 98-99%. At 2 and 3 min p.i., parent 
fractions were in the range of 91-94% and 81-88%, respectively. At the end of the 
measurement (180 min p.i.), authentic tracer accounted for about 7% ([18F]CPFPX), 13% 
([18F]MCBX) and 25% ([18F]CBX) of the total plasma radioactivity. 
Plasma kinetics of [18F]CPFPX and its analogues exhibited a triphasic profile. Although basic 
pharmacokinetic parameters can be derived from the triexponential equations without 
further physiological interpretation of this behaviour, application of a distinct 
pharmacokinetic model may help to elucidate the physiological correlates of the three 
exponential terms and thus to understand the fate of the test compounds in the body. The 
observed triphasic plasma profiles of the evaluated tracers can be well explained by a three-
compartment mammillary PK model in which a central plasma compartment is connected to 
two peripheral tissue compartments with distinct kinetic properties [187, 189]. 
Intercompartmental transfer processes account for an initial rapid distribution phase 
followed by a second slower distribution phase. These phases are described by the first two 
terms of the exponential equation. The third exponential corresponds to the final 
elimination phase which is characterised by a shallow decline of the plasma concentration-
time curve. Application of this model appears reasonable with regard to the 
physicochemical properties of the tested tracers. Being small, non-ionic, polar molecules of 
medium lipophilicity, [18F]CPFPX and similar xanthine derivatives can be assumed to cross 
biological membranes readily and to distribute throughout body tissues [320, 321]. This 
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assumption is supported by the estimated Vd-values which suggest distribution in total body 
water (data on total body water of rats can be found in [322, 323]). Given the fact that the 
main transport vehicle of tracer in the body is blood and that tissues differ with regard to 
blood perfusion, the hypothesis of a central plasma compartment and two distinct tissue 
compartments with individual transport and equilibration kinetics seems appropriate. 
 
A 
B 
Fig. 29. Plasma kinetics of [18F]CBX, [18F]MCBX and [18F]CPFPX following i.v. bolus injection of 
21 ± 3 MBq into male Sprague Dawley rats. (A) Metabolite-corrected arterial plasma time-activity 
curves. SUVs were calculated by normalising plasma radioactivity concentration to amount of 
injected radioactivity and body weight. Values were fit to a triexponential model (solid lines). (B) 
Fraction of plasma radioactivity representing authentic (unchanged) tracer. Solid lines are a guide to 
the eye. Data (mean ± SD) were obtained from 8 ([18F]CBX, [18F]CPFPX) or 9 animals ([18F]MCBX). 
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4.2.2 Plasma protein binding 
According to the free drug hypothesis [324], which is still widely applied in pharmacology, 
only drug molecules which are not bound to plasma proteins are able to cross biological 
membranes and to interact with biomolecules such as enzymes or receptors. Thus, the 
extent of plasma protein binding of a drug may affect its metabolic fate as well as its efficacy 
at biological targets. In order to assess whether or not variations in plasma protein binding 
might lead to differences in metabolism of the evaluated tracers, the free fraction of tracer in 
rat plasma was determined during each PET scan. 
Measured free fractions of the three tracers in rat plasma ranged from 0.02 to 0.04 (Fig. 30). 
Due to the pronounced inter-individual variability in plasma protein binding, statistical 
significance could only be demonstrated for the difference between [18F]MCBX and 
[18F]CPFPX. Despite the high extent of plasma protein binding, all tracers were suspected to 
extensive metabolism almost immediately after i.v. injection (compare Fig. 29B), suggesting 
fast uptake into hepatocytes. In recent years, the impact of plasma protein binding on 
physiological processes and thus the validity of the free drug hypotheses is being 
increasingly questioned [325], since numerous studies reported apparent discrepancies 
between predicted and observed uptake and clearance rates especially of highly bound 
drugs [326–330]. Regarding [18F]CPFPX and its analogues, plasma and brain kinetics 
indicated that tracer uptake into cells was not as restricted by plasma protein binding as 
anticipated from the assumption that cellular uptake is solely driven by the unbound 
fraction of a drug. In light of these observations and as a consequence of the unsolved 
questions concerning the role of plasma protein binding in pharmacokinetics, measured free 
fractions of [18F]CBX, [18F]MCBX and [18F]CPFPX were used only for comparison of the 
tracers’ physicochemical properties and not for kinetic analyses. As measured free fractions 
were in a comparable range, this parameter was not assumed to account for fundamental 
differences in the physiological behaviour of the tracers. 
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Fig. 30. Free fractions of tracer in rat plasma. Unbound fractions were assessed via ultrafiltration of 
plasma samples spiked with the respective tracer. Data (mean ± SD) were obtained from 4 
([18F]CPFPX), 6 ([18F]CBX) or 7 animals ([18F]MCBX). * significantly different (p<0.05, one-way 
ANOVA with post-hoc Tukey test) 
4.2.3 In vitro-in vivo comparison of tracer metabolism 
One of the main difficulties encountered when correlating in vitro metabolic stability data to 
in vivo pharmacokinetics is the almost impossible task of isolating one single aspect from 
the multitude of physiological interactions that constitute the in vivo behaviour of a drug. 
Whereas the microsomal stability assays used in this work provide data only on the intrinsic 
metabolic lability of the test compounds, pharmacokinetic plasma profiles reflect processes 
of distribution, metabolism and elimination occurring in various organs/tissues with 
different kinetic characteristics. Due to the low molecular weight and the non-ionic nature 
of the substances evaluated in the current study, direct renal or biliary excretion (i.e. 
excretion of the unchanged molecule) seems unlikely [331–333]. Consequently, a high 
correlation between metabolism and elimination can be assumed. From plasma time-
activity curves, information on tracer elimination can be extracted in form of total (plasma) 
clearance and terminal half-life. Because terminal half-life is a hybrid parameter depending 
on both clearance and volume of distribution [334], total clearance was chosen as predictive 
parameter and basis for in vitro-in vivo comparison. Total clearance ratios reported above 
were inversed to facilitate direct comparison with in vitro microsomal half-life ratios 
(reported in section 4.1.3). The results of in vitro-in vivo comparison are summarised in 
Table 11. For the sake of simplicity, the terms CBX, MCBX and CPFPX are used for both 
radiolabelled and cold compound in the following discussion. 
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Table 11. Comparison of in vivo total clearance ratios (inversed) and in vitro microsomal half-life 
ratios. For reasons of clarity, both radiolabelled and cold compound are summarised under the same 
term. 
Tracers compared 
In vivo total clearance 
ratio, inversed (SE) 
In vitro microsomal 
half-life ratio (SE) 
Deviation in vitro from 
 in vivo 
   % 
CBX:CPFPX 2.6 (0.12) 3.1 (0.11)* 19 
MCBX:CPFPX 0.82 (0.019) 1.4 ( 0.029)* 71 
CBX:MCBX 3.1 (0.15) 2.2 (0.072)* 29 
* significantly different from inverse in vivo total clearance ratio (p<0.05, two-tailed t-test) 
SE, standard error (estimated from SEs of the individual ratios via error propagation) 
Despite the relatively straightforward approach chosen for kinetic parameter estimation 
and the limitations of the applied PK model, in vitro metabolic stability data obtained from 
microsomal stability assays proved to be predictive for in vivo pharmacokinetics of the 
xanthine-derived A1AR ligands. In vitro half-life ratios deviated between 19 and 71% from 
inverse in vivo clearance ratios. In vitro metabolic stability ranking correlated well with in 
vivo clearance ranking. CBX exhibited considerable higher metabolic stability in vitro and 
lower clearance in vivo as compared to CPFPX and MCBX. Comparing MCBX and CPFPX, in 
vitro metabolic stability of MCBX was slightly higher than that of CPFPX (t1/2 ratio of 1.4). By 
contrast, MCBX was cleared somewhat faster from plasma than CPFPX. Although the 
difference between half-life ratio and inverse clearance ratio was statistically significant, 
this discrepancy has no practical relevance for the development of second generation 
radiotracers with improved metabolic properties since a marginal enhancement of 
metabolic stability would not justify further labour and cost intensive evaluation of a novel 
compound. 
To summarise, for the substances investigated in this study, in vitro microsomal stability 
data (expressed as half-life ratios) proved to be a good predictive tool for pharmacokinetic 
behaviour in vivo, even without extensive kinetic analyses and complex in vitro-in vivo 
extrapolation procedures. This might be, at least partially, due to the favourable 
physicochemical characteristics of this substance class. Intrinsic molecular properties such 
as very high or very low lipophilicity, acidic/basic character and high molecular weight 
frequently entail poor membrane permeability, direct renal/biliary excretion or 
susceptibility to active transport mechanisms which all impede estimation of in vivo 
pharmacokinetics from in vitro data [169, 328, 335–337]. Since the xanthine-based A1AR 
ligands examined in the current study are characterised by low molecular weight, moderate 
lipophilicity and neutral character, the abovementioned interfering biochemical and 
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physiological effects are less likely to occur. Additionally, the approach of relative 
comparison (comparison of ratios) used throughout this work may have contributed to the 
good comparability of in vitro and in vivo behaviour of the test compounds, because several 
obstructive attributes shared by all three tracers may have cancelled out. The predictive 
value of this approach (quantified by the percentage deviation of in vitro t1/2 ratios to 
inverse in vivo clearance ratios; see Table 11) was comparably to sophisticated in vitro-in 
vivo extrapolation strategies which are based on complex model assumptions or empirically 
determined scaling factors [336, 338–347]. A drawback of using comparative approaches to 
evaluate novel candidate radiotracers is the need for a well-characterised reference 
compound which allows for quantitative statements on the biochemical and 
pharmacological behaviour of new chemical entities. Nevertheless, since analytical 
comparison of structurally modified analogues of established drugs with the original 
compound is a common procedure in the development of (radio)pharmaceuticals (analogue 
design) [348, 349], a general acceptance of comparative evaluation approaches can be 
expected. 
4.2.4 Metabolite analysis 
4.2.4.1 Extraction efficiency 
With all three tested tracers, the applied extraction protocol yielded recoveries that slightly 
exceeded 100% throughout the whole measurement period (Fig. 31). For individual times of 
measurement, calculated recoveries of [18F]CBX, [18F]MCBX and [18F]CPFPX were in the 
range of 100 - 111%, 103 - 109% and 105 - 117%, respectively. The decrease in total 
volume of the supernatant, which is a consequence of both volume contraction resulting 
from mixing aqueous plasma with extraction solvent and the precipitation of plasma 
protein, amounted to 8 ± 1%. Recovery of radioactivity from plasma can thus be regarded as 
essentially quantitative for the three tracers. On the basis of these results, it can be 
anticipated that radio-TLC detected all metabolite species formed in vivo. 
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Fig. 31. Recovery of radioactivity from plasma samples after i.v. administration of [18F]CBX (A), 
[18F]MCBX (B) and [18F]CPFPX (C). Plasma was extracted with 3 volumes of a mixture of ACN/MeOH 
(50:50, v/v). Data (mean ± SD) were obtained from 7-8 animals per tracer. 
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4.2.4.2 In vivo metabolite profiles 
Metabolite profiles obtained from rat plasma after administration of [18F]CBX, [18F]MCBX 
and [18F]CPFPX are shown in Fig. 32 (radio-TLC images and densitometer scans). Since 
spectroscopic identification of the individual molecules could not yet be performed, in vivo 
metabolite profiles were only visually compared to the rat in vitro metabolite profiles 
presented in section 4.1.4.2. 
Radio-TLC of [18F]CBX (Fig. 32A) resolved a dominant, relatively lipophilic (low retention on 
the silica TLC plate) metabolite species (MA4, Rf 0.71) and three less abundant metabolites of 
lower lipophilicity (MA1, Rf 0.17; MA2, Rf 0.24; MA3, Rf 0.31).The Rf value of authentic [18F]CBX 
was 0.71. At later time-points, accumulation of non-migrating compounds at the origin was 
observed, which might indicate the appearance of hydrophilic phase II metabolites in 
plasma. The in vivo metabolite profiles of [18F]CBX corresponded well to the in vitro 
metabolite profiles which also showed a dominant metabolite with high retention on the 
C18 stationary phase (A5) and three smaller metabolite peaks eluting shortly after the 
injection peak (A1-A3). 
Radio-TLC of [18F]MCBX (Fig. 32B) showed a major metabolite (MB1, Rf 0.29) exhibiting high 
retention on silica (low lipophilicity). Two smaller activity spots are clearly visible (MB2, 
Rf 0.40; MB3, Rf 0.48), and a fourth spot (MB4) can be recognised at Rf 0.62, in close vicinity to 
the authentic tracer (Rf 0.79). This is in good agreement with microsomal metabolite 
profiles showing an early eluting major compound (B3) followed by two smaller peaks (B5-
B7). The third activity spot on the TLC plate might correspond to peak B9 or B10 in the rat 
microsomal profile. 
In vivo and in vitro metabolite profiles of [18F]CPFPX in rodents have been extensively 
compared in [288]. Bier et al. first recognised the discrepancies between in vitro and in vivo 
metabolism of [18F]CPFPX in rodents. One major metabolite, the enone species 7, was 
generated exclusively in the living animal and not in liver microsomes. In the current study, 
microsomal incubation procedures and HPLC analyses had been slightly modified, thus 
qualitative in vitro-in vivo comparison was repeated. At least four metabolites (MC1-MC4) 
could be detected in rat plasma after [18F]CPFPX administration (Fig. 32C). Rf values of the 
compounds were as follows: [18F]CPFPX, 0.82; MC1, 0.21; MC2, 0.32; MC3, 0.43; MC4, 0.50. The 
most hydrophilic species, MC1, represented the main metabolite during the first 60 min after 
tracer injection. Later, intensity of the MC1 spot deceased continuously, suggesting fast 
clearance of this metabolite from blood. At later time points, the least hydrophilic 
metabolite, MC4, became the dominant species in plasma. A comparison of the rat metabolite 
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profile shown in Fig. 32C and the human metabolite pattern of [18F]CPFPX published in the 
abovementioned paper of Bier et al. (which was generated using comparable 
chromatographic conditions) suggests that MC4 represents the enone metabolite. As 
discussed in section 4.1.4.3, the discrepancy between in vitro and in vivo metabolite pattern 
of CPFPX in rodents could possibly be attributed to the action of extrahepatic P450 isoforms 
or non-P450 enzymes. Except for the absence of the enone metabolite, the microsomal in 
vitro metabolite profiles matched their in vivo counterparts: a major, hydrophilic metabolite 
(C1) and two slightly more lipophilic metabolites (C2, C5) of sufficient peak size to represent 
potential candidates for in vivo metabolites MC2 and MC3. 
Although a conclusive statement on the comparability of in vitro and in vivo metabolite 
profiles cannot yet be made due to the lack of spectroscopic data, a high degree of similarity 
was observed between HPLC analyses of microsomal extracts and radio-TLC analyses of 
plasma. For CBX and MCBX, the number of peaks detected in microsomal extracts (which 
were of considerable peak size) and their chromatographic properties corresponded closely 
to the radio-TLCs obtained from plasma extracts. It can therefore be assumed that the in 
vitro metabolite profiles are comparable to the in vivo metabolite profiles. In the case of 
CPFPX, the observations of Bier et al. regarding the differences between in vitro and in vivo 
metabolic pathways could be confirmed. However, since the formation of 7 in vivo in 
rodents is most probably governed by enzyme systems not contained in liver microsomal 
preparations, the observed discrepancies do not necessarily indicate a lack of validity of 
microsomal data, but might rather illustrate the intrinsic limitations of the reduced 
microsomal model. With regard to the utilisation of liver microsomes for the biosynthesis of 
specific metabolites on the macroscopic scale (quantities large enough for spectroscopic 
identification), the results of the studies on species differences in microsomal metabolism 
reported in section 4.1.4.2 showed that it might be promising to compare the in vitro 
metabolite profiles of several animal species, since a specific metabolic pathway observed in 
vivo in one species might be realised in vitro in another species (e.g. in vitro enone formation 
in humans and beagle dogs). Alternatively, the use of a more complex in vitro metabolism 
model such as hepatocytes might be advisable. 
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Fig. 32. Typical in vivo metabolite profiles obtained from rat plasma after administration of [18F]CBX 
(A+D), [18F]MCBX (B+E) and [18F]CPFPX (C+F). Figures on the left side show the radio-TLC images, 
figures on the right side the corresponding densitometer scans at 60 min p.i. For Rf values of 
authentic tracers and metabolites, see text. 
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4.3 Brain kinetics 
In order to be useful for PET brain imaging, a newly developed tracer must exhibit adequate 
cerebral pharmacokinetics. Candidate tracers may fail due to poor passive brain entry or 
active rejection from brain via efflux transporters [127]. Even if a tracer is able to cross the 
BBB readily, accumulation in the brain may be insufficient for imaging. The amount of tracer 
entering the brain depends on both the ability of the tracer to cross the BBB and the amount 
of tracer delivered to the brain via the blood stream [350]. Extensive peripheral metabolism 
which rapidly decreases tracer concentration in blood may prevent entry of sufficient 
amounts of tracer into the brain. Exemplary for this problem is [18F]CPFPX, which is rapidly 
metabolised in rodents as well as in humans [213, 220, 226, 288]. A study of Matusch et al. 
[289] showed that cerebral uptake of [18F]CPFPX was significantly higher in patients with 
impaired metabolism of the tracer resulting from liver cirrhosis or fluvoxamine treatment (a 
selective serotonin reuptake inhibitor which also inhibits P450 1A2, the major enzyme 
responsible for [18F]CPFPX degradation). Consequently, the development of metabolically 
stable structural analogues of [18F]CPFPX is one approach to improve PET imaging of A1AR. 
In the current study, pharmacokinetics of two recently synthesised [18F]CPFPX analogues, 
[18F]CBX and [18F]MCBX, were evaluated in the rat model. [18F]CBX actually showed 
noticeably delayed metabolic clearance and increased plasma levels in vivo as compared to 
[18F]CPFPX (see section 4.2.1). In order to examine the influence of enhanced tracer delivery 
to brain via plasma, cerebral kinetics of [18F]CBX and [18F]CPFPX were measured by in vivo 
PET. Additionally, cerebral kinetics of [18F]MCBX were also investigated and used for 
comparison, although this compound did not show higher in vivo metabolic stability than 
[18F]CPFPX. Prior to PET measurements, a supplementary in vitro autoradiographic study 
was conducted to gain information on the cerebral binding characteristics of the novel 
tracers. 
4.3.1 In vitro autoradiography 
In vitro autoradiography served primarily for analysis of cerebral tracer distribution and 
estimation of non-specific binding to brain tissue. In vitro autoradiographic binding of 
[18F]CBX, [18F]MCBX and [18F]CPFPX in rat brain is presented in Fig. 33. With all tracers, 
comparable cerebral distribution patterns were obtained. Highest activity accumulation was 
observed in hippocampus, thalamus, cerebellar cortex and neocortex, lowest in midbrain 
and brain stem. This pattern corresponds well with cerebral A1AR distribution as described 
in the literature [212-217]. The fraction of non-specific binding of [18F]CBX, [18F]MCBX and 
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[18F]CPFPX in rat brain amounted to 1.7 ± 0.25%, 1.9 ± 0.24% and 1.0 ± 0.09%, respectively. 
Considering this relatively narrow range, no fundamental variations in cerebral in vivo 
pharmacokinetics are likely to result from this parameter. 
Additionally, in vitro binding affinities of CBX, MCBX, CPFPX toward rat cortical A1AR were 
recently determined in our laboratories via competitive radioligand binding assays 
(experimental procedure as described in [351]). Measured Ki values (mean ± SD, n ≥ 3) were 
0.33 ± 0.06 nM for CPFPX, 1.4 ± 0.05 nM for CBX and 1.4 ± 0.1 nM for MCBX. Affinities of the 
novel cyclobutyl-substituted xanthine derivatives for the A1AR were thus about four times 
lower than that of CPFPX. 
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Fig. 33. Representative autoradiographs of sagittal rat brain slices after incubation with 0.4-0.5 nM 
[18F]CBX (A+D), [18F]MCBX (B+E) and [18F]CPFPX (C+F). Figures on the left side show total binding of 
the tracer, figures on the right side show non-specific binding in the presence of 13 µM DPCPX. High 
accumulation of radioactivity (warm colours) can be recognised in hippocampus (hip), thalamus (th), 
cerebellar cortex (cbl) and neocortex (ctx). 
cbl 
ctx hip 
th 
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4.3.2 Brain PET images 
PET images acquired after administration of [18F]CBX, [18F]MCBX and [18F]CPFPX are 
presented in Fig. 34. With [18F]CPFPX and [18F]MCBX, the rat brain could be clearly 
visualised. High accumulation of radioactivity was observed in A1AR-rich structures such as 
thalamus, hippocampus, neocortex and cerebellar cortex. Average SUVs of [18F]MCBX within 
the selected time window (0-60 min p.i.) were markedly lower than those of [18F]CPFPX. 
These differences in cerebral kinetics are further discussed in the following sections. 
Compared with the two other tracers, cerebral accumulation of [18F]CBX was marginal. 
Brain contours and cerebral structures were hardly identifiable. Only thalamus, 
hippocampus, cerebellar cortex and neocortex showed noticeable accumulation of 
radioactivity. Further kinetic analyses were conducted in order to identify possible 
physiological causes for this unexpected result (see following sections). 
4.3.3 In vivo cerebral kinetics 
Kinetics of [18F]CBX, [18F]MCBX and [18F]CPFPX in the rat brain are compared in Fig. 35. 
Despite the higher concentration of tracer in plasma, cerebral uptake of [18F]CBX was 
considerably lower than uptake of [18F]CPFPX. The brain SUV curve of [18F]CBX remained 
below the plasma SUV curve during the entire measurement period, indicating cerebral 
efflux of tracer rather than accumulation. To gain more insight into the mechanisms 
underlying this phenomenon, additional kinetic analyses were performed (see following 
section). 
Cerebral kinetics of [18F]MCBX deviated noticeable from that of [18F]CPFPX. Whole brain 
SUV curves of [18F]MCBX peaked earlier (4 min) than SUV curves of [18F]CPFPX (12 min) and 
dropped more steeply. However, peak SUV values were comparable for both tracers (about 
4 g/ml). These observations suggest that brain uptake of [18F]MCBX and [18F]CPFPX is 
comparable, but transfer kinetics of [18F]MCBX is faster, resulting in a compressed SUV 
versus time curve. Rapid tracer wash-out also explains the differences in average SUVs 
between [18F]MCBX and [18F]CPFPX as depicted in Fig. 34. These PET images were 
generated by averaging activity data measured from the time point of tracer injection up to 
60 min p.i. (time-weighted average). Within this time window, a much higher fraction of 
[18F]MCBX than of [18F]CPFPX has already left the brain, implying lower average activity 
values. This assumption was substantiated by reanalysis of the [18F]MCBX PET data set with 
a shortened averaging period (0-30 min p.i.). Cerebral SUVs of [18F]MCBX averaged from 
0-30 min p.i. were almost similar to cerebral SUVs of [18F]CPFPX averaged from 0-60 min p.i. 
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(data not shown). A more detailed analysis of cerebral transfer kinetics of [18F]MCBX based 
on compartmental modelling is presented in the following section. 
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Fig. 34. Representative PET images of rat brain after i.v. bolus administration of 20-22 MBq [18F]CBX 
(A+D), [18F]MCBX (B+E) and [18F]CPFPX (C+F). Activity concentration values registered 0-60 min p.i. 
were averaged (time-weighted average) and normalised to body weight and amount of injected 
radioactivity. SUV maximum was set to 5 g/ml (left side: sagittal plane, right side: horizontal plane; 
cbl, cerebellar cortex; ctx, neocortex; hip, hippocampus; hg, Harderian gland; th, thalamus). 
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Fig. 35. Kinetics of [18F]CBX (A), [18F]MCBX (B) and [18F]CPFPX (C) in rat brain (whole brain) and 
arterial plasma following single bolus injection. SUVs were calculated by normalising radioactivity 
concentration to amount of injected radioactivity and body weight. Plasma data were corrected for 
metabolites. Data (mean ± SD) were obtained from 4 animals per tracer. 
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4.3.4 Graphical and compartmental analysis of brain PET data 
Kinetic parameters describing cerebral tracer uptake and distribution were determined 
either graphically (Logan plot, Fig. 36D-F) or via compartmental modelling (Fig. 36A-C). A 
2TCM could be readily fitted to whole brain TACs of [18F]MCBX and [18F]CPFPX. For these 
two tracers, the 2TCM was clearly superior to the 1TCM, as proved by significantly lower 
Akaike information criterion values. In the case of [18F]CBX, the low accumulation of tracer 
in brain and the resulting unfavourable signal-to-noise ratio hampered fitting of the four 
rate constants describing tracer transfer in the 2TCM. A reliable estimation of individual 
rate constants was difficult, therefore only the robust compound parameters VT and VS 
(calculated from all four rate constants) were derived from 2TCM fits of the [18F]CBX PET 
data. Additional 1TCM fits were used to derive the rate constants K1 and k2 which 
characterise the rate of influx and efflux across the blood brain barrier. Results of 
compartmental modelling and graphical analysis are given in Table 12. 
Table 12. Results of graphical analysis and compartmental modelling of cerebral PET data (whole 
brain ROI). K1 and k2 were derived either from 1TCM fits ([18F]CBX) or 2TCM fits ([18F]MCBX, 
[18F]CPFPX). 
Kinetic parameter Model [18F]CBX [18F]MCBX [18F]CPFPX 
VT / ml/cm³ LGA 0.641 (0.184)
bc 2.648 (0.717)a 2.678 (0.980)a 
VT / ml/cm³ 2TCM 0.621 (0.192)
bc 2.716 (0.791)a 2.703 (1.015)a 
VS / ml/cm³ 2TCM 0.469 (0.174) 0.496 (0.205) 0.653 (0.262) 
K1 / ml/cm³/min 1TCM/2TCM 0.124 (0.039)
b 0.366 (0.097)ac 0.172 (0.059)b 
k2 / 1/min 1TCM/2TCM 0.202 (0.022) 0.170 (0.040) 0.093 (0.037) 
k3 / 1/min 2TCM n.d. 0.027 (0.044) 0.025 (0.039) 
k4 / 1/min 2TCM n.d. 0.075 (0.093) 0.039 (0.030) 
K1/k2 / ml/cm³ 1TCM/2TCM 0.621 (0.192)* 2.219 (0.740) 2.049 (0.998) 
k3/k4 / 1/1 2TCM n.d. 0.239 (0.136) 0.418 (0.383) 
LGA, Logan graphical analysis; 1TCM, one-tissue compartment model; 2TCM, two-tissue compartment model; VT, total 
distribution volume; VS, specific distribution volume; K1-k4, transfer rate constants; n.d., not determined; *K1/k2 equals 
VT in 1TCM; 
a significantly different from [18F]CBX; b significantly different from [18F]MCBX; c significantly different from 
[18F]CPFPX (p<0.05, one-way ANOVA with post-hoc Tukey test) 
mean (SD), n = 4 
Total distribution volumes were determined via Logan graphical analysis and 
compartmental modelling. VT of [18F]MCBX and [18F]CPFPX were nearly identical whereas VT 
of [18F]CBX was about 4 times lower. VT values acquired via compartmental modelling 
corresponded closely to the values obtained graphically. Differences in VS between the 
tracers did not reach statistical significance. Values of K1 and k2 were significantly higher for 
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[18F]MCBX than for [18F]CPFPX, whereas K1/k2 was nearly constant. This indicates that 
influx and efflux kinetics of [18F]MCBX are faster compared with [18F]CPFPX, but that the 
extend of tracer uptake into the brain is similar. These results support the assumption that 
the different shapes of the brain SUV curves of the two tracers are caused by variations in 
transport kinetics. Potential causes for these variations may be the faster peripheral 
clearance observed with [18F]MCBX, more rapid diffusion across the BBB (due to the 
somewhat higher lipophilicity of [18F]MCBX) or faster drug–receptor binding kinetics 
(resulting from the lower affinity of [18F]MCBX for the A1AR). Most likely, the observed 
differences in cerebral kinetics of [18F]MCBX are attributed to a combination of all of the 
above mentioned factors. 
The most apparent characteristic of [18F]CBX brain kinetics was the minimal to non-existent 
cerebral accumulation. Tissue to plasma ratio was <1 throughout the whole measurement. 
In view of the multiple factors affecting brain uptake and washout of a radiotracer, the 
deviating cerebral kinetics of [18F]CBX are not readily explainable. The results of in vitro 
competitive binding assay and in vitro autoradiography showed that the affinity of [18F]CBX 
for the rat A1AR (as measured by Ki) is lower than the affinity of [18F]CPFPX (by a factor of 4) 
but similar to that of [18F]MCBX, and that the extent of non-specific binding to brain tissue 
and plasma proteins of [18F]CBX is comparable to both [18F]CPFPX and [18F]MCBX. Although 
differences in VS of the tracers were not statistically significant, the lower affinity of [18F]CBX 
(compared to [18F]CPFPX) will certainly influence specific binding and therefore also VS and 
VT. However, it is questionable whether affinity is the only cause for inadequate cerebral 
kinetics of [18F]CBX, since VT of [18F]MCBX, which exhibited similar affinity for rat A1ARs and 
similar protein binding as [18F]CBX, did not decrease in comparable manner. Another 
potential reason for low cerebral accumulation of [18F]CBX could be insufficient brain entry 
of the tracer. As [18F]CBX is less lipophilic than the other two tracers, it is likely that its 
ability to diffuse across the BBB will also be diminished. The small K1 value of [18F]CBX 
points to this direction, although the difference in K1 between [18F]CBX and [18F]CPFPX did 
not reach statistical significance. Values of k2 must be interpreted with caution, because k2 is 
defined as the ration of K1 and the distribution volume of the tracer in the first tissue 
compartment (k2 = K1/V1). In the 2TCM, V1 not only depends on the transfer of tracer from 
plasma to V1 and back, but also on the transfer of tracer from V1 to V2 (the receptor 
compartment) and back, which is strongly influenced by the affinity of the tracer for its 
receptor. Since affinities of both [18F]CBX and [18F]MCBX were significantly lower than that 
of [18F]CPFPX, direct comparison of k2 values does not seem appropriate. Comparison of k2 
values of [18F]CBX and [18F]MCBX might be justified because of the comparable affinities of 
these two tracers, but the difference in k2 did not reach statistical significance, hence no 
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clear statement can be made about differences in the unidirectional transport of tracer back 
from tissue to blood. A possible explanation for poor brain entry of [18F]CBX might be the 
involvement of drug efflux transporters which actively transport tracer molecules out of the 
brain capillary endothelial cells that form the BBB. With regard to the relatively broad 
substrate specificity of many efflux transporters [136, 142], it is conceivable that also 
[18F]CPFPX, [18F]MCBX and other structurally similar A1AR tracers are susceptible to brain 
efflux, but to a varying extent, which might lead to differences in cerebral tracer uptake. 
However, it is important to note that the significance of the kinetic parameters reported in 
Table 12 is limited due to the small number of animals used, the high inter-individual 
variations in cerebral kinetics and the difficulty of estimating accurate parameters from 
complicated multi-parameter models. Therefore, these data can only serve as an indication 
regarding the potential causes of variations in brain kinetics of the individual tracers. 
Although the underlying mechanisms which cause inadequate brain entry of [18F]CBX 
cannot be conclusively assessed on the basis of the data acquired in the current study, the 
results provide evidence that delivery of the tracer across the BBB might be an important 
factor. Further in vitro and in vivo studies on brain penetration of [18F]CBX and similar 
xanthine-derived A1AR tracers appear promising. With regard to future human application 
of A1AR tracers, particular attention should be paid to potential species-differences in the 
ability of a tracer to cross the BBB. These differences can be particularly pronounced in the 
case of uptake/efflux transporter substrates, impeding translation of a tracer from 
preclinical to clinical phase [352–354]. 
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Fig. 36. Representative 2TCM fits (left row) and Logan plots (right row) of brain activity data 
acquired after i.v. bolus injection of 21-22 MBq [18F]CBX (A+D), [18F]MCBX (B+E) and [18F]CPFPX 
(C+F). Black symbols represent measured data, red solid lines represent model fits (CP, plasma time-
activity curve; CT, tissue time-activity curve). 
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5  Summary and Conclusion 
The development of PET radiotracers for in vivo imaging of molecular targets in the brain is 
an enormous challenge given the large number of physicochemical and pharmacological 
criteria that must be met by these compounds. Metabolism is one important factor 
determining the in vivo performance of a candidate radiotracer. Inadequate metabolic 
stability or formation of brain-penetrant radiolabelled metabolites may render a novel 
compound unsuitable for PET imaging. An initial assessment of the metabolic properties of a 
candidate at an early stage in the development process is therefore essential. In the 
pharmaceutical sector, numerous in vitro metabolism models have been developed for the 
evaluation of drug candidates prior to first animal studies, but little information is available 
concerning the relevance of these models in the context of radiotracer development. 
In this work, the utility of in vitro metabolism data for predicting in vivo metabolic 
properties of PET radiotracers was evaluated using three xanthine-derived A1AR ligands, 
namely 8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX), 8-cyclobutyl-3-(3-
fluoropropyl)-1-propylxanthine (CBX) and 3-(3-fluoropropyl)-8-(1-methylcyclobutyl)-1-
propylxanthine (MCBX), as model compounds. In vivo pharmacokinetics and metabolite 
patterns of the three compounds were studied in the rat model and compared to in vitro 
data generated in rat liver microsomes (RLM). 
Since the choice of incubation conditions may influence the results of in vitro studies, the 
effect of critical assay parameters on substrate depletion was extensively studied prior to 
the actual kinetic characterisation of the microsomal metabolism of the test compounds. For 
the enzyme-substrate systems investigated in the current study, strong influence on 
metabolic activity was exerted by (1) the pH of the incubation medium and (2) the type and 
concentration of the organic solvent used to solubilise the substrate. The effects of changes 
in buffer type, buffer molarity and concentration of the cofactor NADPH were less 
pronounced (although measurable). Alteration of the incubation matrix composition 
resulted in variations in substrate depletion of up to 300% (CBX) or 500% (MCBX, CPFPX). 
On the other hand, the ratios of substrate depletion (CBX to CPFPX and MCBX to CPFPX) 
proved to be highly constant, as well as the in vitro metabolic stability rank order of the 
three compounds (CBX>MCBX>CPFPX). These results suggest that a relative quantification 
approach such as the calculation of depletion ratios allows for quantitative statements on in 
vitro metabolic stability which are rather insensitive to variations of assay conditions. 
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Enzyme inactivation during microsomal incubations proved to be a considerable problem 
which may limit the validity of the results obtained from microsomal assays. Preincubation 
of microsomal protein in the presence of NADPH for 30 min reduced microsomal 
metabolism of CPFPX by 34%. An extended preincubation period of 120 min resulted in 
almost complete (89%) loss of metabolic activity. This phenomenon, which has been 
frequently described in the literature, is generally attributed to the NADPH-dependent 
formation of reactive oxygen species (ROS) in the microsomal matrix. The addition of 
antioxidant enzymes to the incubation matrix was reported beneficious by several authors, 
however, in the present study, addition of catalase and superoxide dismutase did not 
prevent enzyme inactivation. Further investigations on the role of NADPH in enzyme 
inactivation revealed that the concentration of NADPH remained stable during incubation at 
37°C in HEPES buffer containing only MgCl2, but rapidly decreased when incubations were 
conducted in the presence of microsomal protein. It could be demonstrated 
chromatographically that NADPH loss was a consequence of oxidative consumption in the 
microsomal matrix rather than of chemical decomposition. Addition of 
diphenyleneiodonium chloride (DPI), a non-selective inhibitor of numerous flavoenzymes, 
could prevent accelerated loss of NADPH. These observations supported the assumption 
that, even in the absence of P450 substrates, enzymatic processes take place in the 
microsomal matrix which account for the formation of ROS and thus for enzyme 
inactivation. However, the use of DPI as incubation additive for microsomal assays is 
precluded by the inhibitory potential of this compound against P450 and cytochrome P450 
reductase. Since other additives (EDTA, plumbagin) proved equally inadequate to maintain 
enzyme activity in microsomal incubations, the most promising strategy to avoid misleading 
in vitro stability data seems to be the shortening of the incubation period. 
Based on the results of these investigations, the microsomal stability assay was optimised to 
allow for physiological relevant data. Most importantly, the concentration of DMSO in the 
assay was restricted to a level of less than 1% and the concentration of microsomal protein 
was adjusted to a value of 0.5 mg/ml in order to allow for sufficient substrate depletion 
during an maximum incubation period of 30 min. Using this optimised microsomal assay, 
the depletion kinetics of CBX, MCBX and CPFPX in RLM were assessed. Since the depletion 
profiles of all compounds exhibited sigmoidal shapes, Hill-type logistic regression models 
were used to analyse the data. From the logistic fits, in vitro metabolic half-lives of the 
substrates were deduced. Generally, microsomal half-life depends on the concentration of 
both substrate and microsomal protein. In order to derive a parameter which is 
independent of the assay conditions and thus suitable for in vitro-in vivo comparison of 
tracer metabolism, in vitro half-life ratios were calculated from the individual half-lives of 
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the radiotracers. The t1/2 ratios (± SE) of CBX:CPFPX, MCBX:CPFPX and CBX:MCBX were as 
follows: 3.1 ± 0.11, 1.4 ± 0.029 and 2.2 ± 0.033. 
In vivo plasma kinetics of the 18F-labelled test compounds were assessed in anaesthetised 
rats via arterial blood sampling following intravenous bolus injection of the tracer. 
Standardised uptake value (SUV) versus time profiles were generated and fitted to 
triexponential models. From the triexponential fits, volume of distribution (Vd), total 
clearance (CL) and terminal half-life (t1/2γ) were derived. Unlike t1/2γ, CL is independent of Vd 
and therefore more suitable as predictive parameter for in vitro-in vivo comparison. CL 
values (± SE) for [18F]CBX, [18F]MCBX and [18F]CPFPX amounted to 1.50 ± 0.068 ml/min, 
4.65 ± 0.081 ml/min and 3.81 ± 0.057 ml/min. As with in vitro microsomal half-life, CL 
ratios were calculated from the individual values. Since, in contrast to in vitro microsomal 
t1/2, smaller CL values correspond to higher metabolic stability, the in vivo CL ratios were 
inversed to facilitate direct comparison. The inversed CL ratios (± SE) of 
[18F]CBX:[18F]CPFPX, [18F]MCBX:[18F]CPFPX, and [18F]CBX:[18F]MCBX were as follows: 
2.6 ± 0.12, 0.82 ± 0.019 and 3.1 ± 0.15. In vitro t1/2 ratios deviated between 19 and 71% from 
inverse CL ratios. In view of the reduced complexity of the microsomal model and the 
multitude of physiological parameters affecting in vivo pharmacokinetics of a substance, 
these deviations can be considered as small. Free fractions of [18F]CBX, [18F]MCBX and 
[18F]CPFPX in rat plasma ranged from 0.02 to 0.04, with only [18F]MCBX and [18F]CPFPX 
being significantly different. Since the extent of plasma protein binding of the tracers was in 
a comparable range, this parameter is not assumed to account for substantial differences in 
individual pharmacokinetics. Volumes of distribution of the evaluated tracers were in the 
range of 190-362 ml. These values indicate similar distributions of the tracers throughout 
the body of the rat (namely distribution in total body water). Consequently, it seems 
unlikely that the individual distribution characteristics of the three compounds represent a 
confounding factor which may bias the results of pharmacokinetic analysis. 
Visual comparison of in vitro and in vivo metabolite profiles of CBX and MCBX revealed a 
high degree of similarity regarding both number of metabolites and their relative 
abundance. Although spectroscopic identification of the metabolites could not yet be 
performed, the consistent chromatographic properties of metabolites generated in vivo and 
their potential counterparts formed in vitro suggest that in vitro and in vivo metabolite 
profiles of CBX and MCBX are comparable. In vitro and in vivo metabolite profiles of CPFPX 
differed significantly from each other. One major metabolite generated in vivo (MC4) did not 
correspond to any peak in the microsomal profile. This mismatch has already been 
described by Bier et al. [288], which identified the respective metabolite as 
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3-(3-fluoropropyl)-8-(3-oxocyclopent-1-en-1-yl)-1-propylxanthine (“enone metabolite”). In 
rodents, this metabolite is generated in the living animal, but not in the microsomal model. 
In the present work, further investigations on this phenomenon were conducted in order to 
permit an assessment of the suitability of the microsomal model to predict metabolic 
pathways in vivo. It could be demonstrated that in vitro formation of the enone metabolite 
proceeds via an intermediate species (most probably the corresponding alkenol) which is 
finally oxidised to yield the enone. This last reaction step is catalysed by human liver 
microsomes, but not by rodent liver microsomes. However, in the living animal, the 
intermediate metabolite is subjected to systemic circulation and hence exposed to a variety 
of enzyme systems other than hepatic P450 which might be able to oxidise the alkenol and 
complete the metabolic pathway (e.g. alcohol oxidoreductases or extrahepatic P450 
isoforms). The observed differences between in vitro and in vivo metabolite profiles of 
CPFPX in rodents might therefore be an indicator for the intrinsic limitations of the 
microsomal model rather than for the insufficient validity of microsomal data. 
Microsomal metabolism of the test compounds varied considerably among species, both in 
terms of metabolic rates and metabolic pathways. Substrate depletion measured in liver 
microsomes of rats and mice were roughly comparable, as well as those measured in mini 
pig and beagle dog microsomes. In the latter, relatively large, preclinical species, in vitro 
metabolic activity was about 50% lower than in rodents. Metabolic activities observed with 
rhesus monkey microsomes were exceptionally high, exceeding rodent values by a factor of 
10. This is particularly surprising since the constitutive hepatic expression of P450 1A2 in 
macaques has been questioned frequently. Human liver microsomes (HLM), on the other 
hand, showed conspicuously low metabolic activity towards the test substrates. For 
example, depletion of CPFPX in HLM was about 6 times lower than in mini pig and dog 
microsomes, 14 times lower than in rodent microsomes and even 150 times lower than in 
rhesus microsomes. The in vitro metabolic stability rank order of the test compounds was 
well conserved among non-human animal species (CBX>MCBX>CPFPX), but differed in the 
case of human microsomes (MCBX>CPFPX>CBX). The results of these investigations do not 
yet allow for a definitive conclusion on whether the deviating metabolic kinetics observed 
with HLM are an intrinsic property (and yet an indication of significant species differences) 
or an in vitro artefact resulting from variations in post-mortem tissue preparation. 
Interspecies comparison of in vitro metabolite profiles revealed considerable qualitative 
differences in microsomal metabolism of the evaluate compounds. Biotransformation of CBX 
and MCBX led to similar metabolites in all species, but the relative importance of the 
individual metabolic pathways varied markedly. Regarding CPFPX, in vitro formation of the 
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enone metabolite in non-human animals was of special interest. In beagle dog microsomes, 
one metabolite was generated which exhibited an identical retention time as the enone 
reference standard. Although the definitive identification of the chemical structure has not 
been accomplished yet, initial mass spectrometric analyses supported the assumption that 
this metabolite represents the enone species. In summary, none of the investigated animal 
species could accurately predict biotransformation of all three evaluated compounds. With 
regard to future evaluation of novel CPFPX analogues, the beagle dog appears a promising 
preclinical species which could complement standard rodent studies. 
The cerebral binding characteristics of the novel cyclobutyl-substituted A1AR ligands 
[18F]CBX and [18F]MCBX were evaluated in the rat model by means of in vitro 
autoradiography and in vivo PET and compared with the corresponding data of [18F]CPFPX. 
Autoradiographic images demonstrated identical binding patterns of the three tracers in rat 
brain. Highest accumulation of radioactivity was observed in brain regions generally 
associated with high A1AR density such as hippocampus, thalamus, neocortex and cerebellar 
cortex. For all tracers, the fraction of non-specific binding to brain tissue amounted to less 
than 2%. Dynamic brain PET studies revealed substantial differences in cerebral kinetics of 
[18F]CBX, [18F]MCBX and [18F]CPFPX. Whole brain SUV curves of [18F]MCBX peaked much 
earlier and dropped more steeply than SUV curves of [18F]CPFPX, although peak SUV values 
of both tracers were comparable. Compartmental data analysis substantiated the 
assumption that this behaviour might be a consequence of similar brain uptake but faster 
transfer kinetics of [18F]MCBX as compared to [18F]CPFPX, resulting from the slightly higher 
lipophilicity and lower A1AR affinity of [18F]MCBX. With [18F]CBX, on the other hand, 
virtually no brain uptake could be observed (tissue to plasma SUV ratio < 1). A closer 
analysis of the cerebral kinetics of [18F]CBX suggested that these deviating kinetics might be 
attributable to the combined effect of the lower affinity of [18F]CBX (as compared to 
[18F]CPFPX) and insufficient brain entry. The latter effect is of particular interest with 
regard to the design of novel xanthine-based A1AR tracers. Although the exact mechanism 
underlying this phenomenon has not yet been completely elucidated, the results of the 
present work suggest that poor brain entry of [18F]CBX might be a consequence of both 
hampered diffusion through the BBB arising from lower lipophilicity and active efflux 
transport. Further investigations should be conducted in order to assess the impact of the 
specific molecular structure of xanthine-derived A1AR ligands on brain penetration which 
might reveal new strategies for radiotracer optimisation. 
In conclusion, the results of the present work indicate that metabolism data obtained from 
liver microsomal assays are a suitable tool for predicting both qualitative and quantitative 
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aspects of in vivo radiotracer metabolism. Despite the discrepancy between radiotracer 
concentrations occurring in vitro and in vivo and the intrinsic limitations of the simple 
microsomal model system, a reasonable degree of predictive accuracy can be achieved if 
several points are considered. First, on the basis of the molecular structure of the candidate 
compound, it should be estimated whether direct renal/biliary excretion or metabolism via 
non-P450 enzymes are likely to occur which may reduce the significance of in vitro 
metabolism data. Second, microsomal assay conditions should be carefully evaluated and 
adjusted to produce physiologically relevant results. Third, the approach of relative 
comparison (comparison of ratios) might offer advantages in terms of simplicity and 
robustness and could therefore represent an alternative to classical in vitro-in vivo 
extrapolation methods if suitable reference compounds are available for the respective 
substance class. Forth, combined in vitro studies using liver microsomes of several different 
species might help to elucidate potential metabolic pathways of the candidate radiotracer. 
This work demonstrated the application potential of hepatic microsomes in PET radiotracer 
development. The data encourage the implementation of microsomal assays as an integral 
part of preclinical evaluation of novel PET radiotracers and suggest additional studies on the 
ability of human liver microsomes to a priori predict human radiotracer metabolism. 
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7 Appendix 
The calculations are performed exemplarily for one exponential term of each 
polyexponential function. For both functions, λ>0 is assumed. 
7.1 Definite integral of C(t)dt (Eq. 4) 
  	
  Eq. 7.1.1 
Since A is a constant parameter: 
  	
  Eq. 7.1.2 
Substitution: 
 N =  Eq. 7.1.3 
 	N = 	 Eq. 7.1.4 
 
1 	N = 	 Eq. 7.1.5 
Substituting into Eq. 7.1.2: 
  1 ]	N


  Eq. 7.1.6 
 
  ]	N


  Eq. 7.1.7 
 − ]|∞0  Eq. 7.1.8 
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Back transformation: 
 − `∞0  Eq. 7.1.9 
 
Considering the characteristics of the exponential function 
 lim→
  = 0 Eq. 7.1.10 
thus 
 − (0 − 1) =   Eq. 7.1.11 
7.2 Definite integral of tC(t)dt (Eq. 5) 
  	
  Eq. 7.2.1 
Since A is a constant parameter: 
  	
  Eq. 7.2.2 
Substitution: 
 N =  Eq. 7.2.3 
  = N Eq. 7.2.4 
 	N = 	 Eq. 7.2.5 
 
1 	N = 	 Eq. 7.2.6 
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Substituting into Eq. 7.2.2: 
  N ] 	N


  Eq. 7.2.7 
This integral represents a gamma function 
 
 Γ(2) =  Eq. 7.2.8 
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